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Abstract 
Ethanol  is  a  poison  that  adversely  affects  the  health  of  individuals  and  is 
detrimental to society as a whole. Analysis of ethanol in biological matrices is 
the  most  frequent  test  carried  out  in  forensic  toxicology  laboratories  with 
application  across  a  range  of  cases  types  including  fatalities,  road  traffic 
accidents, criminal investigations and workplace drug testing. 
The  interpretation  of  ethanol  concentrations  in  post  mortem  samples  can  be 
challenging in relation to medico-legal investigations. The source of ethanol can 
be as a result of the ingestion of an alcoholic beverage or it may have been 
formed after death. The stability of alcohol is also adversely affected by the 
presence of bacteria, high temperatures and unsuitable storage containers. 
A  robust  and  sensitive  method  was  developed  for  the  analysis  of  common 
volatiles such as ethanol, methanol, isopropanol, acetone and n-propanol using 
headspace gas chromatography coupled with a flame ionization detector (HS-GC-
FID). The method was validated in accordance with ISO/IEC 17025, and was used 
to  investigate  the  stability  of  volatiles  in  blood  when  stored  under  different 
conditions, and to investigate the prevalence of volatiles in different biological 
matrices collected post-mortem.  
Storage  of  blood  samples  in  the  freezer  within  sample  vials  containing 
preservative  and  antioxidant  improved  the  stability  of  all  volatiles  with  the 
exception of methanol which remained stable under all conditions investigated. 
The identification of ethanol or acetone in vitreous humour was found to be a 
suitable  alternative  matrix  in  cases  where  femoral  blood  was  unavailable  or 
ethanol  production  was  suspected.  The  concentration  of  ethanol  in  bile 
correlated well with femoral blood but to a lesser extent than vitreous humour. 
Urine was not a suitable matrix for estimating blood ethanol concentrations. 
Alcohol biomarkers, β-Hydroxybutyrate (BHB) and fatty acid ethyl esters (FAEEs) 
have  been  reported as  useful  markers  for,  investigating  the  role  of  alcoholic 
ketoacidosis  (AKA)  in  post-mortem  cases,  and  foetal  exposure  to  chronic 
maternal  alcohol  consumption,  respectively.  Methods  were  developed  and xvi 
validated in accordance with ISO/IEC 17025 for BHB in blood and urine using gas 
chromatography - mass spectrometry (GC/MS), and for FAEEs in meconium by 
liquid chromatography - tandem mass spectrometry (LC/MS/MS).  
Post-mortem case samples submitted to the Forensic Medicine and Science (FMS) 
toxicology laboratory for routine tests were analysed for BHB using the validated 
method. The findings highlighted the importance of measuring BHB in blood in 
all  cases  where  the deceased  has  a  history  of  alcohol  misuse and  where  the 
cause of death cannot be determined following the post-mortem. The role of 
alcoholic ketoacidosis in the cases analysed in this study was significantly under-
reported. 
Meconium samples collected from infants born at the Princess Royal Maternity 
Hospital,  Glasgow,  were  analysed  for  FAEEs,  using  the  validated  method  to 
investigate the prevalence of each FAEE (ethyl laurate, ethyl myristate, ethyl 
palmitate,  ethyl  stearate,  ethyl  oleate,  ethyl  linoleate,  ethyl  linolenate,  and 
ethyl  arachidonate).  The  study  found  evidence  of  chronic  maternal  alcohol 
consumption in approximately one third of the cases tested, in contrast to self-
reported  use  and  highlights  the  importance  of  screening  for  the  presence  of 
FAEEs  in  meconium.  The  identification  of  suitable  biomarkers  of  excessive 
maternal alcohol consumption during pregnancy, carried out as part of screening 
program, in addition to clinical evaluation would help to diagnose and support 
newborns with Foetal Alcohol Spectrum Disorder (FASD).   
The  method  developed  for  the  analysis  of  BHB  in  blood  and  urine  was 
successfully adapted and validated for analysis of structurally similar drugs such 
as β-hydroxy-β-methylbutyrate (HMB), a legal dietary supplement, in plasma and 
urine collected from 8 subjects, pre- and post-administration of a 3g dose of 
HMB.  A  significant  increase  was  observed  in  urine  and  plasma  following 
administration of of HMB. The method was then applied to the analysis of post-
mortem  blood  and  urine  to  investigate  the  concentrations  of  exogenous  and 
endogenous levels of γ-hydroxybutyrate (GHB).  
 xvii 
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Chapter 1 - Introduction 
1.1 History of Alcohol Use 
The exact date of the first use of ethanol (commonly known as alcohol) as a 
beverage is not known, but it is thought to have occurred  as early as 10,000 
BC.(1) Archaeologists have found evidence that barley had been used to make 
beer  for  centuries.  The  Egyptians  made  beer  from  corn,  while  in  China  an 
alcoholic drink “samshu” appeared around 7000 B.C. along with “sake” in Japan 
which is made from rice. Wine and beer became the daily thirst quenchers for 
many years until water suitable for human consumption became more widely 
available in the 19th century.(1) 
Religious references to alcohol are both positive and negative. In the Bible an 
abundance of wine is used as an example of God's blessing, while a lack of wine 
is used as an example of God's punishment. Negative references include warnings 
against  abusing  alcohol  and  advocating  abstinence  if  drinking  will  cause  “a 
brother to stumble”. (2) In Islam, alcohol consumption is completely forbidden 
as it is believed that the harm associated with alcohol far outweighs its benefits. 
For  the  benefit  and  betterment  of  man,  Islamic  religion  criminalizes  the 
consumption,  production,  transportation,  and  sale  of  alcoholic  beverages, 
although the strictness by which this prohibition was, and is, enforced varies 
between Islamic countries.(3;4)  
The first half of the 20
th century saw a period of alcohol prohibition in several 
countries, including some provinces in Canada (1907 -1948), the United States 
(1920 to 1933), and Russia and the Soviet Union (1914-1925).(4) After several 
years, prohibition was deemed a failure in North America and other countries as 
bootlegging (rum-running) became widespread and organized crime took control 
of the distribution of alcohol. Prohibition generally came to an end in the late 
1920s or early 1930s.(4)  Figure 1-1 is an example of the posters displayed at the 
time. Chapter 1    2 
 
Figure 1-1:  Alcohol Prohibition Poster. 
" Reproduced with permission from druglibrary.org"(5) 
In the United Kingdom, the sale or consumption of commercial alcohol has never 
been prohibited by law and is freely available to purchase in licensed premises if 
you are 18 years of age or older. However, for over 100 years the village of 
Bournville near Birmingham has not sold alcohol in any of their pubs, bars, or 
shops.  Residents  fought  to  maintain  their  alcohol-free  zone,  winning  a  court 
battle in March 2007 with Tesco (the largest supermarket chain in Britain) to 
prevent them from selling alcohol in its local outlet.(4)  
1.1.1 Alcohol Standard Measure 
Alcohol  units  are  a  measure  of  the  volume  of  pure  alcohol  in  alcoholic 
beverages.  The  standard  drink  is  used  in  many  countries  to  quantify  alcohol 
intake.  The  standard  drink  contains  one  unit  of  alcohol  and  varies  from  one 
country to another according to how each country defines the unit of alcohol. 
The terms used for alcoholic drink measures include, units, alcohol by volume 
(%ABV), proof, pints, litres(L) and millilitres(mL).(6) One unit of alcohol in the 
United Kingdom is defined as 10 mL (8.0 grams of pure alcohol). This compares 
with 10 grams (12.7 mL) in Australia, while in the USA 1 unit of alcohol is equal 
to 17.7 mL and 1 pint  equates to 473.176473 mL.(7) Chapter 1    3 
The number of units of alcohol in a drink can be calculated by multiplying the 
volume of the drink in milliliters by the percentage alcohol content and then 
dividing by 1000.  The alcohol content is expressed on the label as (%ABV).(7)  
1.2 Prevalence of Alcohol Use 
In 2005 (Figure 1-2), the total recorded worldwide consumption of alcohol by 
persons aged 15 years or older was 6.13 litres of pure alcohol per person. The 
highest  consumption  levels  can  be  found  in  the  developed  world  whilst  the 
lowest consumption levels can be found in the countries of North Africa and sub-
Saharan  Africa, the  Eastern Mediterranean  region, and  southern  Asia and  the 
Indian  Ocean.  These regions  represent  large  populations  of  the  Islamic  faith, 
which have high rates of abstention.(8;9) 
 
Figure 1-2:  Consumption of Pure Alcohol in Litres Per Person (>15 years old) in 2005.  
" No permission is required if used for research private study or with noncommercial 
document with limited circulation such as an academic thesis or dissertation.(8)" 
Scotland, a small northern European country with a population of approximately 
5 million people has the eighth highest rate of ethanol consumption in the world. 
Estimated  at  11.9  litres  of  pure  alcohol  per  person  based  on  sales  figures, 
alcohol consumption in Scotland is significantly higher than that of England and 
Wales by 2.4 litres (9.6 litres).(10)  In 2009, the population of men in Scotland Chapter 1    4 
exceeding “sensible” drinking limits was more than half (53%) of the 25-34 age 
group, and 44% for women in the same age group. (10)   
The  UK  Governments  guidelines  for  sensible  drinking  recommends  maximum 
daily drinking limits for men that should not exceed more than 3 - 4 alcohol units 
per day and for women a maximum of 2 - 3 units of alcohol per day. It is also 
advised that people should have at least two alcohol free days each week and as 
such weekly limits are set at no more than 21 units for men and 14 units for 
women.(11)  
Although there is no official internationally agreed definition of “binge drinking” 
the Scottish Health Survey 2009(11) used the same definitions that were used in 
the Health Survey for England and the General Lifestyle Survey(12;13) to allow 
for comparability with other major alcohol consumption surveys in Britain. Binge 
drinking was defined as daily alcohol intake of more than 8 units for men and 
more than 6 units for women.(10;11) The prevalence of “binge drinking” was 
reported for 2009 with 26% of men and 17% of women drinking more than twice 
the recommended daily limit. 
1.3 Alcohol-Related Harm  
The World Health Organisation (WHO) objectives for public health policies and 
initiatives are to reduce the hazards caused by the harmful use of alcohol.(8;9) 
Alcohol is identified by the WHO as the third highest risk factor for ill health in 
developed countries, behind only tobacco and high blood pressure.(9) 
Many health medical onditions are linked to alcohol. These conditions may be 
acute or chronic diseases or injuries. Two types of alcohol-related conditions 
were identified in the Scottish report of alcohol statistics for 2011.(10) The first 
were those wholly attributable to alcohol misuse, such as alcoholic liver disease, 
mental  and  behavioural  disorders,  alcoholic  polyneuropathy,  myopathy, 
cardiomyopathy, gastritis, degeneration of the nervous system, intentional and 
accidental poisoning by alcohol, toxic effects of alcohol, foetal alcohol syndrome 
and alcohol-induced chronic pancreatitis. Chapter 1    5 
The second group are those partly attributable to alcohol, such as cancers of the 
lip, oral cavity and pharynx, oesophagus, liver, larynx, colorectum and breast, 
and injuries resulting from road traffic accidents, assaults, fire injuries, falls, 
and intentional self-harm. Other medical issues include coronary heart disease, 
stroke, hypertensive diseases and cardiac arrhythmias, gastrointestinal diseases 
including  liver  disease,  oesophageal  varices,  chronic    pancreatitis,  psoriasis, 
spontaneous abortion, and epilepsy.(10)  
Alcohol  misuse  is  also  associated  with  several  infectious  diseases  including 
Human  Immunodeficiency  Virus  (HIV)/Acquired  Immunodeficiency  Syndrome 
(AIDS), tuberculosis, and sexually transmitted infections. Alcohol consumption 
weakens the immune system and has a negative effect on patients’ adherence to 
antiretroviral treatment.(9)  
To investigate the extent of harm associated with alcohol use in Scotland, adults 
were classified into four different drinking categories based on the number of 
units  consumed  in  one  week.(10)  These  categories  included  “non-drinkers”, 
“moderate drinkers”, “hazardous drinkers” and “harmful drinkers”.  
The study concluded that while those classified as hazardous drinkers  (men who 
consume between 21 – 50 alcohol units weekly and women between 14-35 units) 
may not have serious affects in the short-term, their excessive drinking could 
cause problems in the long-term.(10;11) The harmful drinking category included 
men who consumed over 50 units of alcohol weekly and women over 35 units, 
and  were  associated  with  causing  physical,  social,  or  psychological  harm  to 
themselves. 
1.3.1 Alcohol-Rehlated Social Harm 
Ninety-seven per cent of respondents to the Scottish Crime and Justice Survey 
considered  alcohol  abuse  in  Scotland  to  be  a  problem,  with  almost  three 
quarters  (74%)  perceiving  it  as  a  “big  problem”.  “Vomiting”  and  “having  an 
argument” were the most common negative effects of alcohol to reported by 
children.(10)  It  is  estimated  that  65,000  children  live  with  a  parent  with  an 
alcohol problem. (14)  Chapter 1    6 
In 3 out of 5 incidents of violent crime (62%), victims believed their attacker to 
be under the influence of alcohol, while in almost a third of incidents of violent 
crime, victims were under the influence of alcohol themselves.(10)  
1.3.2 Alcohol-Related Deaths 
Alcohol-related deaths include acute intoxication, chronic alcoholism, trauma, 
hypothermia, accidents, suicides, and homicides.(6;14-16) Alcohol-related death 
rates in Scotland are twice as high as in England and Wales, and have doubled 
over the last 15 years.(14) One Scot dies of an alcohol-attributable cause every 
three hours.(14) and deaths related to alcohol in some areas in Scotland are 6 
times  higher  than  the  UK  average.(17)  The  alcohol-related  mortality  rate  for 
males  was  more  than  twice  that  for  females  (30.0  per  100,000  population 
compared to 14.4 per 100,000 population, respectively).(10) 
The dark purple colour in Figure 1-3 represents the highest mortality rate from 
alcohol misuse, corresponding to northern Scotland and the central belt cities of 
Glasgow, Dundee, and Edinburgh. This data does not include many other causes 
of death to which alcohol may have contributed, such as deaths due to cancer 
and liver disease.(18) 
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  Figure 1-3:  Regional Variations in Alcohol-Related Mortality in Great Britain.  
  "Reproduced with permission from department of Geography University of Sheffield (18)" 
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1.3.3 Road Traffic Incidents Involving Alcohol 
The  offence  of  being  drunk  and  incapable  of  some  tasks,  such  as  operating 
machinery,  was  first  recognised  in  the  18th  and  19th  centuries.(6)    In  1872, 
penalties were imposed for drunkenness of persons who were in charge of the 
safety of others, such as engine drivers, ship masters, taxi drivers, and service 
personnel.(6)  The  prescribed  limits  for  alcohol  in  the  current  UK  legislation 
(Road Traffic Act 1988)(6) are 80 mg/100 mL in blood, 107 mg/100 mL in urine 
and 35 µg/100 mL in breath. The ability of a driver to judge speed and distance 
while  dealing  with  the  unexpected  is  impaired  when  under  the  influence  of 
alcohol with the risk of being involved in an vehicle accident increasing sharply 
if the blood alcohol concentration (BAC) of the driver is above the legal limit.(6) 
The  transport  legal  limits  for  alcohol  in  blood  vary  considerably  in  different 
countries and two alcohol blood legal limits were reported for some countries 
such as india, the reason is not clearly stated but the highest limit is the one 
used as summarised in Table 1-1.  
Table 1-1:  Legal Drink Drive Limit by Country for Ethanol in Whole Blood (19;20)
 
 
 
 
 
In Scotland, there were 8,504 offences of drunk driving in 2009-10(10) which was 
a  decrease  of  13%  from  9,800  drunk  driving  offences  in  2008-09.  A  total  of 
Country
  Legal limit (Blood)
  Legal Limit 
(Blood) mg% 
United States
  0.08 g/100 mL
  80 
Great Britain
  80 mg/100 mL
  80 
Netherlands
  0.50 mg/mL
  50 
Sweden
  0.20 mg/g
  20 
Norway
  0.20 mg/g
  20 
Australia  0.05 %  50 
Canada  0.08 %  80 
Japan  0.03 %  30 
India  0.03/0.015 %  30/15 
Saudi Arabia  0.00 %  0 Chapter 1    9 
18,536 motorists were known to be involved in injury-producing road accidents 
in 2009. This figure does not include drivers involved with hit and run accidents 
who were not traced. Out Of the 18,536 motorists, 10,924 (59%) were requested 
to take a breath test. Of these only 429 (3.9%) cases gave a positive breath test  
including motorists who refused to take the test which equates to 2.3% of the 
total number of tests carried out (18,536).(10) In 2008 it was estimated that 40 
people were killed in accidents involving motor vehicle drivers or riders with 
alcohol levels, above the current drink-drive limit of 80 mg of alcohol per 100mL 
of blood.(10) 
1.3.4 Foetal Alcohol Spectrum Disorders (FASD) 
People have the misguided belief that the effects of ethanol on the foetus have 
only  recently  been  recognised.  However,  the  link  between  ethanol  and  birth 
defects are noted throughout history. The Ancient Greek Philosopher, Aristotles 
(384-322 B.C.) noticed that the children of drunken women were often “morose 
and languid”(21) and in 1500 A.D., St. Francis warned women against consuming 
wine  or  strong  drink  during  pregnancy  to  prevent  the  child  from  becoming 
“lunatic” (one who had imperfect memory).(21) 
 
 Figure 1-4:  William Hogarth 1697-1764 (Gin Lane).  
 "This work has been identified as being free of known restrictions under copyright law"(22)
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In 18
th century Britain, the epidemic consumption of gin made people believe 
that it could lead to birth defects. When the price of gin decreased, the infant 
mortality rate increased and in 1834, the British House of Commons recognised 
the impact of ethanol and reported that “children from alcoholic mothers have a 
starved, shrivelled and imperfect look”. In 1860, a French physician noted that 
children exposed to ethanol have nervousness, a small head, and strange facial 
features.(21) 
Babies born to mothers who are suspected of misusing alcohol during pregnancy 
are at an elevated risk of developing foetal alcohol spectrum disorders (FASD) 
and Foetal Alcohol Syndrome (FAS).(23;24)  Foetal exposure to alcohol can cause 
central  nervous  system  dysfunction,  pre-  and  post-natal  growth  problems, 
cardiac defects in neonates, attention deficit disorders and may also lead to 
mental retardation. Ethanol crosses the placenta and interferes with the brain 
and  other  organ  development  and  can  cause  pre-term  delivery,  spontaneous 
abortion and foetal death. The effects associated with foetal alcohol exposure 
are permanent, irreversible and impact both the child and family for life. The 
greatest incidence of infant cognitive deficiency occurred in pregnant women 
who engaged in binge drinking.(23;25) 
 FASD is a non–diagnostic umbrella term identifying a range of disorders as a 
result of gestational alcohol exposure, including Foetal Alcohol Syndrome (FAS), 
Partial  Foetal  Alcohol  Syndrome  (PFAS),  Alcohol-Related  Birth  Defects  (ARBD) 
and Alcohol-Related Neurodevelopmental Disorders (ARND).(23;26) The severity 
associated with these disorders is thought to depend on the amount of alcohol 
consumed  during  pregnancy  and  at  what  time  point  during  the  pregnancy 
maternal consumption of ethanol occurred. 
FAS is the most clinically recognized of the FASD conditions, exhibiting the full 
presentation  associated  with  a  pattern  of  anomalies  including  facial 
dysmorphism, permanent impairment of brain function due to damage to the 
central nervous system that may also lead to development disabilities, attention 
deficit disorder, hyperactivity, learning disabilities, receptive language deficits 
and pre and post growth deficiency.(23;26) The term partial FAS (PFAS) applies 
when there is a confirmed history of prenatal exposure and some characteristics Chapter 1    11 
of the full syndrome but not enough to establish the diagnosis of FAS. The terms 
ARBD and ARND are two terms used when a complex pattern of behavioural and 
cognitive  abnormalities  are  noted  that could  not  be  otherwise  explained  and 
when there is known significant maternal alcohol use.(26) 
To  facilitate  early  diagnosis  and  treatment  and  to  prevent  undesirable 
outcomes, clinical diagnosis and screening for alcohol biomarkers may confirm 
maternal alcohol consumption. Relying only on the mothers self-report is not an 
accurate  means  of  confirming  alcohol  exposure,  due  to  feelings  of  guilt, 
embarrassment, and fear of punitive action.(27;28)  
Specific assessment techniques used to make definitive clinical diagnosis of FASD 
are still a matter of debate.(29) In order to prevent FASD it requires detection of 
in pregnancy maternal risk drinking. Surveys conducted in the UK have reported 
an increase in the percentage of women who gave up drinking during pregnancy, 
from  24%  in  1995  to  34%  in  2009.(16)  However,  in  2009,  61%  continued  to 
consume alcohol albeit to a lesser extent, while 4% admitted no change in their 
drinking  pattern.    In  contrast,  11.6%  of  pregnant  women  aged  15-44  in  the 
United States admitted to using alcohol in the month prior to the survey, while 
16% of pregnant women aged 15-17 consumed approximately 24 drinks in the 
past month, with an average of 4 drinks on the day that they drank.(30;31) 
The  prevalence  of  FAS  and  FASD  is  underreported  in  the  UK  due  to  lack  of 
reliable data collection methods and consistency. The likely reasons could be the 
complexity  in  diagnosing  FASD  disorders,  the  lack  of  available  standardised 
methods to diagnose FASD and the associated costs.  FAS is now widely known 
and accepted as a clearly diagnosed disorder, however, it is believed that the 
prevalence of FASD is three times greater than FAS.(31)   
It has been reported that in Scotland there are as many as 300 babies a year who 
have been affected by maternal alcohol consumption during pregnancy, however 
the  incidence  of  FAS  in  Scotland  is  based  on  estimates  from  other  European 
countries and USA statistics.(25;32) Considering the difficulty of diagnosing FASD 
Than FAS, a global research suggests that the prevalence of FASD worldwide is 1 
in 100 live births.(33) Using this to estimate FASD in Scotland would correspond Chapter 1    12 
to a cumulative total of approximately 8000 children (infants to 16 years old). 
This figure could be generated if the total population of children (infants to 16 
years old) in Scotland was around 800,000. Relying on the figures from the USA 
statistics, there are approximately 7 cases per 10,000 births according to the 
birth monitoring program in USA and when this is translated to Scotland, the 
cumulative figure is expected to be 560 children (infants to 16 years old) based 
on  a  population  of  800,000.(32)  Table  1-2  summarises  the  statistics  on  the 
prevalence of FAS and FASD by country.  
 Table 1-2:  Summary of Statistics on Prevalence of Foetal Alcohol Exposure by Country 
Country  Prevalence of FASD and FAS  References 
USA 
FAS - 0.3–5.6 per 1000 live births 
FAS - estimated 0.5-2.0 per 1000 live births 
FAS - 2-7 per 1000 live births 
(25) 
(33) 
(34) 
CANADA  FASD - 1 in every 100 live births  (35) 
 
ITALY 
 
FAS - 3.7-7.4 per 1000 children 
FASD - 20.3–40.5 per 1000 children 
 
(36) 
 
FAS - 4.0-12.0 per 1000 children 
PFAS - 18.1-46.3 per 1000 children 
FASD - 2.3-6.3% of children 
(37) 
AUSTRALIA  FASD - 4.7 per 1000 live births  (23) 
SOUTH AFRICA  FASD - 68.0–89.2 per 1000 children  (38) 
ENGLAND  FAS - 95 in 2000–01, 90 in 2001–02 and 128 
in 2002–03 
(23) 
SCOTLAND  FAS - 4 in 2000, 5 in 2001, 4 in 2002, 2 in 
2003 
(23) 
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In  the  USA,  the  recommendation  from  the  Surgeon  General  is  for  pregnant 
women not to drink any alcohol during pregnancy to avoid the negative impacts 
on the health of both mother and foetus and to eliminate the chance of giving 
birth to a baby with FASD.(39) Fifteen states consider substance abuse during 
pregnancy  to  be  child  abuse  under  civil  child-abuse.(40)    Canada  promotes 
alcohol-free  pregnancy  but  has  no  law  against  consuming  alcohol  while 
pregnant.(41) 
In  the  UK,  there  have  been  no  universal  strategies  focusing  specifically  on 
preventing FASD.(23) The Department of Health and the National Institute for 
Health  and  Clinical  Excellence  (NICE)  published  guidance  warning  pregnant 
women or women trying to conceive to avoid drinking alcohol to protect the 
baby. If they choose to drink they should not drink more than 1-2 units of alcohol 
once or twice a week.(42);(43)  
Several governments have introduced a label or logo as a health warning for 
pregnant women to be applied to all alcoholic drinks including different types of 
containers.(21)  In  the  UK,  voluntary  labelling  is  preferred.  For  ethanol  drink 
containers exported outside Britain labelling is sent out with necessary warnings 
as per the requirement of the importing country. However the same ethanol 
drink containers do not have the warning label when sold in Britain.(21) 
1.3.5 Alcohol-Related Harm Reduction Plan in Scotland 
In response to the growing scale of the problem associated with ethanol misuse, 
the Scottish Government published a new strategy for reducing alcohol related 
harm setting out proposed changes to legislation to build on those already in 
place, specifically the Licensing (Scotland) Act 2005 introduced in September 
2009.(44;45) The Alcohol etc. (Scotland) Act 2010 was passed by the Scottish 
Parliament on the 10
th November 2010 and bans quantity discounts on alcohol 
purchases, restricts alcohol-related promotions, introduces a Challenge 25 age 
verification  scheme  for  licenced  premises  and  aims  to  introduce  social 
responsibility for those who profit from the sale of alcohol. The original Bill had 
also  included  minimum  pricing  for  alcohol  but  this  was  not  supported  by  all 
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1.4 Interpretative Challenges Associated with Medico-
legal Investigations Involving Ethanol 
Due to the prevalence of ethanol use and misuse across all areas of society, a 
wide  range  of  case  types  and  samples  are  submitted  to  forensic  toxicology 
laboratories  for  ethanol  analysis.  Modern  laboratories  must  develop  methods 
which are suitably robust, sensitive and specific in accordance with national and 
international standards (e.g. ISO/IEC 17025) but must also consider additional 
factors for better interpretation of alcohol results in medico-legal cases. These 
include; the circumstances surrounding the death, whether there is a history of 
alcohol abuse, the type of sample and site of collection, whether the sample has 
been collected in an appropriate sample container with preservative and stored 
at  the  correct  temperature.  In  addition,  depending  on  the  type  of  case  and 
sample  availability,  the  identification  of  specific  ethanol  biomarkers  could 
provide significant insight into the role of ethanol.  
It is therefore important for forensic toxicologists to understand in addition to 
alcohol distribution and elimination from the body, other factors affecting the 
stability  of  alcohol,  alcohol  biomarkers  and  related  volatiles  to  aid 
interpretation of the measured concentration. 
1.5 Pharmacokinetics of Ethanol 
Ethanol  can  be  absorbed  into  the  body  in  different  ways;  through  the  skin, 
inhalation, intravenously or orally. The oral route is the most common with 80% 
of ethanol absorbed from the small intestine and 20% from the stomach into the 
blood by simple diffusion.(46) Ethanol enters the blood through the portal vein 
to the liver, and then travels to the right side of the heart and on to the lungs 
where gas exchange can occur. Ethanol dissolves in the blood and distributes 
into other tissues or fluids according to their water content, the greater the 
water content, the greater the ethanol concentration. Tissue with high water 
content will have more alcohol than tissues rich with fat.(46)  
It  is  commonly  assumed  that  women  have  less  body  water  than  men  due  to 
smaller body mass and a higher proportion of body fat. However, women achieve 
a higher blood alcohol concentration (BAC) than men after drinking the same Chapter 1    15 
amount of alcohol. Equilibrium between the tissues and blood is achieved within 
1-2 hours.(6) Absorption is most rapid when the stomach is empty.  There is also 
considerable intra and inter individual variation in the absorption rate.(46-48) 
Figure  1-5  summarises  the  many  factors  affecting  the  BAC  in  the  body  after 
drinking. 
 
Figure 1-5:  Factors Affecting Blood Alcohol Concentrations. 
"Reproduced with permission from Dr. Jones A. Wayne".(47) 
The metabolism of ethanol as summarised in Figure 1-6, is predominantly via 
oxidation to acetaldehyde (CH3CHO) by alcohol dehydrogenase (ADH) and then 
by aldehyde dehydrogenase (ALDH) to acetic acid (CH3COOH). Approximately 5% 
is excreted unchanged in breath, urine, and sweat. Less than 0.1% undergoes 
non-oxidative  metabolism  in  the  liver  in  a  phase  II  conjugation  reaction  to 
produce a water soluble metabolite ethyl-glucuronide, which is then excreted in 
urine. 
 
 
 Figure 1-6:  Ethanol Metabolism.  
“Reproduced with permission from Dr. Jones A. Wayne".(47) Chapter 1    16 
The elimination of ethanol from the body occurs mainly by oxidative metabolism 
by a Class I isoenzyme of ADH in the liver.  Ethanol is an example of a drug in 
which the Michaelis-Menten kinetic enzymatic model applies.(49)
 
ADH becomes saturated with substrate after the first few drinks and the rate of 
disappearance  of  ethanol  therefore  follows  zero-order  kinetics  which  is 
adequate to describe the decreasing phase of the BAC profile in most forensic 
situations (BAC >20 mg/dL).(49) When the BAC decreases below 10 mg/dL, the 
ADH is no longer saturated and the rate of disappearance changes to first–order 
kinetics in which only a fraction of ethanol is eliminated per unit time. Low 
BAC’s are however not relevant in most forensic situations.(50)   
The elimination rate on an empty stomach was reported to be lower than in non-
fasting subjects. The presence of the food in the stomach boosts the rate of 
ethanol metabolism and the profile of BAC returns to zero earlier than with an 
empty stomach when the same dose of ethanol was consumed. It is spectaculted 
that ethanol binds with some type of amino acid such as glycine.(49) 
Food in the stomach is an effective way not only to lower and delay the BAC 
peak but also to increase the rate of clearance of ethanol from the body. Food 
increases  the  blood  flow  in  the  liver,  making  the  liver  more  efficient  and 
facilitating exposure of ethanol to metabolizing enzymes in the liver.(50)  
According  to  a  survey  on  ethanol  elimination  rates  carried  out  by  Jones  in 
2010.(49) The survey was based on a large number of peer reviewed publications 
that met defined standards of experimental design, dose of alcohol given and 
blood  sampling  protocol.  It  was  concluded  that  the  physiological  ethanol 
elimination rates range from 10-35 mg/100 mL/h.  In moderate drinkers the rate 
is 15 mg/100 mL/h, while in arrested drivers 19 mg/100 mL/h, many of whom 
were binge drinkers or alcoholics. The results of this survey could be used as a 
guide when questions arise about elimination rates  in alcohol-related crimes. 
Ultra-rapid elimination rates accounting for rapid metabolism could be related 
to  the  induction  of  the  CYP2E1  enzyme  pathway  of  ethanol  oxidation  as  a 
consequence  of  heavy  drinking,  however,  the  dose  and  duration  of  drinking 
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Detoxification with high concentrations of ethanol and genetic predisposition of 
hypermetabolic  rate  could  be  another  reasons  for  ultra-rapid  ethanol 
elimination.(52) 
1.6 Other Volatiles of Interest 
Volatile  compounds  other  than  ethanol  can  be  found  in  blood  in  both  living 
subjects  (acetone,  isopropanol,  n-propanol,  isobutanol,  butanone  and  ethyl 
esters (ethyl acetate), and at post-mortem (acetaldehyde, acetone, isopropanol, 
n-propanol,  butanone,  isobutanol,  iso-amyl  alcohol,  d-amyl  alcohol,  acetate, 
propionate, butyrate, isobutyrate, and ethyl esters such as ethyl acetate and 
glycerol).(53) 
The  significance  of  the  presence  of  these  volatile  compounds  is  particularly 
important as the presence of volatile compounds not found in living subjects 
could be good markers for post-mortem putrefaction or external contamination 
of the body.(53) 
In many cases the presence of these volatiles is a result of microbial production 
postmortem  but  others  are  as  a  result  of  antemortem  alcohol  consumption, 
while  the  presence  of  acetone  may  be  endogenous  in  individuals  who  are 
diabetic or fasting.(53) In addition, acetone concentrations can increase due to 
intoxication from barbiturates or alcohol, hypothermia, metabolic ketoacidosis 
and isopropanol intoxication. Isopropanol is rapidly oxidized to acetone, which 
can be measured for several days afterward.(54) Acetone is one of the ketone 
bodies  that  can  be  considered  as  a  the  potential  markers  of  alcoholic 
ketoacidosis (AKA) in addition to β-hydroxybutyrate (BHB) and acetoacetate.(55)  
Isopropanol  or  rubbing  alcohol  is  commonly  used  as  an  antiseptic  and 
disinfectant.  Although  it  is  less  toxic  than  methanol  and  ethylene  glycol,  it 
produces greater central nervous system depression than ethanol.(54) 
n-Propanol  is  produced  in  large  quantities  post  mortem  and  may  continue 
increasing in concentration even when ethanol has reached its peak. It has been 
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and greater than 5% in blood confirms putrefaction.
(53)  n-propanol is considered 
a marker for ethanol formation as well as an indicator of putrefaction.(54)  
Methanol or wood alcohol is commonly used as a solvent in the chemical industry 
and is highly toxic. It is first converted to formaldehyde and then to formic acid 
by reaction with ADH and ALDH, respectively, and causes metabolic acidosis that 
can be fatal.(54)  
Ethylene glycol is the active constituent of antifreeze.  It is not as volatile as 
methanol and isopropanol and is very toxic compound. The diol converts in the 
body to oxalic acid which then reacts with calcium in the body and produces 
insoluble calcium oxalate. Calcium oxalate precipitates in the kidney and the 
brain leading to death.  Ethylene glycol intoxication is often identified without 
post-mortem toxicological analysis because the crystals of the calcium oxalate 
can be seen microscopically in the kidney or brain section.(46) 
1.7 Sample Selection for the Analysis of Volatiles  
The location from which a specimen is obtained from the body for analysis is 
important. During absorption, the alcohol concentration in different parts of the 
body  may  vary.
(56)  In  living  individuals,  arterial  blood  is  reported  as  an  ideal 
blood  sample  for  ethanol  determination  because  the  ethanol  concentration 
correlates  well  with  central  nervous  system  (CNS)  impairment.(57)  Plasma, 
serum, urine, cerebrospinal fluid (CSF) and saliva contain more water than whole 
blood; therefore, they are expected to have a higher concentration of ethanol at 
equilibrium.  Serum-blood  ethanol  concentration  ratios  vary  from  1.12-1.17, 
whereas  plasma-blood  ratios  range  from  1.10-1.35,  with  an  average  of  1.18. 
There is no significant difference between the serum-blood and plasma-blood 
ratios.(58) The mean saliva-blood alcohol ratio is 1.08, and is independent of the 
sampling time.(59) The advantage of saliva is that it is easy to be collect by non-
invasive  methods  and  there  is  a  high  correlation  between  saliva  alcohol 
concentration and venous blood, and breath-alcohol concentration.(60)  
Many  studies  have  evaluated  the  correlation  between  the  urinary  alcohol 
concentration (UAC) and the BAC. The majority of these studies suggest that the Chapter 1    19 
ratio is 1.3:1, however, many factors may affect the concentrations in urine such 
as the time after drinking when the bladder is emptied and the remainder of any 
residue of alcohol-free urine present before the individual started to drink. This 
would tend to dilute the urine after ethanol consumption.(61) Collecting urine 
specimens for forensic purposes must be carefully supervised to avoid tampering 
with  the  specimen  and  must  also  be  collected  in  a  vial  with  an  appropriate 
preservative.(62)  In  Road  Traffic  cases,  two  successive  void  samples  are 
collected for urine, where the purpose of the first void is to empty the bladder 
from any old urine.(56)  
In postmortem cases, interpretation of the significance of alcohol found is more 
difficult  if  there  is  insufficient  information  regarding  the  type  of  death,  the 
stage of ethanol distribution in the body, storage conditions and temperature of 
the specimens available.  
Whenever  possible,  femoral/peripheral  blood  should  be  collected  at  post 
mortem.  Cardiac  blood  (aorta,  vena  cava)  is  commonly  collected  in  the  US 
forensic centres but interpreted with caution where contamination in a case is 
suspected (56;63), while in the UK and Ireland, collection of heart blood is only 
recommended when femoral blood is unavailable.(64) Blood collected from the 
chest or thoracic (pericardial blood, pleural cavity) cavity are not ideal as they 
may be susceptible to contamination from the stomach.(65) Cardiac blood and 
post-mortem  femoral  venous  blood  ethanol  concentrations  may  reflect  blood 
ethanol  concentrations  at  the  time  of  death,  however,  some  peri-mortem 
physical factors associated with death, e.g. cardio pulmonary resuscitation (CPR) 
or suffering massive bleeding, may affect exogenous ethanol concentrations in 
cardiac blood.(66) 
In many death situations including death from severe trauma, blood from central 
and peripheral sites is not available during autopsy, and other body fluids are 
used to investigate the ethanol concentration, such as urine, vitreous humour 
(VH) and bile.(46)  
With urine, the presence of sugar and yeast can be  converted to ethanol by 
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the  specimen  is  not  stored  properly.  Vitreous  humour  (VH)  is  the  sample  of 
choice in situations where the body has undergone extensive trauma.(69) Post-
mortem formation of alcohol in vitreous humour is negligible and therefore any 
ethanol present in VH most likely reflects alcohol consumed and is not formed. 
(70;71)    De  Lima  and  Midio  (1999)(72)
  reported  that  the  vitreous  alcohol 
concentration (VAC) is higher than the BAC during the post absorption phase due 
to the high water content in VH. According to study that was carried by Honey et 
al.  2005(73)  the  ratios  varied  between  specimens  ranging  from  1.01-2.20. 
Possible  reasons  for  the  BAC  ≥  VAC  would  be  where  death  occurs  before 
equilibrium is achieved, if endogenous ethanol forms in post-mortem, or if the 
blood sample is contaminated during sample collection. 
It has been reported(56) that the bile-BAC is less variable and more reliable than 
other tissues to predict the blood alcohol concentration in both post-absorption 
and pre-absorption phases. A range of alternative biological fluids and tissues 
have been evaluated in comparison to blood for detecting ethanol in the living 
and after death and are summarised in Table 1-3. Chapter 1    21 
Table 1-3:  Ratio of Alcohol in Alternative Biological Specimens to BAC*. 
*BAC- Blood Alcohol Concentration 
The  following  scenarios  may  help  to  differentiate  whether  the  presence  of 
ethanol is endogenous or exogenous; 
1) the presence of ethanol in chest blood but not in vitreous humour or urine;  
2) the presence of ethanol in body fluids, especially VH; 
3) the presence of n-propanol and iso-propanol in the specimens;  
4) the circumstances of the death.(72) 
5) a history of alcohol abuse.
  
Matrix  Ratio Mean (Range)   
N  Ref. 
Urine 
1
rst  Void                            Mean 1.345 (1.68-1.75) 
2
nd  Void                            Mean 1.221 (1.43-1.47) 
 
450  (61) 
Acute Alcohol Poisoning     Mean 1.18  (0.87-1.53) 
Alcohol Death                    Mean 1.30  (0.87-2.10) 
628 
647 
 
(67) 
 
Serum/Plasma 
Plasma                              Mean 1.18  (1.10- 1.35) 
Serum                               Mean 1.16  (1.12- 1.17) 
20 
- 
(58) 
(56) 
 
Vitreous Humour 
                                     Mean 1.19  (0.63-1.75) 
                                     Mean 1.24  (1.01-2.20) 
672 
322 
(71) 
(73) 
Bile 
                                   Mean 1.01  (0.44-1.40) 
                                      Mean 1.03  (0.32- 2.91) 
33 
- 
(74) 
(75) 
Saliva                                         Mean 1.08 (1.065-1.088)  336  (75) 
CSF                                      Mean 1.14  (0.79-1.64)  54  (70) 
Brain                                      Mean 0.86  (0.64-1.2)  33  (70) 
Liver 
Violent Death                    Mean  0.63  (0.51-0.83) 
Acute Alcohol Death          Mean 0.60  (0.54-0.72) 
 
-  (76) 
Kidney                                      Mean 0.66  (0.57-0.76)  -  (76) 
Bone Marrow 
Actual                               Mean 1.94  (1.34-3.22) 
Corrected                         Mean 1.29  (0.94-1.64) 
42 
63 
(74) 
Synovial fluids                                      Mean 1.01  (0.58-2.41)  12  (77) Chapter 1    22 
Finally,  cases  may  be  presented  where  blood  transfusions  have  taken  place 
resulting in antemortem dilution of the blood potentially leading to a low or 
false negative result for alcohol. Although rare in the UK, bodies that have been 
embalmed  present  a  real  challenge  as  embalming  fluid  replaces  most  of  the 
blood  and  the  embalming  fluids  contain  both  formaldehyde  and  methanol. 
Although ethanol may be present in some cavity fluid, vitreous humour would be 
the preferred matrix in these cases.(63) 
1.8 Stability of Alcohol in Post-Mortem Blood 
Understanding the source and stability of common volatiles in blood is important 
when  interpreting  alcohol  results  to  help  distinguish  whether  alcohol  was 
endogenous  or  exogenous.  The  presence  of  alcohol  (ethanol)  in  post-mortem 
samples  can  result  from  the  ingestion  of  an  alcoholic  beverage  or  formation 
after death. The formation of ethanol may be due to physical contamination 
from embalming fluids or from microorganisms in the presence of an appropriate 
substrate  and  ideal  temperature  conditions.(78)  Another  source  of 
contamination  during  the  post-mortem  examination  could  result  from  a  blind 
external  chest  stick  via  cardiac  fluid  or  from  the  stomach  contents  in  cases 
where death occurred soon after alcohol consumption.(79) Ethanol formation in 
post-mortem blood has also been reported in the absence of a preservative in 
the collection vessel.(80) 
There is also the potential for loss or gain of alcohol from the specimen analyzed 
depending upon the time delay from sample collection to analysis. The loss of 
ethanol is due mainly to evaporation, enzyme-mediated oxidation, or as a result 
of the action of micro-organisms.(81;82) Many different microbes utilize ethanol 
as  a  substrate  for  metabolism.(81-83)  Loss  of  ethanol  was  reported  from 
unpreserved specimen containers that contained a high number of microbes and 
a large headspace.(84) Oxidation of ethanol to acetaldehyde is another factor 
affecting ethanol loss, as reported by Brown et al. (1973).(81) 
Dubowski et al. (1997) (85) found that alcohol loss was negligible in the presence 
of an azide, however, the azide-free specimen had losses of less than 5% over a 
one-year period and for that reason, researchers concluded that the use of azide Chapter 1    23 
is unnecessary. In another study, ethanol production increased as glucose levels 
increased, indicating that Candida albicans (C.albicans) produced ethanol from 
glucose especially in blood diluted by ante-mortem intravenous infusions that 
included glucose.(86) Loss of ethanol from preserved blood samples stored in the 
refrigerator  (ranging  from  13  to  39  months)  varied  in  25  samples  out  of  32 
samples,  the  most  significant  loss  was  0.015  g/dL  (15  mg/dL),  which  was 
observed in previously opened tubes compared to a mean loss of 0.010 g/dL in 
unopened tubes.(87)  
Sodium fluoride (NaF) is commonly used as a preservative for biological samples. 
The  fluoride  ions  prevent  the  formation  of  polysaccharides  by  the  microbes 
which  leads  to  the  prevention  of  microbial  growth.(88)  Although  NaF  inhibits 
most  organisms,  ethanol  production  in  the  presence  of  C.albicans  at  room 
temperature has been reported.(89;90) Other reports indicate that 1% NaF is 
efficient at inhibiting C.albicans in urine specimen.(88;91;92) The concentration 
of NaF as a preservative in the ethanol specimens varied from 0.25 to 1%. Two 
percent  NaF is  reasonable in combination  with a  low  temperature  and  might 
prevent alcohol degradation.(82) Sodium metabisulfite is used as a disinfectant, 
antioxidant, and preservative agent and has been used to prevent the oxidation 
of alcohol.(93) 
1.9 Analysis of Ethanol and Related Volatiles 
Ethanol is most commonly measured in breath by police officers at the road-side 
using a hand-held device and in blood or urine by scientists using large high-
throughput  immunoassay-based  analysers  or  headspace  gas  chromatography 
coupled with a flame ionisation detector (HS-GC-FID).  
Immunoassay-based  analysers  are  used  to  screen  large  numbers  of  samples 
quickly to identify presumptive positive samples and eliminate negative samples. 
These screening assays are used by laboratories offering workplace drug testing 
where the majority of samples will be negative. Positive samples required to be 
confirmed  by  HS-GC-FID.  Modern  forensic  toxicology  laboratories  offering 
analysis  of  medico-legal  casework  use  HS-GC-FID  systems  to  ensure  accurate, Chapter 1    24 
robust  and  legally-defensible  identification  and  quantification  of  ethanol  and 
related volatiles. (54;79;80;94;95) 
1.9.1 Headspace Gas Chromatography-Flame Ionization Detection 
(HS-GC-FID) 
Analysis of ethanol using HS-GC-FID (Figure 1-7) requires dilution of the sample 
with an aqueous solution of internal standard, mixed and allowed to equilibrate 
at approximately 50 to 60°C in an airtight glass vial with a rubber septa and 
crimp cap. The vapour of the diluted sample will be aspirated by the automated 
headspace  device  and  then  injected  onto  the  chromatographic  column.  In 
forensic  work,  it  is  advisable  to  use  dual  columns  made  from  two  different 
stationary phases especially with putrefied blood or tissue samples, as this will 
help reduce the risk of obtaining coincident retention times.(50)  
 
 
 
 
 
 
 
 
Figure 1-7:  Gas Chromatogram with Headspace Autosampler (GC-HS)  
 
Ionization of column eluent of the carrier gas and analyte molecules takes place 
where  the  hydrogen  and  air  flame  burns  in  the  flame  ionisation  detectors 
(FID’s).  There is a constant electrical potential between the electrodes in the 
detector and the gap between them acts as a variable resistance. As the analyte 
molecules  ionize,  the  resistance  decreases  and  more  current  flows.  This 
amplified current is the detector response. FID is known to be sensitive with 
broad applicability.(96)  Chapter 1    25 
1.9.2 Selection of a Suitable Internal Standard for Analysis of 
Volatiles  
The  use  of  n-propanol,  isobutanone,  butanone,  and  n-butanol  as  internal 
standards is not recommended, because these volatiles may be present in post-
mortem  blood.  Instead,  Acetonitile  was  recommended  in  literature  as  a 
promising compound to be used as an internal standard since it is not a product 
of microbial activity.(53) 
n-propanol is a major putrefaction product that is  not contained in alcoholic 
beverages or specimens from living subjects and could therefore be considered 
as  a  marker  for  post-mortem  ethanol  synthesis.(66)  n-propanol  is  present  in 
larger quantities because its production continues even when ethanol production 
has reached its maximum limit.(53)  Ethanol that is formed postmortem is more 
likely to be lower than 0.7 g/L (equivalent to 70 mg/dL) and, more commonly, is 
less  than  0.3  g/L  (equivalent  to  30  mg/dL).  (83)  The  ratio  of  ethanol  to  n-
propanol  concentration  has  been  used  to  confirm  postmortem  formation  of 
ethanol.(97)  
The presence of n-propanol in postmortem specimens renders it unsuitable as an 
internal standard when using HS-GC-FID for volatiles in post-mortem specimens 
but this does not apply to samples collected from the living.  
Isobutanol  is  present  in  bodies  recovered  from  water  and  has  been  also 
considered a good indicator of post-mortem ethanol production.(53) 
It has been reported by Kuhlman, et al.(1991), (98) and Schuberth (1991),(99) 
that butanone was not produced in specimens as a result of microbial activity 
and that it, together with methanol, should be considered indicative of either 
ante-mortem  exposure  (e.g.,  consumption  of  alcoholic  beverages)  or 
contamination (e.g., methanol is found in embalming fluid).(100) 
 According to Canfield et al. (1998)(54) 2,800 blood samples from pilot fatalities 
were  analysed  over  8  years  to  assess  levels  of  volatiles  related  to  aviation 
accidents.  An  evaluation  between  three  internal  standards  (propionaldehyde, 
propionic acid methyl ester, and t-butanol) was investigated and  t-butanol met Chapter 1    26 
the selection criteria, namely; the internal standard should not exist either in 
living or post-mortem samples; it should have similar properties to the analyte 
of interest; the retention time should be in the middle range of the retention 
time  of  the  analytes  being  separated;  and  it  should  be  separated  from  all 
components of the mixture.(54) 
 In addition, the standard deviation of replicate measurements of ethanol when 
using  t-butanol  as  internal  standard  was  better  than  n-propanol  and  the 
retention  time  for  t-butanol  was  in  the  middle  range  of  compounds  being 
separated,  while  n-propanol  was  not.  t-butanol  was  not  found  following 
examination of 2,880 post-mortem samples from pilot fatalities.(54) Chapter 1    27 
Table 1-4:  Published advantages and disadvantages of Different Internal Standards Used 
for the Analysis Volatiles by HC-GC-FID 
Internal Standards  Advantages  Disadvantages  Ref 
Methyl Ethyl Ketone 
Resolved from ethanol, acetone, 
methanol & other putrefactive 
volatiles. 
Used  with Carbowax  packed  
column,  No information 
provided about using it with 
GC capillary column 
(53;95) 
Acetonitrile 
Not a product of microbial 
activity- separated well using Rtx 
BAC1 or ALC1 capillary columns  
Not commonly use. 100% 
overlapping with acetone 
using Rtx-BAC2 and ALC2 
capillary columns 
) 53 (  
Propionaldehyde 
Considering internal standard 
criteria, it was selcted as a 
potential replacement fo n-
propanol 
Its retention time close to ethanol 
retention time  
Does not have acceptable base 
line separation for compounds 
commonly found post mortem 
(54) 
Propionic acid methyl 
ester 
Considering internal standard 
criteria , it was selcted as a 
potential replacement fo n-
propanol 
Its retention time close to ethanol 
retention time  
Not stable and decreases over 
time, affecting quantitation  (54) 
t-butanol  Meets the criteria of selection for 
suitable internal standards 
Concentration may decrease 
with increasing fat content.   (54;94) 
n-propanol  Can be separated from acetone 
Major putrefaction product 
and the retention time is not 
in the range of the analytes 
being separated. 
(53;66;79) 
Isobutanol 
Well separated from other 
volatiles using using Rtx-BAC2 
column  
Could  serve as a potential 
indicator of ethanol 
production (post mortem) 
(53;80) 
Methanol    Not produced in specimens as a 
result of microbial activity 
Could be indicative of either 
ante-mortem exposure or due 
to contamination from 
embalming fluid 
(98;99) 
 
Although t-butanol could be a suitable internal standard for volatile analysis, it 
has  been  reported  that  the  level  of  t-butanol  as  an  internal  standard  might 
decrease when the fat content of the sample analysed is increased.(94) Table 1-
4 summarises the advantages and disadvantages associated with using different 
internal standards for the analysis of volatiles. Chapter 1    28 
1.9.3 Analytical Considerations for Method Development 
(Volatiles) 
Before starting the process of developing a method for the analysis of volatiles 
in biological matrices, it is important to first establish the sensitivity and linear 
range required. Table 1-5 summarises the volatile concentrations reported in the 
literature from a range of cases where low levels of volatiles were measured 
through to high concentrations in volatile-related fatalities. These provide an 
indication  of  both  the  lower  limit  of  quantitation  (LLOQ)  and  upper  limit  of 
quantitation (ULOQ) for each volatile. 
For legal purposes it is highly recommended that all determinations of blood-
ethanol concentration are made in duplicate with a cut-off point of 10 mg/dL.  
Table 1-5:  Alcohol and Other Volatile Levels in Blood. 
Alcohol 
Name 
Endogenous 
blood level 
 
Toxic 
(Fatal) 
blood level 
(mg/dL) 
References 
 
Ethanol  0.04-0.1  mg/dL  80-100 
(>350)  (101;102) 
 
Methanol 
      <10  mg/dL 
 
20 
(>89 )  (101;102) 
(0.1-2.3)  mg/dL  Two fatalities (219, 196) 
 
(103) 
Acetone  Serum  2.3-3.5  mg/L 
Non-diabetic (n=218)  <10 mg/L    
20-30 
55  (55;102) 
Isopropanol  0.1 - 0.2   mg/kg  >40 
>150  (102;104) 
n-Propanol 
 
Post-mortem blood  3-7  mg/dL 
 
UK workplace exposure limit  
250ppm (625 mg/m
3)  (53;83;105) 
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1.10 Analytical Biomarkers of Alcohol Consumption  
1.10.1  Introduction 
Biological markers, or biomarkers, are parameters tested and measured in the 
blood, tissue or body fluids as indicators of biologic state and are commonly used 
for  diagnostic  testing  to  monitor  the  presence  of  disease  or  to  predict  the 
various  stages  of  disease  and  mortality.    Biomarkers  have  also  been  used  to 
detect  drug  or  alcohol  consumption.(106)  Biochemical  biomarkers  are  usually 
evaluated in terms of specificity and sensitivity and the ideal marker should be 
100% sensitive and specific but this has not as yet been achieved. (29) 
Alcohol  biomarkers  are  useful  as  indicators  of  chronic  and  acute  alcohol 
consumption, due to the fact that the time frame for a positive identification of 
ethanol is limited with ethanol concentrations decreasing rapidly over time.(107) 
Also, ethanol can be produced naturally at very low concentration as a result of 
yeast proliferation after carbohydrate-rich meals, with formation also occurring 
after sampling due to microbial contamination and fermentation.(108)  
The  three  major  classes  of  alcohol  biomedical  markers  include  “relapse 
markers” which are used in tests sensitive enough to detect even a single intake 
of  alcohol  such  as  ethanol,  methanol  or  5-  Hydroxytryptophol  (5HTOL).  The 
second  class  of  maker  are  called  “state  markers”  for  hazardous  alcohol 
consumption. This type of marker can indicate disturbed metabolic processes or 
malfunctioning body organs and tissue damage caused by long-term exposure to 
alcohol.  Examples  of  these  markers  include,  γ-Glutamyl  transferase  (GGT), 
aspartate (AST) and alanine aminotransferase (ALT), mean corpuscular volume 
(MCV) and carbohydrate-deficit transferring (CDT). “Trait markers” are used in 
tests that indicate whether or not a person has a genetic disposition for alcohol 
abuse, such as the monoamine oxidase (MAO) enzyme.(109) A lower activity of 
MAO in the blood platelets of alcoholics compared with those of control groups 
has been reported.
(110)  It is not only alcohol that may lower the activity of MAO 
as a separate study indicated that tobaco had the same effect on ethanol.(111)
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1.10.2  Markers of Acute and Chronic Alcohol Consumption 
In addition to ethanol, methanol and 5HTOL several biomarkers have been found 
in urine and blood that may indicate recent alcohol consumption. These include; 
acetaldehyde, acetate, the ratio of 5HTOL to 5-Hydroxyindole-3-acetic acid (5-
HTOL/5-HIAA) and the direct ethanol metabolites ethyl glucuronide (EtG) and 
ethyl sulphate (ETS).   
Acetaldehyde is present in low concentrations (<1%  of ethanol concentration) 
and rapidly converts to acetate. Additionally, its binding to various endogenous 
molecules such as protein in the peripheral venous blood will further reduce the 
concentration  of  free  acetaldehyde.(109)    In  the  presence  of  ethanol, 
acetaldehyde may be formed artificially even after sampling. Acetate appears to 
be independent of blood ethanol concentration and remains elevated as long as 
ethanol is being metabolised.(109;112)  
5-HTOL  and  5-HIAA  are  the  minor  and  major  metabolites  of  serotonin 
respectively,  5-HTOL  increases  in  urine  after  drinking  alcohol  and  it  is 
considered to be a marker for recent alcohol consumption. Results are expressed 
as the ratio of 5-HTOL/5-HIAA rather than the 5-HTOL/creatinine to compensate 
for variations in 5-HTOL concentrations caused by urine dilution and to eliminate 
a false positive of those two metabolites in urine due to dietary serotonin from 
food  known  to  produce  serrotinin  such  as  banana,  pineapple,  kiwi  fruit  and 
walnuts. The advantage of 5-HTOL/5-HIAA ratio over ethanol and methanol to 
detect recent drinking is that the serotonin metabolites can persist for several 
hours  longer.  The  disadvatages  are  that  5-HTOL/5-HIAA  ratio  can  be  also 
increased with treatment with aldehyde dehydrogenase (ALDH) inhibitors such as 
disulfiram and cyanamide.(109) Formation of ethanol in urine due to bacterial 
action may be a source of misinterpretation of the 5HTOH/5-HIAA ratio.(113) As 
much  as  80  %  of  5-HTOL  is  excreted  as  glucuronidated  5-hydroxytryptophol 
(GTOL)  which  offers  promising  results  in  the  detection  of  previous  alcohol 
consumption and can be determined by ELISA.(114)  
Less than 0.1% of ingested ethanol undergoes non-oxidative metabolism in the 
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ethyl-glucuronide and ethyl sulfate which are then excreted in urine.(47) Both 
ETG and ETS are considered to be indicators for acute ethanol ingestion.(109)  
The delayed elimination of EtG may lead to false positive results and in cases 
where the deceased died within a few hours of consuming alcohol, the positive 
detection of EtG may be due to a previous episode of drinking.(115)  Secondly, 
the  short  time  lag  between  the  time  ethanol  ingestion  took  place  and  the 
possible detection of EtG in blood, may also lead to false negative results.(115)  
In addition to the classic markers of chronic alcohol intake, namely; CDT, GGT 
and MCV(113), other markers of chronic alcohol consumption include, AST, ALT, 
phosphotidyl-ethanols  (PEth),  fatty  acid  ethyl  esters  (FAEEs)  and  β-
hydroxybutyrate (BHB). 
Carbohydrate–deficient transferring (CDT) is a reliable marker for the detection 
excessive alcohol consumption and refers to changes in the microheterogeneity 
of  the  iron  transport  glycoprotein  transferring  in  serum  after  contenious 
excessive prolonged alcohol consumption. (116) 
The main advantage of CDT, compared with other alcohol biomarkers,  is its high 
specificity for alcohol and the associated lower risk of a false  negative from 
heavy alcohol consumption.(109) Although CDT is able to identify heavy drinkers 
with a higher specificity than GGT, heavy drinkers can be detected only when 
daily alcohol consumption is greater than 60 g. (117) False positive results may 
be  found  for  individuals  with  non-alcoholic  related  diseases,  such  as  biliary 
cirrhosis, or chronic active hepatitis, and with rare defects such as glycoprotein 
defect.(106;109)  
The advantage of GGT, AST and ALT markers is availability with low associated 
costs in most clinical laboratories, however GGT is non-specific for alcohol 
misuse and its level may increase due to other pathological conditions. MCV 
indicates the size of red blood cells and it is a part of routine blood count test.  
An elevated MCV is often observed in alcoholic patients and has a higher 
specificity than GGT and can be used in combination with other biochemical 
parameters. Cell size may take several months to return to normal.(109)       Chapter 1    32 
 PEths  are  phosphatidylethanols  and  refer  to  a  group  of  abnormal  negatively 
charged  diacyl  phospholipids  formed  in  the  presence  of  ethanol  from  other 
naturally occuring phospholipids such as phosphatidylcholines. PEths are direct 
ethanol metabolites that may degrade depending on the storage of specimens.  
Blood samples that contain ethanol can be stored in the refrigerator for up to 72 
hours or frozen in liquid nitrogen and stored at -80ºC without affecting PEth 
levels.(118);(119);(120) Disadvantages associated with PEths are that they are 
impossible  to  analyse  in  clotted  post-mortem  blood  samples  and  can  also  be 
formed in the presence of ethanol.(121)  
FAEEs  have  been  analysed  in  meconium  and  hair  as  indicators  of  gestational 
alcohol exposure,(106) while both FAEEs and EtG have been measured in hair as 
markers for chronic alcohol consumption.(122)
  BHB is considered a potential 
marker of alcoholic ketoacidosis (AKA) and diabetic ketoacidosis (DKA). FAEE's 
and BHB will be discussed in more detail in the following sections.  
Tables  1-6  summarises  information  relating  to  the  many  types  of  acute  and 
chronic alcohol biomarkers, the matrices they are measured in and the detection 
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Table 1-6:  Acute and Chronic Alcohol Biomarkers. 
Alcohol   
Biomarkers  Matrix  Markers of 
Acute/Chronic  Detection time (hours) 
Ethanol  Blood,serum, Plasma ,Urine, 
Saliva, sweat and Breath  Acute   1-2( Depends on dose) 
Methanol  Blood,serum, Plasma ,Urine, 
Saliva, sweat and  Acute   2-3 
Acetaldehyde  Blood  Acute   -* 
Acetate  Blood  Acute   -* 
EtG and EtS  Urine, serum, Hair, Vitreous 
Humor ,bone marrow,  Acute  
EtG in urine was 
elevated 24-48 hours 
after ingestion. 
5-HTOL/5-HIAA  Urine  Acute   Longer that ethanol and 
methanol.(113) 
GTOL  Urine  Acute   -* 
CDT  Serum  Chronic  Over 1.5-2 weeks(109) 
GGT,AST and ALT  Serum, Blood  Chronic  -* 
MCV  Blood  Chronic  -* 
Phosphotidylethanols 
(PEth)  Blood  Chronic  14 days after sustained 
ethanol intake.(123) 
Fatty Acid Ethyl Esters 
(FAEEs)  Serum, Hair and meconium  Chronic 
Decrease within 29 
hours, and can be 
detectable for long time 
after intake. (124) 
β-Hydroxybutyrate 
(BHB). 
Serum,Postmortem Blood , 
Urine  Chronic  -* 
Proteomics  Blood,serum, Plasma  Chronic  -* 
*Detection time not documented Chapter 1    34 
1.11 β β β β-Hydroxybutyrate (BHB)  
BHB is considered a potential marker of alcoholic ketoacidosis (AKA), (125-128)  
a metabolic disturbance resulting from prolonged consumption of alcohol.  AKA 
is  attributed  to  the  combined  effects  of  alcohol  and  starvation  in  glucose 
metabolism. Alcohol blocks the hepatic gluconeogenesis which prevents glucose 
production,  increases  lipolysis,  and  fatty  acid  metabolism  and  results  in  the 
formation of ketone bodies as summarised in Figure 1-8.(129)  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8:  Formation of Ketone Bodies 
[Reproduced from Iten&Meier (127) and Umpierrez, et al.(130)] 
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The accumulation of ketone acids reduces the pH of the body and results in 
ketoacidosis.  The  most  common  ketone  bodies  produced  in  the  body  are 
acetone, acetoacetate and β-hydroxybutyrate. 
In  many  alcohol-related  sudden  death  cases,  the  pathologist  is  unable  to 
determine the cause of death with little findings of note at autopsy (other than 
a  severely  enlarged  fatty  liver)  and  no  indications  of  the  cause  of  death 
following routine histological, microbiological and toxicological investigations. In 
some  cases  the only positive  findings,  other  than a  fatty  liver,  are  traces  of 
ethanol in the blood and elevated acetone levels.(131) It is commonly believed 
that alcoholic cases of unexpected sudden death with no indication of the cause 
of death may be due to AKA.(108)
  
BHB is the analyte of choice among other ketone bodies when investigating AKA 
because BHB concentrations are higher (approximately two-thirds of all ketone 
bodies in healthy persons) compared with acetoacetate and acetone. There is a 
close association with the increase in NADH:NAD
+ and BHB. According to Iten et 
al.(127) there is no indication of BHB formation during storage or degradation in 
blood in vitro or in the corpse.(127)
 Acetone is neutral and does not contribute 
to an acidosis, and both acetoacetate and acetone are unstable in the blood. 
The production of volatile compounds due to putrefaction may interfere with 
acetone analysis. (55;127)  
In contrast diabetic ketoacidosis (DKA) is a metabolic acidosis associated with 
type 1 diabetes and is related to insulin deficiency. Insulin controls the level of 
glucose in the body coupled with an increase in glucagon levels and produces 
maximum  gluconeogenesis.  This  leads  to  severe  hyperglycaemia  and 
accumulation of ketone bodies due to the enhanced metabolism of free fatty 
acids  that  are  librated  from  peripheral  adipose  tissue  and  may  end  with 
ketoacidosis.(129),(125)
  Both  DKA  and  AKA  are  common  medical  emergencies 
and are life threatening if they are not treated promptly.(130)  
Diabetic alcoholics may present with AKA; however, this distinction is difficult, 
particularly when the blood glucose level is moderately or mildly elevated. In Chapter 1    36 
cases of starvation, ketosis alone usually causes a mild ketoacidosis, and the 
clinical presentation of AKA might distinguish it from starvation ketosis.(132)  
Umpierrez  et  al.(130)
  concluded  that  differentiation  between  DKA  and  AKA 
should  be  based  on  the  history  of  diabetes  or  alcoholism  and  on  the  blood 
glucose level at admission. The clinical diagnosis with AKA and DKA are similar; 
and  they  are  both  associated  with  vomiting,  nausea,  abdominal  pain, 
dehydration,  Kussmaul  breathing  (slow  deep  respiration  associated  with 
acidosis),  and  coma.  A  summary  of  the  differences  between  AKA  and  DKA  is 
shown in Table 1-7.  
Table 1-7:  Main Differences Between AKA and DKA.(55;130)  
DKA   AKA  
Glucose level ( Hyperglycaemia) 
 578± 67 mg/dL  
Glucose level ( Hypoglycaemia)  
118 ± 11 mg/dL 
BHB/Acetoacetate Ratio 3:1  BHB/Acetoacetate Ratio 7:1 
Lactate/Pyruvate Ratio 11:1  Lactate/Pyruvate Ratio 19:1 
Glycated Haemoglobin (HbA1) 5-13%  Glycated Haemoglobin (HbA1) <5.6% 
 
Low or absent blood ethanol along with elevated levels of acetone do not in 
themselves determine the cause of death, but these  findings, in combination 
with a history of chronic alcohol abuse, suggest alcoholic ketoacidosis. 
The concentration of acetone in the blood could be considered as a indicator of 
the development or severity of AKA. Acetone blood levels can increase due to 
intoxication from barbiturates or alcohol, diabetes and hypothermia, metabolic 
ketoacidosis, and isopropanol intoxication. Isopropanol is rapidly oxidized to 
acetone, which can be measured for several days after isopropanol intoxication, 
while the isopropanol will disappear much earlier. Normal values in the serum of 
a living person range from 2.3-3.5 mg/L. In deaths due to diabetic coma the 
acetone level ranges from 16-864 mg/L with most values between 300-400 mg/L. 
(55) In non-diabetic controls acetone values are <10 mg/L. Out of 24 chronic Chapter 1    37 
alcoholic cases, nine had acetone levels  ranging from 74-400 mg/L with a mean 
value of 183 mg/L. (55)  
It is generally believed that, in cases of alcoholic ketoacidosis, ethanol is low 
(<10 mg/dL) or absent, the absence of acetone does not preclude ketoacidosis; 
rather, it means that BHB still needs to be measured. Normal levels in post-
mortem  blood  were  reported  as  less  than  52  mg/L,  elevated  to  toxic  levels 
ranged from 52 – 260 mg/L, while levels exceeding 260 mg/L are considered 
pathologically  significant.(127)    Other  studies  measured  BHB  in  urine  and 
vitreous humour from a range of cases including individuals who were known to 
be alcoholics or diabetics and are summarised in table 1-8. 
Table 1-8:  Levels of BHB Measured in post-mortem Blood, Urine and Vitreous Humour from 
a Range of Case Types. 
Category 
Blood 
(mg/L) 
Urine 
(mg/L) 
Vitreous Humour 
(mg/L)  N  Ref. 
Elevated/Toxic  52-260  N/A  N/A  25 
(127)  Fatal  >260  N/A  N/A  25 
Control Group  <52  N/A  N/A  69 
Alcoholics with unknown 
cause of death 
N/A 
267 - 850  106 - 850  6 
(133)  Alcoholics with known 
cause of death 
N/A 
20 - 2000  0 - 850  6 
Control group  N/A  <100  <100  36 
Normal  N/A  8.5 - 34.7  N/A  30 
(134) 
Diabetic  N/A  4.9 - 4520  N/A  20 
 
Analysis of ketone bodies in both AKA and DKA may provide analytical evidence 
to  support  clinical  diagnosis  and  may  possibly  provide  information  about  the 
cause  of  death  in  the  absence  of  other  pathologically  significant 
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1.11.1  Analysis of BHB in Biological Matrices 
The  small  polar  nature  of  BHB  and  compounds  of  similar  structure,  such  as 
gamma-hydroxybutyrate  (GHB),  make  the  chromatographic  and 
spectrophotometric analysis of this compound complicated. The presence of two 
hydroxyl groups in the structure of BHB makes it suitable for silyl derivatization 
as illustrated in Figure 1-9.  
 
Figure 1-9:  BHB and BHB-TMS-Derivative 
 
Table  1-9  summarises  published  methods  where  BHB  and  related  compounds 
were measured in biological matrices.  
The  majority  of  the  methods  utilised  gas  chromatography-mass  spectrometry 
with  electron  ionization  detection  (GC/MS-EI)  with  full  scan  mode  for  ion 
identification. Separation was carried out for most of the GC/MS methods with 
similar  types  of  capillary  column  and  using  deuterated  internal  standards  for 
quantification. This combination provides greater specificity and accuracy unlike 
the methods utilising UV spectrometry. Head space-GC/MS has been also used 
for BHB determination however this involves many steps for sample preparation 
and involves conversion of BHB to acetone and a long incubation time. Ideally a 
wide linear range is preferable to eliminate additional work required to dilute 
and  re-analyse  the  higher concentrations  found  in  post  mortem  samples  with 
confirmed AKA or DKA, however only a few methods have a linear range up to 
500 mg/L.   
1.11.2  Gas Chromatography/Mass Spectrometry (GC/MS) 
Gas  chromatography  uses  a  gaseous  mobile  phase  to  transport  the  sample 
components through a packed column.  Chapter 1    39 
Before analysis of the analytes of interest by mass spectrometry, they must be 
converted  into  gas  phase  ions.  Derivatization,  which  changes  the  chemical 
properties of the analytes of interest, is normally used to increase volatilization 
and ionization to promote chromatography, improve peak shape, and increase 
sensitivity and specificity. Analytes of interest are separated from the compound 
mixture  by  gas  chromatography.    The  most  common  ionization  techniques  in 
GC/MS are electron impact (EI) (figure 1-10) and chemical ionization (CI). 
 
Figure 1-10:  Electron impact ionization.  
 
In  electron  impact  (EI),  the  parent  molecules  usually  enter  the  ionization 
chamber in the mass spectrometer ion source and are impacted by an electron 
beam of high energy around 70eV which is enough to ionize the molecules. This 
leads  to  the  formation  of  positive,  negative,  and  neutral  molecular 
fragments.The  fragments  (usually  positive)  are  introduced  to  the  mass 
quadropole analyser to filter masses and to monitor ions by either scanning them 
in full scan, a selected m/z ratio range, a type of acquisition usually used for 
qualitative analysis or by selected ion(s) monitoring (SIM), a type of ionization 
known to be sensitive and specific. SIM is a scan mode used for quantification. 
(96;136)  
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1.12 Fatty Acid Ethyl Esters (FAEEs) 
FAEEs are non-oxidative products of ethanol metabolism and are formed by the 
esterification of ethanol with free endogenous fatty acids and acyl-CoA/fatty 
acids. These reactions are catalyzed by the two enzymes FAEEs synthase and 
acyl/CoA/ethanol  O-acyl-transferase.(142-145)  After  being  synthesized  in  the 
liver and the pancreas, FAEEs are transported through the blood, while bound to 
lipoprotein  and  albumin  and  to  the  adipose  tissue.(146)  FAEEs  persist  in  the 
blood for approximately 24 hours after ethanol intake has ceased.(147) Figure 1-
11  illustrates  the  structure  of  common  FAEEs  and  deuterated  analogues 
commercially  available  to  purchase  as  analytical  standards.    A  shorter 
alternative nomenclature is commonly used for FAEEs, including one letter and 
two  numbers  separated  by  a  colon.  This  corresponds  tothe  chain  length  and 
number of double bonds: for example;  ethyl oleate is (E18:1), with 18 being the 
number of carbons and the number 1 being the number of  double bonds.(148)  
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Figure 1-11:  FAEES and D5-FAEES Structures 
 
Ethyl Laurate (E12:0)   Ethyl Linoleate (E18:2) 
Ethyl Myristate (E14:0)   Ethyl Linolenate (E18:3) 
Ethyl Palmitate (E16:0)  Ethyl Arachidonate (E20:4) 
Ethyl Palmitoleate (E16:1)     Deuterated Ethyl Palmitate 
Ethyl Stearate (E18:0)  Deuterated Ethyl Stearate 
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1.12.1  Sample Selection for the Analysis of FAEEs 
FAEEs can be analysed in variety of biological samples such as blood, plasma, 
hair  and  meconium.  FAEEs  in  serum  correlate  well  with  blood  alcohol 
concentrations  (BAC)  and  start  to  decrease  within  2  hours  after  ethanol 
administration has stopped.(146)  FAEEs persist in the blood for approximately 
24 hours after ethanol intake.(147)  
In  patients  with  a  positive  BAC,  ethyl  palmitate  (E16:0)  was  detected  in  all 
plasma  samples.  Ethyl  stearate  (E18:0)  was  detected  in  49%  of  the  patients, 
ethyl oleate (E18:1) in 64%, ethyl linoleate (E18:2) in 13% and ethyl arachidonate 
(E20:4) was found in only 5% of patients. FAEEs were not detected in the control 
group who screened positive for ethanol.(149) 
According to Borucki et al.(124), FAEEs in serum decrease rapidly within 29 hours 
following ethanol intake; then they stabilize at values ranging from 0.007–0.025 
mg/L with no further decrease and remain detectable for long periods of time 
after intake. FAEEs take time to be released from the storage in adipose tissues, 
thus,  FAEE  determination  in  serum  is  limited  to  detecting  recent  ethanol 
consumption. 
It  has  been  observed  that  the  total  FAEE  concentration  of  ethyl  palmitate 
(E16:0), ethyl stearate (E18:0), ethyl oleate (E18:1), and ethyl linoleate (E18:2) 
in  the  plasma  of  patients  with  a  history  of  chronic  ethanol  abuse  was 
significantly higher than in patients with a history of acute ethanol abuse.(149)  
Refaai et al.(150) found good correlation between BAC and FAEEs in the liver 
and between BAC and fat. Ethyl arachidonate (E20:4) is thought to be a highly 
specific  marker  of  premortem  alcohol  ingestion,  and  has  been  detected  at 
concentrations greater than 0.066mg/kg in individuals with a positive BAC. 
When ingested, FAEEs are rapidly hydrolysed in the duodenum but remain intact 
in the stomach; therefore, FAEEs may reach the bloodstream after absorption 
from the stomach.(151) It was concluded that kinetics of FAEEs are different in 
heavy drinkers compared with healthy subjects and that FAEEs are of limited 
value for the detection of a prior single ethanol intake.(124)  Chapter 1     43 
Meconium  is  a  complex  composition  of  greenish  mucus  material  excreted  by 
newborns  approximately  2–3  three  days  after  birth  (may  be  delayed  in 
premature infants). The advantage of meconium is that the collection is easy 
and  non-invasive  and  it  is  a  cumulative  matrix  in  which  xenobiotics  and 
endogenous substances accumulate from the 13th week of gestation till birth, 
providing a wider window for detection of long-term exposure.(28) All samples 
must be stored immediately after collection in the freezer. 
Although it has been shown that FAEEs do not cross the human placenta unlike 
ethanol, FAEEs can be produced in vivo in the human placenta.(28)  
In a study by Chan et al. 2004, approximately 14% of meconium samples (N=142) 
tested  positive  for  prenatal  alcohol  exposure  with  a  level  greater  than  2.0 
nmol/g,  equivalent  to  between  458-666  ng/g  of  corresponding  FAEEs.  Ethyl 
oleate, linoleate, palmitate, and arachidonate were detected most often and at 
the  highest  levels.  In  95%  of  positive  samples,  a  minimum  of  3  FAEEs  were 
detected.(27)  A  high  correlation  was  found  between  FAEEs  in  meconium 
collected from 124 infants and maternal ethanol. It has also been reported that 
ethyl linoleate (E18:2) and ethyl arachidonate (E20:4) are biomarkers with high 
specificity  for  detecting  prenatal  alcohol  exposure.  Ethyl  arachidonate  levels 
were  significantly  higher  in  the  alcohol-exposed  groups  than  in  the  control 
groups.(152)  
In a separate study, 17 of 682 meconium samples tested positive for significant 
prenatal ethanol exposure (>2.0 nmol/g). The 95% confidence interval of FAEEs 
results  that  were  less  than  the  cut-off  was  0.38–0.49  nmol/g  [87-163  ng/g] 
versus  those  that  were  positive  and  greater  than  the  cut-off  which  ranging 
between 7.74–151.28 nmol/g [1772-50376 ng/g].   
Meconium  FAEEs  analysis  demonstrates  a  fivefold  increase  in  sensitivity  over 
self-report–based  screening  methods  for  the  detection  of  ethanol-exposed 
pregnancies in a clinical setting.(152)  
The  total  FAEEs  in  the  study  carried  out  by  Moore  et  al.  2003  (153)  was  an 
accumulation  of  7  FAEE  concentrations  not  including  ethyl  laurate  and  ethyl Chapter 1     44 
myristate.  Cumulative  FAEE  acid  concentration  greater  than  10,000ng/g  may 
indicate that the newborn has been exposed to significant amounts of ethanol 
during  the  pregnancy.  The  presence  of  laurate  and  myristate  ethyl  esters  in 
meconium is considered non-specific.(153)  
Ethyl linoleate (E18:2) was positive in a meconium specimen of a neonate whose 
mother admitted to an intake of at least 10 drinks  per week during the last 
month of gestation. It was also reported in negative cases where the mother had 
less than 3 drinks per week. Ethyl oleate (E18:1) is the most prevalent individual 
ester in meconium, followed by ethyl palmitate (E16:0) and ethyl palmitoleate 
(E16:1);  whereas  ethyl  laurate  (E12:0)  and  ethyl  myristate  (E14:0)  were  also 
detected in alcohol-free mothers.(154) 
In addition  It has been reported that ethyl linoleate (E18:2) is the best marker 
of foetal alcohol spectrum disorder FASD.(155)  
Maternal  FAEEs  in  hair  has  also  been  recommended  as  an  alternative  to 
meconium. The reason behind this is due to the additional cost of developing an 
effective  meconium  assay  with  the  limitation  of  providing  information  on 
maternal drinking only after childbirth, and even then only for the latter two 
trimesters. Also, other research is on-going on a range of other biomarkers, such 
as potential proteomic and metabolic marker.(26)   
1.12.2  Analysis of FAEEs in Biological Matrices 
Kulig et al.(156) utilised GC-MS with a nonpolar dimethylpolysiloxane column to 
analyse  FAEEs  in  plasma.  FAEEs  analysis  methodology  includes  acetone 
precipitation and extraction with hexane, using amino propyl silica solid phase 
extraction. These methods have been shown to have high sensitivity, specificity 
and accuracy (156) 
The internal standard used was either ethyl heptadecanoate (for several studies 
carried out using LC/MS/MS), or in-house prepared deuterated FAEE standards 
with  other  analytical  techniques  such  as  headspace-gas  chromatography  mass 
spectrometry (HS-GC/MS) coupled with or without solid-phase microextraction. 
The methods showed high sensitivity, specificity, and accuracy.(157-159)  Chapter 1     45 
The recommended method to be used for FAEEs determination by the Society of 
Hair  Testing  (SOHT)  is  head  space  (HS)-solid-phase  microextraction  (SPME)  in 
combination with GC/MS with a deuterated internal standard.(160)  
Table 1-10 is a summary of the advantages and disadvantages of using different 
techniques for determining the FAEEs in different matrices. 
Table 1-10:  The Difference of the Techniques Used for the Determination of FAEEs in 
Biological Samples  
Techniques  Advantage  Disadvantage 
LC/MS/MS   High specificity  Many sample preparation steps 
Sensitive  High solvent volume used  
Same  chromatographic  method 
column can be used to detect opiates, 
cocaine, and FAEEs in meconium 
Large sample size  
HS-SPME-GC-MS   Eliminating  the  need  for  the  organic 
solvent 
Needs  optimization  of  the  HS-
SPE 
Minimal sample preparation  Equal  or  less  specificity  than 
LC/MS/MS 
Obtaining  clean  extract  less  matrix 
effect 
Require small amount of sample 
Using  deuterated  internal  standard 
improve the accuracy, sensitivity  
Ideal for routine analysis. 
GC/MS   Alternative  method  when  no 
LC/MS/MS or HS-SPME available in the 
laboratory 
Using  CI  is  better  than  EI  mode 
because EI yields identical fragments 
for various FAEEs  
Less  specific  than  LC/MS/MS 
and  less  sensitive  than 
LC/MS/MS and HS-SPME method  
GC-FID   Can be used as screening method 
 
Not specific  
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Most techniques used deuterated FAEEs-D5 internal standards prepared in-house 
with  HS-SPME-GCMS  instruments  for  analysis  of  FAEEs  in  hair  and  meconium. 
Only  recently  did  four  deuterated  internal  standards  become  commercially 
available  to  purchase,  namely;  ethyl  myristate-D5,  ethyl  palmitate-D5,  ethyl 
oleate-D5 and ethyl stearate-D5.  Although HS-SPME-GCMS has more advantages 
as previously indicated in Table 1-10, and is recommended by Society of Hair 
Testing  for  use  when  analysing  FAEEs  in  hair,  it  has  also  been  used  for  the 
analysis of FAEEs in meconium. Only two LC-MS/MS methods have been published 
for the analysis of FAEEs in meconium and both used a non-deuterated internal 
standard (ethyl heptanoate) as listed in Table 1-11. A summary table of all of 
the  different  techniques  used  to  analyse  FAEEs  in  different  matrices  can  be 
found in Appendix 1-1. 
1.12.3  Liquid  Chromatography  Tandem  Mass  Spectrometry 
(LC/MS/MS) 
A  triple  quadropole  LC/MS/MS  consists  of  an  HPLC  coupled  with  a  triple 
quadropole  mass  spectrometry.  HPLC  uses  a  suitable  liquid  mobile  phase  to 
transport the sample through a column packed with stationary phase material. 
A  triple  quadrupole  mass  spectrometer  (QQQ)  consists  of  two  mass  analysers 
(MS1 and MS2) separated by a collision cell arranged in series. The first mass 
analyser  allows  only  the  ions  of  interest  (precursor  or  parent  ions)  to  pass 
through, the ions enter the collision cell where fragmentation takes place and 
produces  product  or  daughter  ions  which  are  analyzed  in  the  second  mass 
analyser (third quadrupole) and detected by the mass detector using specialist 
software  for  analysing  and  processing  the  data  for  quantification  and 
identification Figure 1-12.(161;162)   
Five scan modes can be used in the triple quadrupole mass analyser. The product 
ion scan to detect all fragments produced by a single precursor, the precursor 
ion scan to detect all precursors producing a common fragment ion, neutral loss 
scan to detect all precursors undergoing a loss of a common neutral moiety, the 
single reaction monitoring (SRM) to detect a specific fragment ion produced from Chapter 1    48 
a  single  precursor,  and  the  multiple  reaction  monitoring  (MRM)  to  detect 
multiple specific fragment ions produced from a single precursor. Both SRM and 
MRM  are  the  most  scan  mode  used  in  LC/MS/MS  for  identification  and 
quantification. (161;162) 
 
 
 
 
 
 
Figure 1-12:  Illustration of Triple Quadrupole Mass Spectrometry. 
This figure has been modified and redrawn(161)  
The most common atmospheric pressure ionization techniques (API) in LC/MS/MS 
are  electrospray  ionization  (ESI),  atmospheric  pressure  chemical  ionization 
(APCI)  and  atmospheric  pressure  photo  ionization  (APPI).  Both  ESI  and  APCI 
provide high sensitivity and specificity for a wide range of analytes(163) 
Electrospray ionization (ESI) is an ionization process whereby ions are formed 
from  liquid  phase  droplets  when  sprayed  through  a  small  tube  into  a  strong 
electrical  field in the  presence  of  a  flow of  warm  gas  (nitrogen)  to assist  in 
formation of ions Figure 1-13. As the solvent vaporizes, the droplets disappear, 
leaving highly charged analyte molecules. Nebulisation, desolvation and further 
evaporation are three important steps for transferring sample molecules from a 
liquid to gas phase in the presence of a flow of warm gas (nitrogen) to assist in 
the formation of ions (162;163).  
The first step is nebulisation and charging the sample nebulises through a needle 
at  ground  potential  surrounded  with  electrodes  with  a  high  voltage.  The 
potential difference between the nebuliser and the electrode produces a strong 
Electro-
Spray  
Ion 
Bridge 
Q1 
(MS1) 
Q2 
Collision 
Cell 
Q3 
(MS2) 
Detector  Data Analysis Chapter 1    49 
electric  field  that  charges  the  surface  of the  sample  droplets. In  the  second 
step, desolvation occurs by shrinking the charged droplets with a flow of heated 
drying nitrogen. The uncharged material will be carried out of the system. Ion 
evaporation further shrinks the droplets until the analyte ions are desorbed into 
a gas phase and then passed through the sample capillary into a low pressure 
region of the ion source on the mass analysed. (162;163) 
 
(A) 
 
(B) 
Figure 1-13:  Electrospray Ionization (ESI) (A) and (B).  
"(A) This media is in public domain Permission is granted (164)" 
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1.13 Aims and Objectives: 
From  the  literature  it  is  clear  that  there  are  many  variables  that  must  be 
considered when interpreting the presence of volatiles and alcohol biomarkers in 
medico-legal  investigations.  A  better  understanding  of  the  stability  of  these 
analytes  in  samples  collected  from  the  living  and  at  post-mortem,  and  an 
evaluation  of  their  prevalence  in  different  matrices  will  greatly  aid 
interpretation. The aims of this study and how they will be achieved are listed 
below: 
1.  To  investigate  the  prevalence  of  ethanol  and  other  volatiles  (methanol, 
acetone, isopropanol and n-propanol) in different matrices by: 
•  Developing a dual-column HS-GC-FID method for the determination of 
ethanol and other volatiles in different biological matrices, involving 
the  optimisation  of  GC  conditions  and  the  selection  of  a  suitable 
internal standard; 
•  Validating the developed method in accordance with ISO/IEC 17025; 
•  Selecting  and  analysing  post-mortem  cases  where  femoral  blood, 
urine, vitreous humour and bile samples are available to investigate 
the presence of volatiles in these matrices.  
2.  To investigation the stability of volatiles in blood under different conditions 
(temperature and preservative) by: 
•  Analysing  blank  (volatile-free)  blood  spiked  at  different  volatile 
concentrations,  with  or  without  preservative  following  storage  at 
room temperature, in a refrigerator and a freezer;   
•  Analysing preserved blood samples collected from individuals arrested 
under section 5 of the Road Traffic Act (1988) after storage at room 
temperature for a time span ranging from 1-5 years; Chapter 1    51 
•  Analysing  paired  preserved  and  unpreserved  postmortem  blood 
samples following storage in the refrigerator and freezer. 
3.  To investigate the role of beta-hydroxybutyrate (BHB) in diagnosing alcoholic 
ketoacidosis by:  
•  Developing and validating a GC-MS method for the determination of 
BHB in blood in accordance with ISO/IEC 17025;  
•  Quantifying  BHB  concentrations  in  postmortem  blood  samples  and 
comparing  these  findings  with  case  histories  and  incidence  of 
alcoholic ketoacidosis (AKA);  
•  Collating  all  cases  on  the  Forensic  Medicine  and  Science  in-house 
database  (GUFM)  that  have  been  analysed  for  BHB,  ethanol  and 
acetone  and  evaluate  the  relationship  between  these  analytes,  the 
case history, the cause of death and the potential role of AKA. 
4.  To investigate the role of fatty acid ethyl esters (FAEEs) as an indicator of 
foetal alcohol exposure by: 
•  Developing and validating an LC-MS-MS method for the determination 
of  FAEEs in accordance with ISO/IEC 17025;  
•  Analysing meconium samples collected from babies born to mothers 
(some of whom were on a methadone maintenance programme) at the 
Princess Royal Maternity Hospital, Glasgow. 52 
Chapter 2 - Evaluation of Common Volatiles in Post-
Mortem Blood by HS-GC-FID 
2.1 Introduction 
Use of a dual-column system is advisable in forensic casework especially when 
analysing highly putrefied samples. This involves using two columns with different 
stationary phases, providing two sets of data and reducing the number of false 
positive results due to other post-mortem volatiles that may be eluting at the 
same  retention  time  as  the  target  analytes.(50)  In  addition,  many  forensic 
toxicology  laboratories  also  offer  blood  alcohol  analysis  for  road  traffic  cases 
where accuracy and precision are of higher importance than issues relating to co-
elution of volatiles. A summary of published methods for the analysis of volatiles 
in biological matrices is summarised in Appendix 2-1. 
The main aim of this study was to optimise the current FMS in-house method for 
the determination of ethanol, acetone, isopropanol, methanol and n-propanol in 
blood  and  other  body  fluids.  Method  development  was  achieved  by  improving 
separation of the volatiles through use of different temperature programmes; to 
evaluate use of two different internal standards (n-propanol and t-butanol) and 
different  capillary  column  stationary  phases.  The  developed  method  was 
validated and applied to the analysis of real case samples.  
2.2 Materials and Methods 
2.2.1 Statistical methods  
Excel  Windows  2003  data  analysis  was  used  to  calculate  average,  median, 
standard deviations and regression. The chart wizard was also used for drawing 
histograms, pie charts and bar charts. Minitab software manufactured by Minitab, 
Inc.USA,  version  15.1.2  and  15.1.3  and  Minitab16  were  obtained  from  the 
University of Glasgow Computing Services. Various statistical tests were used in 
this thesis including paired–t test, regression and correlation calculations, scatter 
plot and bestfit line plots.  Chapter 2    53 
The P value was also calculated to decide whether there is a significance 
difference between measured and standard amounts.  A statistical test known as 
the significance test can be employed by testing the truth of the hypothesis that 
is known as null hypohesis (H0). The term null is used to imply that there is no 
difference between two sets of data under test. If null hypothesis is rejected the 
difference between the two sets of data is real. Usually the null hypothesis is 
rejected when the probability of difference is less that 1 in 20 (i.e. 0.05 or 5%) in 
such cases the difference is said to be significant at 0.05 (or 5%) level. (165) The 
criteria used to assess the null hypothesis in normally distributed data: 
Calculated value<Tabulated value          Accept null hypotheis 
Calculated value ≥ Tabulated value        Reject null hypothesis 
 
The tabulated t value can be found in t distribution tables in statistics books.  
Calculated value can be calculated manually as following: 
 
In order to decide whether the difference between   (sample mean) and µ (true 
value or population mean) is significant to test the H0. The statistic t is 
calculated, where s= sample standard deviation and n=sample size  
 
In order to decide whether the difference between two sample means  1 and  2 
is significant to test H0: µ1= µ2.  The statistic t is calculated  
 
 
 
 
Paired t tests are used to test whether n paired results are drawn from the same 
population, that is H0: µd= 0, The statistic t is calculated. Paired t-test compare if 
there is a significant difference between the results obtained by two methods. 
The  D and SD indicate the mean and standard deviation respectively of D, the 
difference between paired values.  
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2.2.2 Chemicals and Reagents 
Ethanol 99.9% was purchased from Joseph Mills (Denaturants) Limited, Liverpool, 
methanol 99.8% from Sigma Aldrich, acetone 99.9% and n-propanol from BDH-VWR 
International, isopropanol and acetonitrile (HPLC grade) from VWR-PROLAB-BDH 
and t-butanol 99.8% (GC) from Fluka. Sodium chloride (NaCl) was purchased from 
BDH Chemical Ltd (Poole, England). Double distilled water was obtained from the 
in-house Millipore system. 
2.2.3 Preparation of Blank (Volatile-Free) Blood 
Expired packed red blood cell pouches were obtained from the Blood Bank at the 
Western  Infirmary  Hospital,  Glasgow  to  be  used  for  preparing  quality  control 
samples. The red blood cells were collected according to the United Kingdom 
Blood Services guidelines,(166;167) and were frozen on receipt within Forensic 
Medicine and Science (FMS). The volume of packed red blood cells was measured 
once fully defrosted and diluted 1:1 with 1% saline solution, which was prepared 
by adding 9.5g sodium chloride into a volumetric flask and dissolving in 1 litre of 
deionized water. 
2.2.4 Preparation of Working Standards and Quality Controls 
Internal standard working solutions were prepared for n-propanol and t-butanol 
at concentrations of 33 and 40 mg/dL respectively by preparing a 10 g/dL w/v 
standard of each and then by adding 3.3 and 4 mL to 1 litre of deionised water, 
respectively. Separate mixed volatile working standard solutions were prepared 
for  use  with  each  internal  standard,  both  internal  standards  stored  at  room 
temperature for 1 month. 
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Table 2-1:  Preparation of Mixed Working Standard Solutions 
    Method 1  Method 2 
Analyte  Final 
Concentration 
Volume from Stock (10g/dL) 
in 100 mL water 
Ethanol  500 mg/dL  5  5 
Methanol  500 mg/dL  5  5 
Isopropanol  500 mg/dL  5  5 
Acetone  500 mg/L  0.5  5 
n-Propanol  500 mg/dL  N/A  5 
 
Preparation of mixed volatile working standard for use with n-propanol: These 
solutions were prepared from stock standards (each at a concentration of 10 g/dL 
w/v) to contain 500 mg/dL of ethanol, isopropanol and methanol and 500 mg/L of 
acetone as summarised in Table 2-1 below. The calibration solutions were diluted 
from  the  freshly  prepared  working  standard  with  deionized  water.  The  final 
concentration of the calibration solutions were 10, 25, 50, 80, 100, 200, 300, 400, 
and 500 mg/dL for ethanol, isopropanol and methanol and the equivalent mg/L 
for acetone. The preparation of these calibration solutions is summarised in Table 
2-2.  
Table 2-2:  Preparation of Calibration Standards  
 
 
 
 
 
 
 
Calibrator 
Levels 
Volume of  
working 
standards (mL) 
Volume of 
Water 
(mL) 
[Analytes] 
(mg/dL) 
[Acetone] 
(mg/L) 
BLANK  0  2  0  0 
LEVEL 1  0.02  1.98  5  5 
LEVEL 2  0.04  1.96  10  10 
LEVEL 3  0.1  1.9  25  25 
LEVEL 4  0.2  1.8  50  50 
LEVEL 5  0.32  1.7  80  80 
LEVEL 6  0.4  1.6  100  100 
LEVEL 7  0.8  1.2  200  200 
LEVEL 8  1.2  0.8  300  300 
LEVEL 9  1.6  0.4  400  400 
LEVEL 10  2  0  500  500 Chapter 2    56 
Preparation of mixed volatile working standard for use with t-butanol: prepared 
as described above but also including n-propanol at a concentration of 500 mg/dL 
as  summarised  in  Table  2-1.  The  calibration  solutions  were  also  diluted  as 
described above and their preparation summarised in Table 2-2 
A  second  set  of  mixed  volatile  working  standard  solutions  were  prepared  as 
described  above  to  make  the  quality  control  (QC)  samples.  QC  material  was 
prepared in expired (volatile-free) blank blood screened negative for volatiles at 
concentrations  of  30,  80,  and  300  mg/dL  for  all  volatiles  except  for acetone, 
which was spiked at 30, 80, and 300 mg/L. The quality control materials were 
aliquoted and transferred to 1.5 mL polypropylene tubes and stored at -22°C. 
Table 2-3 summarises the preparation of the control material. 
Table 2-3:  Preparation of QC Material 
 
 
 
2.2.5 Post-Mortem Case Samples 
One  hundred  and  twenty  one  preserved  post-mortem  blood  samples  were 
selected where there was a history of decomposition as indicated in the post-
mortem  report  or  specimens  stored  within  the  laboratory  were  noted  as 
putrefied.  All  preserved  post-mortem  blood  samples  were  stored  within 
recommended screw-capped vials containing 2 mg/mL of sodium fluoride and 3 
mg/mL of potassium oxalate. 
2.2.6 Instrumentation 
HS-GC-FID  analysis  was  carried  out  using  a  Thermo  Trace  GC  2000  series 
instrument supported with Thermo Co. Chromoquest software version 2.41. The 
instrument has dual column capability connected with a y-splitter and was fitted 
with DB-ALC1 (30 m x 0.53 mm id x 3 µm) and DB-ALC 2 (30 m x 0.53 mm id x 2 
QC 
Points 
Volume of 
working standards 
(mL) 
Volume of 
blood 
(mL) 
[Analyte] 
(mg/dL) 
[Acetone] 
(mg/L) 
QC 1  1.5  23.5  30  30 
QC 2  4  21  80  80 
QC 3  15  10  300  300 Chapter 2    57 
µm)  supplied  by  J&W  Scientific,  Agilent  technologies,  USA.  A  Compudil  300 
automatic diluter was used for sample preparation. 
2.2.7 Optimisation of GC Conditions 
The  FMS  in-house  method  for  the  analysis  of  ethanol  and  acetone  using  the 
Thermo Trace GC 2000 series achieved separation under isothermal conditions, 
with an oven temperature set at 60°C. In order to achieve optimum separation of 
all  six  volatiles,  several  GC  program  were  investigated  in  combination  with 
changes to the flow rate.  
2.2.8 Sample Preparation 
200 µL of blank blood, calibration standard, quality control (QC) or case sample 
was  aspirated  with  500  µL  of  internal  standard  solution  using  an  automatic 
diluter. The mixture was dispensed into a 20 mL head-space vial, then capped 
and loaded onto the HS-GC-FID auto-sampler. 
2.2.9 Method Validation 
Two  methods  were  validated;  method  1  involved  the  use  of  n-propanol  as  an 
internal standard, while method 2 involved the use of t-butanol as an internal 
standard. As n-propanol was being used as the internal standard in method 1, it 
was only validated as a volatile of interest using t-butanol as an internal standard 
in method 2.  
Linearity was assessed over a concentration range of 5-500 mg/dL for ethanol, 
methanol,  n-propanol  and  isopropanol  and  from  5-500  mg/L  for  acetone.  The 
limit  of  detection  (LOD)  and  limit  of  quantification  (LOQ)  were  evaluated  by 
preparing samples and carrying out a serial dilution of the volatiles in duplicate 
Regression analysis  was undertaken, and the LOD and LOQ were calculated in 
accordance with Miller and Miller.(168) 
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LOD was calculated by using Equations 1 and 2: 
YLOD=YB+3SB           Equation 1 
LOD = (YLOD-YB)/m          Equation 2 
 
where YLOD is the standard error, YB is the intercept, and m is the gradient.  
LLOQ values are calculated using the same method of LOD but using 10 times the 
standard error of the regression line. LOQ was calculated using Equations 3 and 4: 
YLOQ=YB+10SB           Equation 3   
LOQ= (YLOG-YB)/m           Equation 4 
           
where YLOQ is the standard error, YB is the intercept, and m is the gradient . 
Intra-day  precision  (within  run  precision)  was  determined  at  five  independent 
preparations  of  spiked  blood  control  samples  at  three  different  concentration 
levels  (30,  80,  and  300  mg/dL)  for  ethanol,  isopropanol,  methanol  and  n-
propanol,  and  equivalent  in  mg/L  for  acetone.  Controls  were  prepared  in 
duplicate and analysed on the same day in the same analyser and same run. The 
percentage coefficient of variance was calculated (%CV), and acceptance criteria 
was set at <15%.(169)  
Inter-day precision (between day precision) was determined at eight independent 
preparations of spiked blood and urine control samples at three different levels 
(30, 80, and 300 mg/dL) for ethanol, isopropanol, methanol and n-propanol, and 
equivalent mg/L for acetone. Controls were prepared in duplicate and analysed 
over eight days. The percentage coefficient of variance was calculated (%CV), 
and acceptance criteria was set at < 15%.(169)  
The recovery and accuracy of the methods were assessed at concentrations of 30, 
80,  and  300  mg/dL  (n=5)  for  ethanol,  isopropanol,  methanol,  and  n-propanol 
equivalent  in  mg/L  for  acetone.  Recovery  was  assessed  by  calculating  the 
percentage of the ratio of the measured value of spiked blood to the measured 
value in water. The accuracy was assessed by calculating the percentage of the 
ratio of measured value of the spiked blood to the expected theoretical value. Chapter 2    59 
2.3 Results and Discussion 
2.3.1 Optimisation of GC Conditions 
Table 2-4 summarises the different GC conditions used to optimise the separation 
of the volatiles in both capillary columns. 
Table 2-4: Summary of GC Conditions Used to Optimise Separation of Volatiles 
Conditions 
(1)  (2)  (3)  (4)  (5)  Final 
RD  LD  RD  LD  RD  LD  RD  LD  RD  LD  RD  LD 
Oven Temperature 
(˚C)  60  60  40  40  40  40  40  40  40  40  40  40 
 
Right inlet 
Base Temperature  
 (˚C) 
 
200  200  200  200  200  200  200  200  200  200  200  200 
Hydrogen Flow 
(mL/min)  35  35  35  35  35  30  30  35  30  35  30  35 
Air Flow       
(mL/min)  350  350  350  350  350  300  300  350  300  350  300  350 
Right and Left FID 
Base temperature  
(˚C) 
250  250  250  200  250  250  250  250  150  150  250  250 
Split injection mode 
flow rate ( mL/min)  48  48  24  24  20  20  20  20  24  24  24  24 
Carrier gas flow 
rate(mL/min)  16  16  12  12  10  10  10  10  12  12  8  8 
Run Time (min)  6  6  8  8  9  9  10  10  9  9  9  9 
  *RD-Right Detector and LD-Left Detector Chapter 2    60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A)                       (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C)                (D) 
Figure 2-1:  Separation of Volatiles by HS-GC-FID 
 
Figure 2-1 (A-D) illustrates the separation achieved for each of the volatiles of 
interest in a standard alcohol mixture (water spiked at 300 mg/dL or mg/L for 
acetone) using HS-GC-FID and the final conditions listed in Table 2-4. (A) and (B) 
are chromatograms of the right and the left inlet respectively using n-propanol as 
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an internal standard (method 1). (C) and (D) are chromatograms of the right and 
left inlet respectively using t-butanol as an internal standard (method 2).  (A) and 
(C)  were  connected  to  the  right  inlet  with  DB-ALC1  while  (B)  and  (D)  were 
connected to the left inlet with DB-ALC2.  
Good  separation  was  achieved  when  using  n-propanol  as  an  internal  standard 
using DB-ALC1 (Figure 2-1A) and DB-ALC2 (Figure 2-1B). Co-elution of t-butanol 
and acetone could not be resolved with DB-ALC-1 (as illustrated in Figure 2-1C) 
even after adapting the oven and base temperatures, gas and split flow rates and 
trying numerous combinations, as summarised in Table 2-4. 
From the literature, it has been reported that separation of the volatile mixtures 
including t-butanol and acetone can be achieved using RTX-BAC2 (80;95) (30m x 
0.53mm x 2um) and DB-ALC2(170)(see Figure 2-1D) as they are similar stationary 
phases.  Separation  on  RTX-BAC1  (30m  x  0.53mm  x  3um)  was  not  indicated. 
Although a similar stationary phase to DB-ALC1, the RTX-BAC1 was investigated to 
see  if  separation  of  t-butanol  and  acetone  could  be  achieved,  as  expected, 
resolution of t-butanol and acetone was not achieved with RTX-BAC1. Separation 
of t-butanol and acetone has been reported using carbowax,(54) in a 6-foot x 1/4 
inch OD glass-packed column
.(54)  
Acetonitrile was also included at the start of the project to assess its potential as 
an alternative internal standard but as it also co-eluted with acetone and so no 
further investigation was undertaken.  
The optimised GC parameters are summarised in Table 2-5. The only difference 
(indicated * in Table 2-5) was in relation to the carrier gas flow which was set at 
10 mL/min for method 1 (n-propanol) and 8 mL/min for method 2 (t-butanol). 
This resulted in a slightly different run time of 6 and 9 minutes respectively.   Chapter 2    62 
Table 2-5:  Optimised GC Parameters used to Evaluate Methods 1 and 2  
Conditions  Column 1  Column 2 
GC Parameters 
DB-ALC1 
 (30m x 0.53 mm id x 3µm) 
DB-ALC 2 
 (30m x 0.53 mm id x 2µm) 
Right Detector   Left Detector 
Oven Temperature(˚C)  40ºC  40ºC 
Right Inlet Base Temperature(˚C)  200  200 
Hydrogen Flow (mL/min)  30  35 
Air Flow  (mL/min)  300  350 
Right and Left FID Base temperature(˚C)  250  250 
Post temperature(˚C)/time(minute)  120 for 1 min.  120 for 1 min 
Split/Splitless mode   Split  Split 
Split injection mode flow rate ( mL/min)  24  24 
Incubation temperature(˚C) and 
time(minute)   60 for 4 min. 
Carrier gas flow rate(mL/min) 
10* 
8 
10* 
8 
Injection Volume (mL)  2  2 
Run Time (min) 
6* 
9 
6* 
9 
 
2.3.2 Method Validation 
The correlation coefficients (R
2) were >0.999 for ethanol, isopropanol, methanol, 
acetone,  and  n-propanol  over  the  linear  range  of  10–500  mg/dL  (mg/L  for 
acetone) using either internal standard, as demonstrated in (Figure 2-2). 
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          (A)                                                               (B) 
Figure 2-2:  Volatile Calibration Curves  
(A) Ethanol, acetone, isopropanol, and methanol using n-propanol as an internal standard 
(Method 1). (B) Ethanol, acetone, isopropanol, methanol and n-propanol using t-butanol as an 
internal standard (method 2). 
 
The LOD for both methods 1 and 2 for ethanol, isopropanol and methanol was 1 
mg/dL and 1 mg/L for acetone for both methods. The LOQ for all volatiles was 
slightly  lower  when  using  t-butanol  as  an  internal  standard  as  summarised  in 
Table 2-6.  
Table 2-6:  LOD and LOQ for Validated Methods 
Method 
Ethanol 
mg/dL 
Acetone 
mg/L 
Isopropanol 
mg/dL 
Methanol 
mg/dL 
n-propanol 
mg/dL 
LOD  LOQ  LOD  LOQ  LOD  LOQ  LOD  LOQ  LOD  LOQ 
Method 1 
(n-propanol)  1  3  1  4  1  3  1  4  N/A 
Method 2 
(t-butanol)  1  2  1  3  1  2  1  2  1  2 
 
When analysing case samples, results less than 10 mg/dL for ethanol and less than 
10 mg/L for acetone were reported as negative, in accordance with FMS reporting 
criteria. Results of isopropanol, methanol, and n-propanol that were less than the 
LOQ  were  reported  as  negative.  Determinations  greater  than  the  highest 
calibration point were reported as present >500 for all analytes.  A cut-off of 10 
mg/dL  was  not  applied  to  isopropanol,  methanol,  and  n-propanol  to  allow  a Chapter 2    64 
thorough evaluation of the expected concentration range of these analytes in the 
post-mortem blood.  
The intra- and inter-day precision ranged from 1-5% in blood for both methods as 
summarised  in  Table  2-7.    In  general,  the  %CV  when  using  n-propanol  as  an 
internal  standard,  was  higher  compared  with  using  t-butanol  as  an  internal 
standard. 
Table 2-7:  Intra-day and Inter-day Precision for Volatiles in Blood 
 
Analyte 
 
Internal 
Standard 
30   80   300 
Intraday 
%CV 
(n=5) 
Interday 
%CV 
(n=8) 
Intraday 
%CV 
(n=5) 
Interday 
%CV 
(n=8) 
Intraday 
% CV 
(n=5) 
Interday 
%CV 
(n=8) 
Ethanol       
     
n-propanol  3.17  2.51  3.23  3.34  2.08  3.81 
t-butanol  2.32  1.56  0.77  3.10  1.25  1.15 
Acetone       
     
n-propanol  3.92  3.22  3.91  3.98  1.93  3.86 
t-butanol  3.41  4.49  1.96  2.56  2.81  1.04 
Isopropanol  
  
n-propanol  3.28  2.64  3.39  3.46  1.97  2.87 
t-butanol  2.63  2.07  1.04  2.48  1.95  1.04 
Methanol       
n-propanol  3.48  2.66  3.32  3.41  2.28  4.81 
t-butanol  2.46  2.53  0.80  3.65  1.25  1.23 
n-propanol   t-butanol  2.50  1.22  0.83  2.68  1.64  1.07 
* The unit is mg/dL for all except acetone in mg/L 
The  average  recovery  for  spiked  blood  controls  (30,  80,  and  300  mg/dL  and 
equivalent mg/L in acetone) was 99-107% for method 1 (n-propanol) and 99-109% 
for method 2 (t-butanol). Corresponding accuracy ranged from 95-98% and 95-
101%,  for  method  1  and  2  respectively.  Table  2-8  contains  a  full  list  of  the 
recovery and accuracy data for each volatile by method.  Chapter 2    65 
      Table 2-8:  Recovery and Accuracy for Methods 1 and 2 in Blood 
  Method (2)   
t-butanol (%) 
Method (1)  
n-propanol (%) 
BLOOD 
(N=5) 
Control 
mg/dL or 
mg/L 
EtOH  ACET  IPOL  MeOH  N-PROP  EtOH  ACET  IPOL  MeOH 
Recovery  30  99  104  99  99  99  99  104  99  99 
Accuracy  30  98  96  97  98  98  98  96  97  98 
Recovery  80  102  107  102  101  101  102  107  102  101 
Accuracy  80  95  95  95  96  96  95  95  95  96 
Recovery  300  105  109  103  106  94  105  109  103  106 
Accuracy  300  95  97  97  95  101  95  97  97  95 
 
Although the validation data indicated that t-butanol was marginally better with 
respect  to  accuracy  and  precision  compared  with  n-propanol  as  an  internal 
standard, both methods were acceptable for the analysis of volatiles in blood. 
2.3.3 Prevalence of Volatiles in Post-Mortem Blood 
Post-mortem blood samples (n=121) were tested using both methods to evaluate 
the prevalence of each volatile and to compare the results to assess the effect of 
n-propanol present due to post-mortem putrefaction.  
Ethanol  was  present  in  63  samples  with  concentrations  ranging  from  10  –  397 
mg/dL (see Table 2-9) and acetone in 46 samples with concentrations ranging 
from  10  –  443  mg/L  (see  Table  2-10).  Methanol  and  isopropanol  were  not 
identified in any of the samples tested and n-propanol was present in all samples 
at concentrations ranging from 2 – 14 mg/dL. 
A total of 7 samples were mismatched for ethanol when tested by both methods 
and are highlighted in Table 2-9 and they are in the range from 10-20 mg/dL, 
while ten samples were mismatched for acetone and are highlighted in Table 2-8 
and they are with in the range of 10-12 mg/L.  All mismatched results for ethanol 
and acetone are close to the cut-offs established provide likely explanation for 
the contradictory result.  Chapter 2    66 
 
Table 2-9:  Ethanol Concentrations Measured in Post-Mortem Blood by two Methods  
(Methods1=n-propanol; Method2=t-butanol) 
 
 
Table 2-10:  Acetone Concentrations Measured in Post-Mortem Blood two Methods 
Ethanol (mg/dL) 
Case 
Number 
Method 
(1) 
Method 
(2) 
Case 
Number 
Method 
(1) 
Method 
(2) 
Case 
Number 
Method 
(1) 
Method 
(2) 
1  110  100  38  76  75  78  155  162 
2  12  10  39  65  60  82  202  212 
3  10  NEG  40  10  NEG  83  250  257 
5  208  177  43  16  11  86  11  11 
7  13  NEG  45  29  17  87  340  349 
8  297  264  46  20  NEG  93  245  291 
9  NEG  10  47  17  NEG  95  236  241 
10  73  67  50  200  169  96  230  229 
13  60  44  51  73  70  97  265  266 
14  65  61  52  89  92  99  220  234 
15  365  357  54  157  157  101  45  46 
17  173  158  55  162  153  102  28  28 
18  24  23  56  216  210  103  114  117 
20  125  113  58  12  11  109  111  112 
21  30  29  59  233  245  110  78  87 
26  179  172  61  167  191  113  237  152 
27  223  196  62  30  32  115  NEG  11 
28  18  13  64  186  194  116  165  178 
29  19  16  67  296  289  117  380  397 
31  244  216  68  22  22  118  107  115 
33  257  237  72  199  221  121  33  35 
37  12  13  74  185  171   
Acetone (mg/L) 
Case 
Number 
Method 
(1) 
Method 
(2) 
Case 
Number 
Method 
(1) 
Method  
(2) 
Case 
Number 
Method 
(1) 
Method 
(2) 
1  NEG  13  41  NEG  11  83  16  13 
7  14  11  42  NEG  10  86  25  21 
9  405  411  45  296  369  88  21  21 
13  74  59  46  92  134  91  53  36 
14  NEG  11  58  443  372  97  35  40 
21  17  24  60  12  NEG  100  16  13 
22  48  31  62  29  33  102  12  10 
25  NEG  11  64  NEG  10  103  20  17 
26  13  17  65  NEG  11  107  13  12 
31  NEG  11  69  20  21  109  32  34 
32  83  72  70  11  12  110  173  139 
33  NEG  11  71  51  48  111  79  67 
34  36  31  74  11  12  115  48  46 
36  17  18  75  93  64  118  44  38 
37  17  21  76  55  45  121  82  70 
      81  78  79       Chapter 2    67 
 
The correlation coefficient (R
2) for ethanol was 0.984 (P = 0.084) and 0.954 (P = 
0.536) for acetone. As the P values are greater than 0.05 for both ethanol and 
acetone this indicates that there is no significant difference between the two sets 
of results. 
Figure  2-3  illustrates  the  correlation  between  post-mortem  blood  volatile 
concentrations for ethanol (A) and acetone (B) when measured using n-propanol 
as an internal standard (Result 1) compared with t-butanol (Result 2).  
400 300 200 100 0
400
300
200
100
0
M e thod 2
M
e
t
h
o
d
 
1
R-S q 98.4%
Ethanol 
Ethanol M ethod1 =  2.015 + 0.9993 Ethanol  M ethod 2
 
(A) 
400 300 200 100 0
500
400
300
200
100
0
Method 2
M
e
t
h
o
d
 
1
 
R-S q 95.4%
Acetone 
Acetone M ethod 1  =  0.820 + 0.9978 Acetone M ethod 2
 
(B) 
Figure 2-3:  Correlation of Ethanol (A) and Acetone (B) concentrations in post-mortem blood 
using n-propanol (Method 1) versus t-butanol (Method 2) as an Internal Standard. 
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Looking more closely at the levels of n-propanol found in post-mortem blood, the 
majority of samples were positive at concentrations close to the LOQ of 2 mg/dL. 
Six cases had elevated n-propanol concentrations ranging from 5 – 14 mg/dL as 
summarised in Table 2-7. 
  Table 2-11:  Elevated Post-mortem Blood n-propanol Concentrations. 
Case 
Number 
Ethanol     
(n-propanol) 
Ethanol     
(t-butanol) 
n-propanol  
(t-butanol) 
Ethanol:               
n-propanol                
Ratio 
18  24  23  5  5 
21  30  29  5  6 
26  179  172  5  34 
72  199  221  9  25 
93  245  291  14  21 
110  78  87  11  8 
 
It has been reported that n-propanol is produced in larger quantities than other 
volatiles and can be detected in postmortem cases when ethanol production is 
suspected.  n-propanol  concentrations  continue  to  increase  even  when  ethanol 
concentrations  have  peaked  and  start  to  decline.  The  reason  being  that  n- 
propanol  can  be  produced  postmortem  from  fermentation  of  amino  acids, 
glycerol, fatty acids and could last until the advanced stage of putrefaction.(53)  
It is expected that the presence of n-propanol in putrefied post-mortem blood 
samples  will  increase  the  peak  area  of  n-propanol  when  used  as  an  internal 
standard and this may lead to an underestimate in the calculation of ethanol and 
other volatile concentrations. This is certainly the case with the 3 samples (# 72, 
#93 and #110) in Table 2-7 with higher concentrations of n-propanol. The ethanol 
concentrations are higher by between 11 and 19% when using t-butanol compared 
with n-propanol as an internal standard. However, interpretation of the ethanol 
concentrations  in  all  six  cases  would  not  be  affected  by  the  presence  of  n-
propanol due to the putrefaction process.  Chapter 2    69 
The concentrations in this study are much lower than those reported in previous 
studies, where n-propanol was present in post-mortem blood at concentrations 
ranging from 30 - 70 mg/L. (60;83) However, it should also be noted that there is 
no  mention  in  these  publications  regarding  validation  of  the  methods  used  to 
quantify n-propanol.   
Nanikawa and Kotoku(171), Nanikawa et al.(172) and Moriya and Hashimoto(97)  
have considered n-propanol as an indicator of post-mortem ethanol production 
and have evaluated the ratio of n-propanol to ethanol in post-mortem blood to 
identify ethanol formation. In these studies, n-propanol was detected in all cases 
of  suspected  post-mortem  ethanol  production.  Nanikawa  and  Kotoku(171)  also 
suggested that the antemortem ethanol concentration could be estimated from 
the  postmortem  n-propanol  concentration.  The  authors  state  that  in  previous 
studies they found that the potential range of ethanol produced postmortem was 
20 times the amount of n-propanol produced.  
Moriya  and  Hashimoto(97)  concluded  that  n-propanol  cannot  be  used  as  an 
internal standard for post-mortem blood samples unless a screen has first been 
conducted to confirm its absence from the specimen.  
Ziavrou  et  al.(173)  suggested  that  due  to  significant  variability,  no  valid 
estimation of antemortem ethanol production can be made from the postmortem 
n-propanol  and  ethanol  concentrations.  In  another  study  of  the  relationship 
between ethanol and n-propanol in 62 post-mortem cases, only 17 of the cases 
samples had a detectable level of n-propanol. This  finding is in variance with 
Nanikawa et al.(172) whose study indicated that n-propanol could be used as an 
indicator for ethanol formation and further showed that all positive results for 
ethanol were also positive for n-propanol. (83)  
The ratios were calculated for the cases with elevated n-propanol concentrations 
in this study and are summarised in Table 2-7. The ratios range from 5 to 34 but 
with  conflicting  evidence  on  the  suitability  of  this  ratio  for  estimating  post-
mortem production of ethanol, no further conclusions can be made.  Chapter 2    70 
Although  studies  have  concluded that  n-propanol  is  produced  in  all  specimens 
along  with  ethanol(171;172;174),  it  may  in  fact  be  detected  in  only  a  small 
percentage of postmortem cases. Further, Schuberth(99) and Kronert et al.(175) 
identified  n-propanol  in  living  subjects  along  with  other  common  volatiles  at 
concentrations  below  the  limit  of  quantitation  (10  mg/dL)  utilised  by  many 
forensic toxicology laboratories today.  
The  majority  of  samples  in  this  study  had  n-propanol  concentrations  below  5 
mg/dL and must be interpreted with caution as the presence of n-propanol in 
these cases may or may not be as a result of post-mortem production. 
2.4 Conclusion 
Two methods have been developed and validated for the quantitative analysis of 
common  volatiles  (methanol,  ethanol,  isopropanol,  n-propanol  and  acetone) 
utilising dual-column HS-GC-FID and two internal standards, namely n-propanol 
and  t-butanol.  Both  methods  demonstrated  excellent  linearity,  precision  and 
accuracy.  The  analysis  of  real  case  samples  to  evaluate  the  meaning  of  the 
presence  of  n-propanol  in  putrefied  blood  samples  found  no  significant  effect 
with levels in this study much lower than previously reported in the literature. 
The correlation between both methods was excellent and although the presence 
of elevated levels of n-propanol resulted in lower ethanol concentrations, the 
decreases had no impact on the interpretation of ethanol in the cases.  
It  is  however  recognised  that  this  study  looked  at  a  relatively  small  data  set 
(N=121) and that a much larger study is required to investigate the prevalence of 
n-propanol in putrefied post-mortem blood samples. The findings in this study do 
not support the findings reported by other authors that n-propanol should not be 
used as an internal standard. n-propanol is an ideal internal standard for use with 
the dual-column system used in this study and when applied to the analysis of 
ethanol in blood from living subjects, e.g. road traffic arrests. Although using n-
propanol  as  an  internal  standard  in  post-mortem  cases  may  result  in  an 
underestimate of the concentration of other volatiles, the risk associated with 
this appears to be minimal with the majority of samples in this study having n-
propanol  concentrations  close  to  the  LOQ  and  therefore  negligible.  It  is Chapter 2    71 
impractical to consider screening all post-mortem blood samples for the presence 
of n-propanol prior to its use as an internal standard, as has been suggested by 
other authors, but further investigations are required into the prevalence and 
range of concentrations of n-propanol to fully assess the risks associated with the 
use of this volatile as an internal standard to quantify volatiles in post-mortem 
blood.   
The use of ethanol to n-propanol ratio to determine whether ethanol formation 
has occurred is unlikely to be an effective indicator and other criteria must be 
considered, including the case history, condition of the specimens, distribution of 
ethanol  in  different  matrices,  presence  or  absence  of  ethanol  in  different 
specimens  of  the  case  sample,  presence  of  volatile  compounds  and  the 
concentration of ethanol. (83)  
The internal standard t-butanol offers an effective alternative internal standard 
for the quantification of volatiles in post-mortem blood, including the ability to 
measure n-propanol. However, co-elution with acetone when using DB-ALC1 or 
RTX-ALC1 rules out the use of this internal standard with these types of columns. 
It has also been reported that the level of t-butanol as an internal standard may 
decrease when the fat content of the sample analysed increases. The fat content, 
as well as protein and salt, may affect the accuracy of the head-space method. 
Increased  concentrations  of  ethanol  may  be  a  consequence  of  the  stronger 
affinity of isobutyl alcohol when used as an internal standard for fatty aqueous 
slurry. The peak height of t-butanol decreases as the amount of fat in the sample 
analysed is increased.(94)  72 
Chapter 3 - Application of a Validated Method for 
the Analysis of Volatiles in Biological Matrices  
3.1 Introduction 
Following validation of a method for the analysis of common volatiles (ethanol, 
methanol, isopropanol, n-propanol and acetone) with t-butanol as an internal 
standard (detailed in Chapter 2), the method was utilized to investigate: 
•  The stability of volatiles in blood; 
•  The  prevalence  and  correlation  of  volatiles  measured  in  different 
biological matrices; 
•  The evaluation of a commercially available enzymatic assay for screening 
ethanol in blood. 
 
The  aims  of  the  stability  study  were  three-fold;  to  evaluate  the  effect  of 
preservative  and  antioxidant  on  the  stability  of  volatiles  at  different 
concentrations during short-term storage at different temperature conditions; to 
evaluate  the  stability  of  ethanol  and  acetone  in  paired  preserved  and 
unpreserved post-mortem blood samples, and to evaluate the stability of ethanol 
in preserved blood after long-term storage at room temperature. 
The aims of the study involving the analysis of volatiles in different biological 
matrices were; to assess the prevalence of volatiles in femoral blood, vitreous 
humour, urine and bile and to evaluate the correlation between the different 
matrices for ethanol and acetone.  
The final study aim was to evaluate the performance of the enzymatic assay 
manufactured  by  Immunalysis  Corporation  as  a  semi-quantitative  screening 
method for ethanol in blood, in comparison to the validated method utilising HS-
GC-FID. Chapter 3    73 
3.2 The Effect of Preservative and Antioxidant Reagents 
on the Stability of Volatiles in Blood 
3.2.1 Introduction 
An evaluation of the stability of common volatiles in blood was carried out by 
spiking  blood  at  two  concentrations  with  ethanol,  isopropanol,  acetone, 
methanol  and  n-propanol  and  adding  different  amounts  of  preservative  and 
antioxidant.  Spiked  samples  were  stored  at  room  temperature  (25±2ºC), 
refrigerated  (4±2ºC),  and  frozen  (-22±2ºC).  Tests  were  carried  out  at  regular 
time intervals over a period of 50 days.  
3.2.2 Sample Preparation 
Two 250 mL class A volumetric flasks were labelled (A) and (B). To flask (A), 0.5 
mL  of  each  volatile  stock  standard  (10%  w/v)  and  0.05  mL  of  acetone  stock 
standard  (10%  w/v)  were  added  for  a  final  concentration  of  20  mg/dL  for 
ethanol,  isopropanol,  n-propanol  and  methanol,  and  20  mg/L  for  acetone  in 
blood.  
To Flask (B), 2 mL of each each volatile stock standard (10% w/v) and 0.2 mL of 
acetone stock standard (10% w/v) were added for a final concentration of 80 
mg/dL  for  ethanol,  isopropanol,  n-propanol  and  methanol,  and  80  mg/L  for 
acetone.  Each flask was further sub-divided into five 50 mL class A volumetric 
flasks. The flasks were labeled as groups 1, 2, 3, 4, and 5, containing varying 
amounts  of  preservative  (sodium  fluoride)  and  antioxidant  (sodium 
metabisulfite) as summarised in Table 3-1. 
         Table 3-1:  Preservative and Antioxidant Concentrations by Group 
Groups  PRESERVATIVE 
(Sodium Fluoride) 
ANTIOXIDANT 
(Sodium Metabisulfite) 
GROUP 1  NO  NO 
GROUP 2  0.2%  NO 
GROUP 3  0.2%  0.2% 
GROUP 4  1%  NO 
GROUP 5  1%  0.2% Chapter 3    74 
The  concentration  of  sodium  fluoride  (NaF)  at  0.2%  was  selected  to  be 
representative of the commercially available specimen containers submitted to 
Forensic  Medicine  and  Science  (FMS)  for  blood  alcohol  analysis.  From  each 
group, 1 mL aliquots were placed into labeled 1.5 mL polystyrene screw cap 
tubes. The aliquots for each group were stored under three different conditions; 
at room temperature (RT) at 25±2 ºC, in the refrigerator at 4±2ºC, and in the 
freezer at -22 ±2ºC as illustrated in Figure 3-1. Temperatures were monitored by 
using a certified calibrated thermometer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1:  Stability Study Design and Spiked Sample Preparation Guide 
 
3.2.3 Results and Discussion 
Figure 3-2 illustrates the changes observed in volatile concentrations for blood 
spiked  at  80  mg/dL  (mg/L  for  acetone)  and  stored  at  room  temperature 
(25±2°C).  
  Stability Study Design  
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(A) Ethanol, (B) Acetone, (C) Isopropanol related to figure 3-2 continued next page 
Stability of Volatiles Spiked in Blood at Room Temperature (25 ±2°C)  
 Chapter 3    76 
50 40 30 20 10 0
120
100
80
60
40
20
Day
C
o
n
c
e
n
t
r
a
t
i
o
n
s
n-propanol S tability S tudy (8 0 mg/ dL ) 
 
(D) 
 
50 40 30 20 10 0
120
110
100
90
80
70
60
50
40
30
Da y
C
o
n
c
e
n
t
r
a
t
i
o
n
s
M e tha nol S ta bility  S tudy  (8 0 m g/ dL )
        
(E) 
 
Key: 
—•—   (No preservative)  
—■—    (0.2%  NaF)                                   —♦—   (0.2%  NaF + antioxidant)      
—▲—   (1%     NaF)                          —►—  (1%     NaF + antioxidant) 
 
Figure 3-2:  Stability of Volatiles Spiked in Blood at Room Temperature (25 ±2°C)  
(Spiked at 80 mg/dL and equivalent mg/L for acetone for (A) Ethanol, (B) Acetone, (C) 
Isopropanol, (D) n-propanol and (E) Methanol). 
 
The  corresponding  figures  and  tables  summarizing  the  changes  observed  in 
volatile concentrations for blood spiked at 20 and 80 mg/dL (mg/L for acetone) 
following storage at different temperatures are summarized in Appendix 3-1.  Chapter 3    77 
Ethanol  levels  initially  increased  and  then  decreased  when  stored  in  the 
refrigerator or at room temperature with or without preservative. The observed 
increase was greater at room temperature when no preservative or antioxidant 
was present as illustrated in Figure 3-2 A. The subsequent ethanol decrease is 
most likely due to oxidation of ethanol to acetaldehyde. However, the improved 
stability  of  ethanol  in  the  presence  of  the  sodium  fluoride  preservative  was 
unaffected  by  the  presence  or  absence  of  the  antioxidant  sodium 
metabisulphite.  
At room temperature, acetone concentrations increased and isopropanol levels 
decreased  from  the  start  of  the  stability  study  for  all  groups.  This  inversely 
proportional  relationship  between  acetone  and  isopropanol  is  most  likely 
explained by the oxidation of isopropanol to acetone. This is further supported 
by  the  less-pronounced  increase  in  acetone  concentrations  for  the  samples 
containing the antioxidant, sodium metabisulphite as illustrated in Figures 3-2 B 
and 3-2 C. 
n-Propanol mirrored the same profile as that observed with isopropanol, namely 
a  decreasing  concentration  as  seen  in  Figure  3-2D.  The  decrease  was  less 
pronounced when the samples were stored in the refrigerator or freezer and 
when both sodium fluoride and sodium metabisulphite were present. 
Methanol  was  stable  under  all  conditions  and  was  the  only  volatile  of  those 
studied  whose  stability  was  unaffected  by  temperature,  preservative  or 
antioxidant as illustrated in Figure 3-2 E. 
All volatiles were stable in blood over the study period of 50 days when stored in 
the freezer (-22±2ºC) whether preservative or antioxidant was present or not. 
Samples spiked at 20 mg/dL (mg/L for acetone) had a similar pattern to samples 
spiked at 80 mg/dL (mg/L for acetone).  
The  stability  study  was  also  carried  out  using  method  1  (n-propanol  as  an 
internal  standard  and  not  an  analyte  of  interest).  Similar  results  were  also 
observed and are summarized in Appendix 3-2. Chapter 3    78 
3.3 Stability of Ethanol and Acetone in Paired Preserved 
and Unpreserved Post-Mortem Blood 
3.3.1 Introduction 
Post-mortem  examinations  carried  out  in  the  West  of  Scotland  requiring 
toxicological investigation are routinely tested for alcohol and drugs. Femoral 
blood samples are collected and submitted as both preserved and unpreserved 
samples. The preserved samples are stored within screw cap vials containing 2 
mg/mL  of  sodium  fluoride  and  3  mg/mL  of  potassium  oxalate.  Following 
submission  to  the  toxicology  laboratory  within  FMS,  the  preserved  sample  is 
tested for alcohol and may also be tested for known labile drugs, e.g. cocaine, 
while the unpreserved blood sample is tested for a wide range of prescription 
and illicit drugs. Samples are stored in the refrigerator for approximately 1 to 2 
months while investigations are on-going before being moved to a freezer for 
long-term storage.  
The analysis of paired preserved and unpreserved post-mortem samples from a 
range of cases will provide an insight into the role of the preservative on the 
stability of ethanol and acetone in real cases.  
3.3.2 Methodology 
Seventy-one paired preserved and unpreserved post-mortem blood samples were 
re-analyzed  after  storage  in  the  refrigerator  for  six  months  and  a  further  10 
months  following  storage  at  -22  ±1ºC.  The  selection  criteria  required  paired 
preserved and unpreserved post-mortem blood, stored in the refrigerator for 6 
months with a selection of cases that were positive and negative for ethanol in 
post-mortem blood.   
The initial analysis was carried out by FMS Technical Staff in accordance with 
the ISO/IEC 17025 accredited method for the analysis of ethanol in post-mortem 
blood and urine. Acetone was quantified in these cases using a positive control 
and the calibration curve for ethanol which was linear over the range of 0-400 
mg/dL.  Chapter 3    79 
The first re-test of the preserved blood and paired unpreserved blood six months 
later was carried out using the validated method described in Chapter 2 utilising 
n-propanol as internal standard. The second re-test after a further 10 months 
was carried out using the validated method described in Chapter 2 utilising t-
butanol as internal standard including n-propanol as an analyte. 
3.3.3 Results and Discussion 
Table  3-2  and  3-3  summarizes  the  results  of  the  paired  samples  positive  for 
ethanol and/or acetone. All samples with volatile concentrations lower than 10 
mg/dL (or 10mg/L for acetone) were classified as negative. A total of ten cases 
were negative for all volatiles. The stability of methanol, isopropanol and n-
propanol  could  not  be  assessed  as  too  few  samples  were  positive  for  these 
volatiles. Four cases were positive for methanol, two for isopropanol and two for 
n-propanol at low concentrations ranging from 11 to 29 mg/dL.  
The results for the original test of the preserved blood sample (OP) are included 
for  ethanol  and  acetone  along  with  subsequent  analysis  (after  6  months 
refrigeration) of both preserved and unpreserved blood (P1, UP1) and re-analysis 
(after a further 10 months in the freezer) of both the preserved and unpreserved 
blood (P2, UP2). Chapter 3    80 
Table 3-2:  Ethanol Concentrations in Paired Post-Mortem Blood Samples. 
Ethanol (mg/dL) 
Case  
Number  OP  P1  P2  UP1  UP2  Case 
Number  OP  P1  P2  UP1  UP2 
1  158  73  70  141  120  37  374  340  349  412  355 
2  136  89  92  118  131  38  N  N  N  N  N 
3  N  N  N  11  10  39  N  N  N  11  11 
4  186  157  157  128  142  41  N  N  N  N  N 
5  223  162  153  222  228  42  16  N  N  N  10 
6  220  216  210  196  209  43  260  245  291  212  272 
7  N  N  N  N  N  44  26  N  N  N  N 
8  23  12  11  24  23  45  325  236  241  N  N 
9  280  233  245  286  340  46  226  230  229  222  237 
10  N  N  N  22  15  47  308  265  266  149  153 
11  323  167  191  256  270  48  40  N  N  N  N 
12  71  30  32  45  54  49  191  220  234  49  52 
14  246  186  194  223  211  50  17  N  N  N  N 
15  N  N  N  N  N  51  20  45  46  80  94 
17  362  296  289  365  377  52  70  28  28  73  81 
18  44  22  22  43  46  53  128  114  117  126  138 
19  N  N  N  N  N  54  N  N  N  21  24 
20  N  N  N  N  N  57  N  N  N  N  N 
21  N  N  N  N  N  58  N  N  N  21  30 
22  231  199  221  172  189  59  134  111  112  138  145 
24  278  185  171  256  264  60  131  78  87  126  157 
25  17  N  N  24  21  61  N  N  N  N  N 
26  N  N  N  N  N  62  N  N  N  N  N 
27  N  N  N  17  17  63  174  237  152  169  173 
28  187  155  162  141  146  64  N  N  N  N  10 
29  N  N  N  N  N  65  23  N  11  53  56 
31  N  N  N  N  N  66  212  165  178  185  185 
32  236  202  212  14  46  67  391  380  397  406  436 
33  297  250  257  268  277  68  N  107  115  33  36 
34  10  N  N  21  24  71  54  33  35  30  27 
36  19  11  11  N  N             
(OP - Original results for the preserved sample; (P1 & P2) preserved blood retested after 6 months and 
a further 10   months; (UP1 & UP2) corresponding unpreserved blood samples). 
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Table 3-3:  Acetone Concentrations in Paired Post-Mortem Blood Samples 
Acetone (mg/L) 
Case 
Number 
OP  P1  P2  UP1  UP2  Case 
Number 
OP  P1  P2  UP1  UP2 
1  N  N  N  15  15  37  N  N  N  N  N 
2  N  N  N  N  N  38  N  21  21  10  11 
3  N  N  N  N  N  39  N  N  N  N  N 
4  N  N  N  10  12  41  43  53  36  70  55 
5  N  N  N  23  N  42  N  N  N  N  N 
6  N  N  N  N  N  43  N  N  N  N  N 
7  N  N  N  16  11  44  N  N  N  N  N 
8  260  443  372  310  258  45  N  N  N  10  12 
9  N  N  N  N  N  46  N  N  N  N  N 
10  N  12  N  10  11  47  N  35  40  41  42 
11  N  N  N  N  N  48  N  N  N  N  N 
12  93  29  33  N  N  49  N  N  N  N  N 
14  N  N  10  10  11  50  N  16  13  162  101 
15  N  N  11  14  18  51  N  N  N  N  N 
17  N  N  N  N  N  52  N  12  10  N  N 
18  N  N  N  N  N  53  N  20  17  17  19 
19  N  20  21  11  12  54  N  N  N  N  N 
20  N  11  12  22  18  57  N  13  12  10  11 
21  N  51  48  54  50  58  N  N  N  N  N 
22  N  N  N  N  N  59  N  32  34  25  29 
24  N  11  12  N  N  60  N  173  139  24  32 
25  30  93  64  40  31  61  94  79  67  70  73 
26  N  55  45  40  43  62  N  N  N  19  10 
27  N  N  N  N  N  63  N  N  N  N  N 
28  N  N  N  N  N  64  N  N  N  N  N 
29  N  N  N  21  18  65  38  48  46  46  49 
31  63  78  79  107  75  66  N  N  N  N  10 
32  N  N  N  N  N  67  N  N  N  N  N 
33  N  16  13  13  15  68  N  44  38  N  N 
34  N  N  N  N  N  71  N  82  70  13  15 
36  28  25  21  32  27             
(OP - Original results for the preserved sample; (P1 & P2) preserved blood retested after 6 months 
and a further 10   months; (UP1 & UP2) corresponding unpreserved blood samples). 
 
 
3.3.3.1  Ethanol Stability in Preserved Blood After 6 Months Refrigeration 
and 10 Months in the Freezer 
The mean ethanol concentration of the original results (OP) was 109 mg/dL. The 
mean ethanol results for preserved and unpreserved samples stored for 6 months 
refrigeration and 10 months in the freezer were 90, 92, 90 and 96 for P1, P2, 
UP1 and UP2 respectively. The percentage of mean loss ranged between 22-27% 
of preserved and unpreserved samples.  
A total of 40 preserved blood samples originally tested (OP) positive for ethanol. 
Following re-analysis after a period of 6 months in the refrigerator, 90% (N=36) Chapter 3    82 
had lower levels of ethanol (P1), indicating loss of ethanol during the six-month 
storage period. A loss of greater than 20% was evident in 58% (N=21) of these 
samples. Ethanol production was also evident in five cases: four samples had 
higher  levels  of  ethanol  (#46,  #49,  #51  and  #63),  while  case  #68,  originally 
negative  had  an  ethanol  concentration  of  107  mg/dL  when  retested.  This 
concentration  increased  further  to  115  mg/dL  after  an  additional  10  months 
storage in the freezer (P2). Thirty cases were negative for all tests, indicating no 
ethanol formation.  
The  correlation coefficient (R
2)  was  calculated  when  comparing  the  different 
data sets and fitted line plots were plotted as illustrated in Figure 3-3 (A-D) for 
ethanol and Figure 3-4 (A-D) for acetone. A summary of the values are listed in 
Table 3-3 along with the P values.  
An assessment of the correlation between the results generated for the original 
preserved blood ethanol concentrations (OP) compared with those measured in 
the same preserved blood sample after 6 months (P1) and a further 10 months 
(P2) storage are summarized in Table 3-3. Although the values for the original 
test (OP) versus P1 and P2 were 92.6% and 92.9%, respectively, the P values 
were  less  than  0.05  at  the  95%  confidence  interval,  indicating  significant 
differences between the initial analysis and the two subsequent analyses.  
Figure 3-3A illustrates the correlation between the ethanol concentrations in the 
original  preserved  blood  (OP)  and  the  reanalysis  after  6  months  in  the 
refrigerator. Although ethanol loss was observed in most of the cases over the 
initial 6 months refrigeration, no significant differences in ethanol concentration 
were observed following a further 10 months storage in the freezer (P1 versus 
P2, 
 = 98.5%, p = 0.993). Chapter 3    83 
Table 3-4:  Summary of Correlation Data for Ethanol in Blood. 
  Ethanol  Acetone 
    Regression 
Equations 
P 
value    Regression 
Equations 
P 
value 
OP vs. P1  0.926  OP=8.353+1.110P1  0.00   0.724  OP=-1.528+0.5136P1  0.006 
OP vs. P2  0.929  OP=8.398+1.088P2  0.00   0.738  OP = - 2.081 + 0.6196P2  0.005 
P1 vs. P2  0.985  P1=0.754+0.9743P2  0.334   0.993  P1=-0.8029+1.192P2  0.037 
P1 vs. UP1  0.766  P1=11.38+0.8500UP1  0.947   0.696  P1 =  1.256 + 1.108 UP1  0.422 
P2 vs. UP2  0.775  P2=9.366+0.8436UP2  0.570   0.787  P2=-0.577+1.220UP2  0.330 
UP1 vs. UP2  0.984  UP1=-1.291+0.9580UP2  0.334   0.973  UP1=-1.053+1.220UP2  0.075 
(P value of paired preserved (P) post-mortem blood and  unpreserved(UP). OP: Original   
preserved blood.  P1: Preserved blood retested after 6 months in fridge. P2: Preserved 
blood retested after additional 10 months in freezer. 
 
3.3.3.2  Ethanol Stability in Unpreserved Blood after 10 Months in the Freezer 
An  excellent  correlation  (R
2=  98.4%)  was  observed  (see  Figure  3-3D)  for  the 
unpreserved  blood  ethanol  concentrations  measured  following  10  months  of 
storage in the freezer (UP1 versus UP2) with a P value of 0.334 indicating no 
significant differences. The unpreserved blood samples were not analysed at the 
same time as the original preserved blood so no assessment of the stability of 
ethanol  in  unpreserved  blood  following  6  months  refrigeration  can  be 
undertaken.  
3.3.3.3  Ethanol Stability in Preserved Blood versus Unpreserved Blood 
When comparing the unpreserved blood (UP) ethanol concentrations with those 
of the original preserved samples (OP), 70% (N=28) of preserved samples and 60% 
(N=24)  of  unpreserved  samples  had  lower  levels  of  ethanol,  with  about  54% 
(N=15) of these samples recording a loss of greater than 20% over the six-month 
period. Ethanol production was also evident in 18 and 23 cases respectively for 
both  UP1  and  UP2  with  7  of  these  cases  originally  negative  having  ethanol 
concentrations ranging from 10 to 36 mg/dL when retested. Chapter 3    84 
As would be expected, the preserved samples demonstrated less variability than 
the  unpreserved  samples  regarding  formation  of  ethanol;  however,  both 
preserved  and  unpreserved  samples  had  significant  loss  of  ethanol  over  the 
period  of  six  months  when  stored  in  a  refrigerator.  There  are  a  number  of 
factors  that  must  also  be  considered  when  interpreting  the  data.  The 
unpreserved  samples  are  commonly  retained  within  Forensic  Medicine  and 
Science for analysis of a range of analytes and as such the vials are opened and 
closed on numerous occasions depending on the number of tests carried out, 
increasing  the  risk  of  ethanol  loss  due  to  evaporation.  In  addition,  the 
circumstances  surrounding  the  cases  were  not  considered  (i.e.,  body  badly 
decomposed).  Chapter 3    85 
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Figure 3-3:  Fitted Line Plots of Ethanol concentrations in Paired Blood Samples. 
(A) Original [EtOH] in preserved blood(OP) versus preserved blood [EtOH](P1) after 6 
months in the refrigerator (B) Preserved blood [EtOH]  versus unpreserved [EtOH]  following 
16 months storage(6 months fridge+ 10 months freezer). (C) preserved blood [EtOH](P1) 
versus preserved blood [EtOH](P2) after 10 months storage in freezer. (D) Unpreserved 
blood[EtOH] (UP1) versus Unpreserved blood [EtOH](UP2) after 10 months storage in 
freezer.  Chapter 3    86 
5 0 0 4 0 0 3 0 0 2 0 0 1 0 0 0
2 5 0
2 0 0
1 5 0
1 0 0
5 0
0
P 1
O
P
R - S q 7 2 . 4 %
A c e t o n e
O P   =     -   1 . 5 2 8   +   0 . 5 1 3 6   P 1
 
(A) 
2 5 0 2 0 0 1 5 0 1 0 0 5 0 0
4 0 0
3 0 0
2 0 0
1 0 0
0
U P 2
P
2
R - S q 7 8 . 7 %
A c e t o n e
P 2 =     -   0 . 5 7 7   +   1 . 2 2 0   U P 2
 
(B) 
4 0 0 3 0 0 2 0 0 1 0 0 0
5 0 0
4 0 0
3 0 0
2 0 0
1 0 0
0
P 2
P
1
R - S q 9 9 . 3 %
A c e t o n e  
P 1   =     -   0 . 8 0 2 9   +   1 . 1 9 2   P 2
 
(C) 
2 5 0 2 0 0 1 5 0 1 0 0 5 0 0
3 5 0
3 0 0
2 5 0
2 0 0
1 5 0
1 0 0
5 0
0
U P 1
U
P
1
R - S q 9 7 . 2 %
A c e t o n e  
U P 1   =     -   1 . 0 5 3   +   1 . 2 2 0   U P 2
 
(D) 
Figure 3-4:  Fitted Line Plots of Acetone concentrations in Paired Blood Samples. 
(A) Original [Acetone] in preserved blood(OP) versus preserved blood [Acetone](P1) after 6 
months in the refrigerator (B) Preserved blood [Acetone]  versus unpreserved [Acetone]  
following 16 months storage(6 months fridge+ 10 months freezer). (C) preserved 
blood[Acetone](P1) versus preserved blood [Acetone](P2) after 10 months storage in 
freezer. (D) Unpreserved blood[Acetone EtOH] (UP1) versus Unpreserved blood [Acetone 
EtOH](UP2) after 10 months storage in freezer. Chapter 3    87 
3.3.3.4  Acetone Stability in Preserved Blood versus Unpreserved Blood 
The mean acetone concentration of the original results (OP) was 11 mg/L. The 
mean  acetone  results  for  preserved  and  unpreserved  samples  stored  for  6 
months refrigeration and 10 months in the freezer were 24, 21, 21 and 18 for P1, 
P2, UP1 and UP2 respectively.   
Acetone was detected in 35 cases at concentrations ranging from the LOQ to 443 
mg/L,  however  acetone  was  not  present  in  all  of  the  paired  samples.  The 
correlation between the original acetone concentration (OP) and the re-analysis 
after 6 months (P1) and 10 months (P2), as illustrated in Figures 3-4 A and C 
respectively, was greater than 70% but with significant differences (p<0.05) in 
the measured concentrations. However, the linear range and LOQ of the original 
analysis were not comparable with the current method developed and reported 
here. As a consequence, further comparison of the significance of the results in 
relation to stability of acetone is not possible. 
When comparing acetone concentrations in preserved blood (P1 versus P2) and 
unpreserved blood (UP1 versus UP2) after a period of 10 months storage in the 
freezer, 17 preserved and 13 unpreserved samples showed acetone loss of on 
average  20%  and  26%,  respectively.  Acetone  production  was  evident  in  7 
preserved samples and 17 unpreserved samples with gains in the range of 9-14%.  
The  values  for  P1  versus  P2  and  UP1  versus  UP2  were  99.3%  and  97.3% 
respectively with corresponding P values >0.05 indicating that there is a good 
correlation  between  the  two  results.  This  in  turn  means  that  acetone 
concentrations  may  not  increase  or  decrease  significantly  when  samples  are 
stored for over 10 months in the freezer. 
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3.4 Stability  of  Ethanol  in  Preserved  Blood  Following 
Long-Term Storage at Room Temperature 
3.4.1 Introduction 
Blood samples collected from individuals arrested under section 5 of the Road 
Traffic Act 1988 (United Kingdom) are regularly submitted to Forensic Medicine 
and Science for quantitative analysis of ethanol. Prior to 2007, on completion of 
the  case,  the  samples  were  removed  from  cold  storage  and  kept  at  room 
temperature as no disposal process was in place. This provided an ideal study to 
evaluate the stability of ethanol in preserved blood samples that were stored in 
crimped  cap  vials  containing  sodium  fluoride  and  potassium  oxalate  at 
concentrations ranging from 1 to 2%.   
3.4.2 Methodology 
Two hundred and nineteen preserved blood samples collected from individuals 
arrested under section 5 of the Road Traffic Act 1988 (United Kingdom) were 
analysed for the presence of alcohol on receipt within the laboratory of Forensic 
Medicine and Science (Result 1). The blood samples were refrigerated until the 
case  was  heard  in  court  (approximately  1  month  after  analysis).  Following 
completion of the court case the samples were removed from the refrigerator 
and stored at room temperature for varying periods of time spanning 5 years. 
The blood samples were removed from long-term storage at room temperature 
and re-analysed (Result 2).  
The initial analysis (Result 1) was carried out by FMS Technical Staff prior to 
attaining  ISO/IEC  17025  accreditation  for  the  analysis  of  ethanol  in  blood. 
Acetone  was  quantified  in  these  cases  using  a  positive  control  and  the 
calibration curve for ethanol (linear over the range of 0-400 mg/dL). 
The re-test (Result 2) of the blood was carried out using the validated method 
described in Chapter 2 utilising n-propanol as internal standard and HS-GC-FID. Chapter 3    89 
3.4.3 Results and Discussion  
Preserved  blood  samples  (N=219)  collected  from  individuals  arrested  under 
section  5  of  the  Road  Traffic  Act  were  initially  tested  following  short-term 
storage (Result 1) in a refrigerator and then re-tested after long-term storage of 
between  1  and  5  years  (Result  2)  at  room  temperature.  The  correlation 
coefficient  (R
2)  between  the  ethanol  concentrations  measured  was  0.85  as 
illustrated in Figure 3-5 with a P value of <0.05. Out of the 219 samples tested, 
208 when retested were positive at concentrations >10 mg/dL. The mean and 
median  ethanol  concentration  of  the  original  results  were  102  and  88 
respectively  and  for  retested  results  the  mean  and  median  were  71  and  60 
respectively. The vast majority (85%) had an ethanol recovery greater than 50% 
as summarized in Figure 3-6.  
Five samples were negative for ethanol at both the initial and second analysis 
times. Only 1% (N=3) of samples demonstrated ethanol formation Figure 3-7. One 
sample was originally negative for ethanol but when retested had an ethanol 
concentration  of  76  mg/dL  and  two  samples  positive  for  ethanol  at 
concentrations of 19 and 65 mg/dL after the initial analysis had significant gains 
when retested with ethanol concentrations of 46 (247%) and 138mg/dL (212%) 
respectively. This is most likely as a result of a lack of sufficient preservative in 
the collection vial or the blood in the collection vial was not mixed appropriately 
with preservative and anticoagulant powder.   
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Figure 3-5:  Correlation Between Road Traffic [Ethanol] following Long-Term Storage  
(Result 1 versus Result 2) Chapter 3    90 
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Figure 3-6:  Road Traffic Preserved Blood Percentage Recovery of Ethanol  
(Result 1 versus Result 2). 
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Figure 3-7:  Road Traffic Preserved Blood - Percentage Recovery of Ethanol following Long-
Term Storage at Room Temperature. 
 
 
With the exception of the two samples with excessively high gains in ethanol 
concentration,  the  average  recovery  of  ethanol  was  71%  with  a  standard 
deviation of 48.3, following long-term storage from between 1 and 5 years. As 
can be seen in Figure 3-7 the variation in recovery increases in proportion with 
the increasing number of years in storage. Only  23% of the samples retested 
after  more  than  3  years  in  storage  at  room  temperature  had  recoveries  of 
greater than 50% of the initial ethanol concentration.   Chapter 3    91 
3.5 Evaluation  of  the  Prevalence  of  Volatiles  in  Urine, 
Vitreous Humour and Bile and their Correlation with 
Femoral Blood. 
3.5.1 Introduction 
Interpretation  of  alcohol  concentrations  in  post-mortem  cases  is  more 
challenging if there is insufficient information about the type of death, the stage 
of the ethanol distribution in the body, incubation period, storage conditions and 
temperature  of  the  specimens.  Analysis  of  other  body  fluids,  mainly  vitreous 
humour,  bile  and  urine,  in  addition  to  blood  samples,  may  help  with 
interpretation. Ethanol distributes throughout other tissue or fluids according to 
their  water  content.  The  body  fluids  and  tissues  containing  more  water  will 
contain  more  alcohol.  Even  within  the  blood,  there  may  be  differences  in 
ethanol concentrations depending on the stage of absorption.(46)  
Samples of blood and urine are regularly submitted to FMS for the determination 
of volatiles, with ethanol and acetone most commonly identified but vitreous 
humour and bile are only submitted in a small proportion of cases. The sample 
database within FMS was used to extract all cases where alternative matrices 
(vitreous humour and bile) were analysed for volatiles in addition to femoral 
blood.  The  prevalence  of  volatiles  in  these  cases  was  evaluated  and  any 
correlations  between  urine,  vitreous  humour,  bile  and  femoral  blood 
investigated. 
3.5.2 Methodology 
The method used for the analysis of ethanol and acetone was fully validated, 
robust, and sensitive and was carried out by FMS Technical Staff. Acetone was 
quantified in these cases using a positive control and the calibration curve for 
ethanol (linear over the range of 0-400mg/dL).(132)  
Paired vitreous humour and blood (N=109), bile and blood (N= 20) and urine and 
blood (N=942) post-mortem case samples were analysed using HS-GC-FID.   Chapter 3    92 
Comparisons between the paired matrices were carried out by calculating the 
correlation coefficient (R
2) and P values to evaluate if there were significant 
differences between the volatile concentrations in both matrices.  
The ratio of the ethanol and acetone concentrations in vitreous humour, bile and 
urine versus those in femoral blood were calculated. The ratio range, at a 95% 
95%  confidence  interval  (95%  CI),  were  also  calculated  for  both  ethanol  and 
acetone.  The  calculated  ratios  were  compared  with  those  published  in  the 
literature.  
3.5.3 Volatile Standards 
n-Propanol  was  used  as  the  internal  standard  as  described  in  section  2.2.3. 
Certified solutions of ethanol were purchased from LGC Standards (Teddington, 
UK) at concentrations of 10, 25, 50, 80, 100, 200, 300 and 400 mg/dL. Quality 
control  (QC)  samples  were  purchased  from  Medichem  (Germany)  at 
concentrations of 30, 80 and 300 mg/dL. Acetone was quantified in these cases 
using a positive control (water spiked at 250 mg/L) and extrapolated using the 
ethanol calibration curve. 
3.5.4 Results 
3.5.4.1  Comparison of Ethanol Concentrations in Paired Blood and Vitreous 
Humour Samples 
Of the 109 paired blood and vitreous humour (VH) samples, 89% of the pairs 
were  positive  (N=43)  or  negative  (N=54)  for  ethanol  in  both  matrices  as 
summarised in Table 3-5. The remaining 12 paired case samples were negative in 
vitreous humour and positive in blood with ethanol concentrations ranging from 
12-70 mg/dL. The P value for VH versus blood was >0.05 with a value of 94.4% as 
summarised in Table 3-6 and illustrated in Figure 3-8. The mean ratio of VH:BAC 
in this study was 1.13 with a range of 1.00-1.26 in comparison with published 
ratios ranging from 0.63 – 1.75 (n=672) with mean value 1.19, median 1.18.(71) 
in  another  study  the  ratio  ranged  from  1.0  to  2.20(n=209)  mean  value  1.24, 
median 1.19.(73). Chapter 3    93 
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Figure 3-8:  Comparison of Ethanol Concentrations in Paired Blood and Vitreous Humour 
Samples  
 
 
Table 3-5:  Comparison of Positive and Negative Results for Ethanol in BloodVersus 
Vitreous Humour 
ETHANOL 
N= 109  Positive Vitreous 
Humour 
Negative Vitreous 
Humour 
Positive Blood  43  12 
Negative Blood  0  54 
 
 
Table 3-6:  Summary of Mean Ethanol Ratio and Correlation for Blood in Comparison to 
Vitreous Humour (VH), Bile and Urine. 
Ethanol 
Ratio 
Mean 
Ratio/(n)  
Median  St Dev.  SE 
Mean  95% CI 
Regression Equations   
  P value 
VH/Blood  1.13 
(n=43)  1.11  0.4319  0.0659  1.00-1.26  EtOH _Blood =  7.584 + 
0.8449 EtOH_VH  94.4  0.356 
Bile/Blood  1.04 
(n=13)  1.07  0.469  0.135  0.74-1.33  EtOH _Blood =  7.30 + 
0.7739 EtOH_Bile  92.0  0.122 
Urine/Blood  1.35 
(n=461)  1.31  1.0917  0.0491  1.25-1.44  EtOH _Blood =  0.559 + 
0.7607 EtOH_Urine  90.0  0.0001 
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3.5.4.2  Comparison of Ethanol Concentrations in Paired Blood and Bile 
Samples 
Of the 20 paired blood and bile samples, 80% of the pairs were positive (N=13) or 
negative (N=3) for ethanol in both matrices as summarised in Table 3-7. The 
remaining 4 paired case samples were negative in blood and positive in bile with 
ethanol concentrations ranging from 10-39 mg/dL.  
The  P  value  for  bile  versus  blood  was  >0.05,  this  indicates  no  significant 
difference between the ethanol concentrations in blood and bile.  The value of 
92% as summarised in Table 3-6 and illustrated in Figure 3-9. The mean ratio of 
bile to blood in this study was 1.04 with a range of 0.74-1.33 in comparison with 
published ratios ranging from 0.32 -2.91.(75) 
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Figure 3-9:  Comparison of Ethanol Concentrations in Paired Blood and Bile Samples 
 
Table 3-7:  Comparison of Positive and Negative Results for Ethanol in Blood Versus Bile 
ETHANOL 
N = 20  Positive Bile  Negative Bile 
Positive Blood  13  0 
Negative Blood  4  3 
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3.5.4.3  Comparison  of  Ethanol  Concentrations  in  Paired  Blood  and  Urine 
Samples 
Of  the  942  paired  blood  and  urine  samples,  85%  of  the  pairs  were  positive 
(N=461) or negative (N=338) for ethanol in both matrices as summarised in Table 
3-8.  Of  the  remaining  paired  case  samples,  34  were  negative  in  urine  and 
positive in blood with ethanol concentrations ranging from 10-303 mg/dL, and 
109 were negative in blood and positive in urine with ethanol concentrations 
ranging from 10-174 mg/dL. The P value for urine versus blood was <0.05 with a  
value of 90% as summarised in Table 3-6 and illustrated in Figure 3-10. The mean 
ratio  of  urine  to  blood  in  this  study  was  1.35  with  a  range  of  1.25-1.44  in 
comparison with published ratios ranging from 0.53 -2.17.(61;67;68). In another 
study the first void ethanol mean ratio was 1.34 with the range of 1.68-1.75 and 
the second void ethanol urine to blood ratio was 1.22 with a range of 1.43-1.47. 
(61) 
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Figure 3-10:  Comparison of Ethanol Concentrations in Paired Blood and Urine Samples 
 
Table 3-8:  Comparison of Positive and Negative Results for Ethanol in Blood Versus Urine 
ETHANOL 
N = 942  Positive Urine  Negative Urine 
Positive Blood  461  34 
Negative Blood  109  338 
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3.5.4.4  Comparison of Acetone Concentrations in Paired Blood and Vitreous 
Humour and Paired Blood and Bile Samples 
Tables  3-9  and  3-10  summarise  the  results  for  acetone  in  paired  blood  and 
vitreous humour samples and paired blood and bile samples respectively. Of the 
104 paired blood and vitreous humour samples, 100% of the pairs were positive 
(N=2) or negative (N=102) for acetone in both matrices, while 84% of the paired 
blood and bile samples were positive (N=3) or negative (N=13) for acetone in 
both matrices. Of the remaining paired blood and bile samples, 2 were negative 
in bile but positive in blood with acetone concentrations of 44 and 62 mg/L. One 
case  was  negative  in  blood  <10  mg/L  but  positive  in  bile  with  an  acetone 
concentration of 15 mg/L.  
Table  3-11  summarises  the  ratios  and  correlations  values  for  both  vitreous 
humour and bile acetone concentrations versus blood acetone concentrations. 
The  P  values  for  both  were  >0.05  for  both  which  indicates  that  there  is  no 
significant difference between two sets of results (VH-Blood and Bile-blood). The 
mean ratio values which was 2.61 for VH: blood acetone concentrations and 0.54 
for bile: blood acetone concentrations.  
Table 3-9:  Comparison of Positive and Negative Results of Acetone in Blood versus 
Vitreous Humour 
ACETONE 
N = 104  Positive Vitreous 
Humour 
Negative Vitreous 
Humour 
Positive Blood  2  0 
Negative Blood  0  102 
 
Table 3-10:  Comparison of Positive and Negative Results of Acetone in Blood Versus Bile 
ACETONE 
N = 19  Positive Bile  Negative Bile 
Positive Blood  3  2 
Negative Blood  1  13 
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Table 3-11:  Summary of Mean Acetone Ratio and correlation for Blood in Comparison to 
Vitreous Humour (VH), Bile and Urine. 
Acetone 
Ratio 
Mean 
Ratio/(n)   Median  St Dev. 
SE 
Mean  95% CI  Regression Equations 
 
  P value 
VH/Blood  2.61  
(n=2) 
2.61  1.85  1.31  0-19.27 
Acetone 
_Blood=0.2351+0.3820 
Acetone_VH 
74.4  0.248 
Bile/Blood  0.54  
(n=3) 
0.64  0.281  0.126  0-1.08 
Acetone _Blood 
=6.083+1.749 
Acetone_Bile 
0.41  0.064 
Urine/Blood  2.11 
(n=70) 
1.56  2.262  0.270  1.57-2.65 
Acetone _Blood 
=1.101+0.5021 
Acetone_Urine 
0.69  0.0001 
 
3.5.4.5  Comparison  of  Acetone  Concentrations in  Paired  Blood and  Urine 
Samples 
Of the 934 paired blood and urine samples, 96% of the pairs were positive (N=70) 
or negative (N=828) for acetone in both matrices as summarised in Table 3-12. 
Of the remaining paired case samples, 7 were negative in urine and positive in 
blood  with  acetone  concentrations  ranging  from  56-339  mg/L,  and  29  were 
negative in blood and positive in urine with acetone concentrations ranging from 
25-861 mg/L.  There were three samples not included in the calculation and 
were considered as outliers and they were at concentrations of 1482 mg/L in 
urine  with  a  corresponding  negative  blood),  2879  mg/L  in  urine  and 
corresponding  negative  blood)  and  1581  mg/L  in  urine  and  117  mg/L 
corresponding in blood). (The P value for urine versus blood was <0.05 with a 
value of 68.6% as summarised in Table 3-11 and illustrated in Figure 3-11. The 
mean ratio of urine to blood in this study was 2.11 with a range of 1.57-2.65.  
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Figure 3-11:  Comparison of Acetone Concentrations in Paired Blood and Urine Chapter 3    98 
 
Table 3-12:  Comparison of Positive and Negative Results for Acetone in Blood Versus Urine 
ACETONE 
N = 934  Positive Urine  Negative Urine 
Positive Blood  70  7 
Negative Blood  29  828 
 
 
3.5.5 Discussion 
Ethanol  concentrations  in  vitreous  humour  and  bile  samples  were  not 
significantly different from the blood ethanol concentrations. The ratio of VH 
ethanol concentration to blood ethanol concentration  was reported to be higher 
during the post absorption phase as a result of the higher percentage of water in 
VH than in blood.(73) The mean ratio of VH/Blood in this study was 1.13 which is 
in agreement with published ratios as previously indicated.  It was also observed 
that 12 of the 109 case samples were negative for ethanol in VH but positive in 
the paired blood sample. The most likely explanation for this is neo formation of 
ethanol  in  blood  by  microorganisms  or  that  the  death  occurred  before 
equilibrium was achieved.  
The bile to blood ratio range of ethanol concentration obtained from this study 
was within the published range. Four bile samples were positive for ethanol but 
negative in paired blood samples. A possible reason behind this could be that the 
sample  was  collected  during  the  post-absorption  phase  after  ethanol  was 
eliminated from the blood. There was a significant difference between urine and 
blood ethanol concentration, although the R
2 was approximately 90% and the 
ratio of urine to blood was in agreement with published ratios. 34 out of 942 
case samples were negative for ethanol in urine but positive in blood. This may 
be due to several factors, such as formation of ethanol in blood due to bacterial 
action;  or  death  occurred  in  the  pre-absorption  phase;  or  the  urine  may  be 
diluted or contaminated. It could also be due to loss of ethanol from the urine 
sample  due  to  microorganisms  especially  in  non-preserved  samples  or  the 
container may not have been sealed properly or was an unsuitable size. Another Chapter 3    99 
reason might be that there is still a residue of negative urine in the bladder that 
diluted the urine after alcohol consumption.  
A total of 109 urine samples were positive for ethanol in urine but negative in 
blood. This could be due to the sample being collected in the post-absorption 
phase, formation of ethanol due to microorganism action in the urine sample or 
if the sample was collected and stored in unpreserved samples.  
The P values were > 0.05 for acetone concentrations in vitreous humour and bile 
paired  with  blood,  indicating  that  there  is  no  significant  difference  in  these 
matrices. However, a large proportion of the samples tested were negative and 
as such any conclusions from this study must be made with caution and it is 
recommended that a much larger study be carried out with more positive paired 
samples.  
The two samples that were negative for acetone in bile but positive in blood 
could be because the sample was collected in the pre-absorption phase, due to 
acetone formation or as a result of oxidation of isopropanol to acetone.  
A significant difference was indicated between acetone concentrations in blood 
and urine. Seven cases were negative for acetone in urine but positive in blood 
and this may be due to formation of acetone in blood due to microorganisms, or 
due to oxidization of isopropanol to acetone. Twenty nine cases were positive 
for acetone in urine but negative in blood. This may be due to the samples being 
collected after elimination of acetone from blood or due to loss of acetone due 
to evaporation. There are no published ratios for acetone in body fluids versus 
blood to make any further comparison with those calculated in this study. Chapter 3    100 
3.6 Evaluation  of  the  Immunalysis  Ethyl  Alcohol 
Enzymatic  Assay  as  a  Semi-Quantitative  Test  in 
Comparison to HS-GC-FID 
3.6.1 Introduction 
Testing each sample received in the forensic laboratory by complicated methods 
and instrumentations will need more manpower, time, and high cost especially 
when the workload is high. The purpose of the immunoassay screening tests is to 
eliminate  the  negative  samples  from  the  more  lengthy  confirmation  testing 
process. There are different types of immunoassays including radioimmunoassay 
(RIA),  fluorescence  polarization  immunoassay  (FPIA),  enzyme  multiplied 
immunoassay technique (EMIT), and enzyme linked immunosorbant assay (ELISA). 
Several biological matrices can be tested with immunoassays, including blood, 
hair, oral fluid, plasma, post-mortem blood, serum, urine, and sweat. Sample 
pre-treatment is required before applying the samples to the microplate.  
The  basic  principle  is  that  immunoassays  can  be  used  to  screen  biological 
samples for an antigen, such as a drug of interest. Establishing the cut-off point 
in an enzymatic method is important in order to distinguish between positive 
and  negative  results  and  provide  a  balance  between  false  positive  and  false 
niegative results.  
Cross-reactivity  may  occur  in  tested  specimens  with  structurally  similar 
compounds  or  due  to  interference  from  the  matrix.  In  terms  of  result 
interpretation,  a  false  negative  result  means  that  it  was  negative  by 
immunoassay and positive with a confirmatory test. A false positive result means 
that the screening was positive and the confirmatory test was negative. 
The  signal  changes  associated  with  binding  to  form  a  labelled  "antibody  and 
drug–derivative immune complex" can be measured either qualitatively or semi-
quantitatively. The qualitative mode is used as a screening test to identify the 
presence or absence of the analyte of interest relative to the cut-off value. The 
semi-quantitative mode is conducted by comparing the signal value of a known 
sample to a calibration curve to estimate the concentration of in the sample.  Chapter 3    101 
The Immunalysis ethyl alcohol assay is an enzymatic method used for the semi-
quantitative analysis of ethyl alcohol in human blood. Positive alcohol results 
generated  from  using  the  enzymatic  method  should  be  confirmed  with  an 
alternative non-enzymatic method such as head space gas chromatography flame 
ionization detection (HS-GC-FID).(176)  
Enzymatic assays used for the detection of ethanol in humans are based on the 
same  reaction  that  occurs  in-vivo  (see  Figure  3-12).  Ethanol  is  converted  to 
acetaldehyde  in  the  presence  of  alcohol  dehydrogenase  (ADH)  with  the 
accompanying formation of the nicotinamide adenine dinucleotide reduced form 
(NADH). NADH is then measured spectrophotometrically at a wavelength of 340 
nm.(176;177) 
 
Figure 3-12:  Enzymatic Alcohol Reaction 
 
3.6.2 Chemicals and Reagents 
Certified  ethanol  standard  solutions  were  purchased  from  LGC  Standards 
(Teddington, UK). The concentrations were: 25 mg/dL 50 mg/dL, 80 mg/dL, 100 
mg/dL, 200 mg/dL, 300 mg/dL, and 400 mg/dL. The Enzymatic Kit for alcohol 
determination  in  blood  was  manufactured  by  the  immunalysis  Corporation 
(Pomona, CA, USA) and contained one bottle of 0.5 N perchloric acid, Reagent A 
(RA) containing 0.6 M tris buffer, and Reagent E (RE) containing ADH and NAD in 
tris  buffer  as  a  stabilizer.  Both  RA  and  RE  contain  0.1%  sodium  azide 
preservative.  Other  materials  included  96-well  flat-bottom  polysterene 
microtiter plates; pipettes with volumes of 10, 20, and 100 µL with disposable 
tips, disposable 1.5 polypropylene conical bottom centrifugal tubes with caps, 
and a timer. 
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3.6.3 Methodology 
A total of 60 post-mortem blood samples, 50 preserved in 0.2% sodium fluoride 
(NaF) and 10 unpreserved were analysed for ethanol, acetone, isopropanol, and 
methanol utilizing a validated HS-GC-FID as described in Chapter 2. The same 
samples were screened for ethanol using the enzymatic assay.(176)  
The cut-off point used to distinguish positive from negative utilizing HS-GC-FID 
was  10  mg/dL  for  ethanol  and  10  mg/L  for  acetone.  Although  the  LOD  was 
established  by  the  immunalysis  manufacturer  at  10  mg/dL,  the  cut-off  point 
used  for  the  ethanol  results  generated  from  the  enzymatic  method  was  25 
mg/dL, equivalent to the lowest point of the calibration curve.  
A tabulated cross-match between the positive and negative results was carried 
out in addition to evaluating any correlation between the two tests.  
3.6.3.1  Enzymatic Ethyl Alcohol Assay 
An aliquot of 100 µL of the standard, sample or quality control material was 
added with 400 µL 0.5N perchloric acid to each centrifuge tube. The tubes were 
vortexed and left at room temperature for 5 minutes. All tubes were centrifuged 
at 4000 RPM for 5 minutes. A 10 µL aliquot of the clear solution was transferred 
to a microplate well in duplicate and 100 µL each of RA and RE added to each 
well. The plate was covered and placed in the dark for 30 minutes, then the 
plate was read at 340nm using microplate RXM reader.  
3.6.3.2  HS-GC-FID 
The validated method utilizing HS-GC-FID and n-propanol as internal standard 
was carried out as described in chapter 2. 
3.6.4 Method Validation 
For  the  enzymatic  assay,  validation  was  carried  out  by  the  Immunalysis 
manufacturer  as  per  the  manufacturers  insert  package  instructions.(176)  The 
linearity was assessed by preparing the calibrators at 0, 20, 100, 200, and 400 
mg/dL.  Intra-assay  (within-run)  and  inter-assay  (between-run)  precision  was Chapter 3    103 
obtained by preparing 8 replicates of treated samples at concentrations of 0, 20, 
100,  200,  and  400  mg/dL.  In  terms  of  accuracy,  two  sets  of  data  (n=50) 
generated from the HS-GC-FID and enzymatic method were compared and the R
2 
was calculated. Specificity was assessed with various structurally similar organic 
compounds tested at different levels, such as acetaldehyde, acetone, n-butane, 
ethylene glycol, isopropanol, methanol, n-propanol, and urea. The linearity was 
assessed by preparing a concentration range of 25-400 mg/dL for ethanol. The 
cut-off point used in this method was at the concentration of the first calibrator 
(25 mg/dL).  
3.6.5 Results and Discussion 
The  cross-reactivity  studies  were  carried  out  by  the  manufacturer  and  were 
reported as low for all volatiles assessed: n-butanol (9%), ethylene glycol (2.5%), 
isopropanol (6.5%) and n-propanol (11.5%). 
Linearity was assessed using certified standards and ranged from 25-400 mg/dL 
with an >0.997 (Figure 3-13). 
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Figure 3-13:  Calibration Curve for Ethanol using the Enzymatic Assay 
 
 
Table 3-13 summarises the semi-quantitative results for the samples tested using 
the enzymatic assay and the quantitative results following analysis by HS-GC-
FID.  Of  the  60  samples,  24  (21  preserved  and  3  unpreserved)  samples  were 
positive  in  both  methods,  while  31  (26  preserved  and  5  unpreserved)  were 
negative in both. These results are summarised in Table 3-14 and highlight four Chapter 3    104 
samples (3 preserved and 1 unpreserved) that were positive by HS-GC-FID but 
negative  by  the  enzymatic  assay,  and  1  unpreserved  blood  sample  that  was 
negative by HS-GC-FID but positive by the enzymatic assay. 
Table 3-13:  Ethanol Results for HS-GC-FID versus Enzymatic Assay highlighted 
mismatched cases in yellow 
 UP-Unpreserved 
Case 
No. 
Enz 
(mg/dL) 
GC 
(mg/dL) 
Case 
No. 
Enz 
(mg/dL) 
GC 
(mg/dL) 
Case 
No. 
Enz 
(mg/dL) 
GC 
(mg/dL) 
1  33  73  16  <25  <10  34  <25  <10 
1UP  57  141  16UP  <25  <10  35  <25  <10 
2  48  89  17  355  296  36  <25  11 
3  <25  <10  18  25  22  36UP  <25  <10 
4  118  157  19  <25  <10  37  366  340 
5  109  162  20  <25  <10  38  <25  <10 
5UP  161  222  21  <25  <10  39  <25  <10 
6  187  216  22  231  155  40  <25  <10 
7  <25  <10  23  <25  <10  41  <25  <10 
8  <25  12  24  <25  <10  42  <25  <10 
8UP  <25  24  25  <25  <10  43  351  245 
9  226  233  26  370  199  44  <25  <10 
10  <25  <10  27  <25  <10  45  319  236 
11  166  167  28  329  185  45UP  <25  <10 
12  <25  30  29  <25  <10  46  259  230 
13  <25  <10  30  <25  <10  47  342  265 
13UP  <25  <10  31  <25  <10  48  <25  <10 
14  213  186  32  362  202  49  321  220 
15  <25  <10  32UP  134  14  50  <25  <10 
15UP  <25  <10  33  247  250  50UP  29  <10 Chapter 3    105 
Table 3-14:  Ethanol in Blood (Enzymatic-v-HS-GC-FID) 
Ethanol in Blood GC vs. Immunoassay Method 
N = 60  Positive 
(Enzymatic) 
Negative 
(Enzymatic) 
Positive (GC result)  24  4 
Negative (GC result)  1  31 
 
The correlation coefficient (R
2) between the two sets of the results was 87.6% as 
illustrated in Figure 3-14). The P value was 0.056, indicating that there is no 
significant difference between the results of the two methods. 
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Figure 3-14:  Blood Ethanol Correlation between HS-GC-FID and the enzymatic method 
 
Table 3-15 highlights the five unmatched ethanol results. The first four samples 
were all positive by HS-GC-FID and negative by the enzymatic assay, however 
the different cut-off points used for each method provide an explanation for the 
difference in these results. Although the manufacturer's cut-off was 10 mg/dL 
for ethanol and 10 mg/L for acetone and because the immunoassay method used 
for the purpose of comparison with HS-GC-FID, validation of this method has not 
been carried out. Instead the lower point used for the immunoassay calibration 
curve which are 25 mg/dL for ethanol and 25 mg/L for acetone was used as a 
cut-off for the immunoassay method. Chapter 3    106 
Table 3-15:  Mismatched Ethanol Results (Enzymatic versus HS-GC-FID)  
Case 
No. 
Sample 
Condition 
Acetone 
HS-GC-FID  
(mg/L) 
Ethanol 
HS-GC-FID 
(mg/dL) 
Ethanol 
Enzymatic Method 
(mg/dL) 
8  Preserved  443 (POS)  12 (POS)  (2) <25 (NEG) 
8  Unpreserved  310 (POS)  24 (POS)  (9) <25 (NEG) 
12  Preserved  29 (POS)  30 (POS)  (22) <25 (NEG) 
36  Preserved  25 (POS)  11 (POS)  (11) <25 (NEG) 
50  Unpreserved  162 (POS)  <10 (NEG)  (29) (POS) 
 
One sample, number 50, was negative using HS-GC-FID and positive using the 
enzymatic method. Two possible explanations are that as the sample contains no 
preservative and there was a delay between the initial test by HS-GC-FID and the 
enzymatic assay, the formation of ethanol may have taken place, or it may be 
due  to  interference  from  other  volatile  compounds  that  were  present  in  the 
sample. The cross-reactivity of acetone was not reported by the manufacturer so 
this may provide an explanation. However, acetone was also present in the other 
samples  and  is  a  particularly  high  concentration  in  both  preserved  and 
unpreserved  samples  of  case  8  with  corresponding  negative  enzymatic  assay 
response. 
3.7 Conclusion 
All  volatiles  investigated  in  this  study,  with  the  exception  of  methanol,  had 
improved stability when stored in containers with preservative (0.2 or 1% sodium 
fluoride)  and  antioxidant  (0.2%  sodium  metabisulphite).  Storage  at  -22°C  is 
preferred for optimal stability rather than at room temperature (25°C) or in the 
refrigerator  (4°C).  Isopropanol  concentrations  decreased  and  acetone 
concentrations increased over the 50-day testing period, confirming oxidation of 
isopropanol  to  acetone.  The  oxidation  process  for  both  isopropanol  and  n-
propanol was significantly reduced with the addition of the antioxidant, sodium 
metabisulphite.  
Blood  samples  collected  following  suspected  drink-driving  offences  which 
contain both preservative and antioxidant were stored at room temperature for 
a period of between 1 to 5 years following initial tests for ethanol. Recoveries of Chapter 3    107 
50% or more of the original ethanol concentration were achieved in 85% of the 
samples tested. However, recoveries decreased with increasing number of years 
of storage with only 23% of the samples retested after more than 3 years with 
recoveries achieving 50% or more.  
Over a period of six months refrigerated storage, significant loss and formation 
of  ethanol  occurred  in  both  preserved  and  unpreserved  paired  post-mortem 
blood samples from cases submitted to the toxicology laboratories of Forensic 
Medicine and Science. However, further losses were not significant following an 
additional storage period of 10 months in the freezer at -22°C. 
Further investigations  are  needed  to  evaluate  the  effect  of  anti-coagulant  in 
terms  of  anti-oxidation  and  to  investigate  the  optimum  antioxidant 
concentration with the additional evaluation of a longer period of storage to 
optimize the conditions required to prevent loss or formation of volatiles.  
These  findings  support  the  conclusions  of  the  author  of  a  2007  report  who 
highlighted the importance of understanding the stability of analytes of interest 
and ultimately interpretation for medico-legal casework.(178)  
Several different specimens should be collected from different sites of the body, 
mainly  vitreous  humour,  or  bile  and  urine  if  they  are  available  for  better 
interpretation of alcohol results. Many other factors might be useful for better 
interpretation of alcohol results (e.g. the circumstances of the death and the 
peri-mortem status, medical history of the deceased if any ante-mortem dilution 
occured due to transfusions of blood or fluids at the hospital, contamination of 
specimen by diffusion from the stomach to surrounding organs in case of trauma, 
or stage of absorption in the body, post- mortem decomposition and embalming 
effect). Collection of post-mortem samples for alcohol analysis should be under 
hygienic procedures, with proper storage in a container that includes a suitable 
preservative and is stored at a low temperature. These measures may help to 
eliminate the alteration of the alcohol level from the time of collection until 
analysis, however this will not prevent the action of microorganisms between 
death  and  time  of  sample  collection,  especially  in  cases  of  advanced 
decomposition.  Chapter 3    108 
Although femoral blood is recommended for the analysis of alcohol, this sample 
is  not  always  available.  In  this  study,  the  comparison  showed  a  correlation 
between  bile,  vitreous  humour  and  blood,  which  may  indicate  that  the 
distribution in the majority of the case samples was in post-absorption. Vitre 
Humor, urine and bile/blood ratios were within the published range with the 
urine  alcohol  results  significantly  different  with  blood  for  both  ethanol  and 
acetone.  Vitreous  humour  and  bile  seem  to  be  more  reliable  than  urine  as 
alternative samples in a post-mortem casewoek for alcohol and acetone analysis. 
A  wide  range  of  data  needs  to  be  analysed  for  alcohol  and  acetone  with 
consistent  sample  conditions  in  order  to  confirm  this  conclusion;  also  many 
factors (as mentioned previously) that may affect the alcohol level should be 
considered when using urine as an alternative sample. More investigation needs 
to be carried out in relation to acetone such as: cut of points in the post-mortem 
formation, stability and the ratio between blood and other body fluids. Analysis 
of ethanol biomarkers may help with interpretation. 
The  enzymatic  assay  demonstrated  good  correlation  with  HS-GC-FID.  Further 
evaluation  and  optimization  of  the  LOD  and  LLOQ  is  required.  However,  its 
application to post-mortem or criminal toxicology is of limited value. 109 
Chapter 4 - Determination of β β β β-Hydroxybutyrate 
(BHB) in Post-mortem Blood and Urine Using Gas 
Chromatography -Mass Spectrometry (GC-MS) 
4.1 Introduction 
β-Hydroxybutyrate (BHB) has the potential as a biomarker for sudden deaths in 
chronic alcoholics caused by alcoholic ketoacidosis (AKA). The aim of this study 
was  to  develop  and  validate  a  method  for  the  determination  of  BHB  in 
postmortem  blood  and  urine  using  GC-MS  following  silyl  derivatisation.  The 
validated  method  was  then  applied  to  the  analysis  of  real  case  samples  to 
investigate the prevalence of BHB in medico-legal cases. 
A further database study of all samples tested for BHB, ethanol and acetone 
within  Forensic  Medicine  and  Science  (FMS)  was  carried  out  to  evaluate  the 
relationship  between BHB,  ethanol,  and acetone  levels  in  post-mortem  blood 
and urine.  
4.2 Method Development 
4.2.1 Materials 
4.2.1.1  Chemicals and Reagents  
The  internal  standard  used  was  deuterated  γ-hydroxybutyrate  (GHB-d6,  1 
mg/mL)  purchased  from  LGC  Standards  (Teddington,  UK).  β-Hydroxybutyrate 
(BHB)  and  o-bis  (trimethylsilyl)  trifluoroacetamide  (BSTFA)  with  1% 
trimethylchlorosilane  (TMCS)  were  sourced  from  Sigma-Aldrich.  (Basingstoke, 
England). Acetonitrile (ACN), methanol (MeOH) and ethyl acetate (EtOAc) were 
all  HPLC  grade,  sulphuric  acid  was  98%  and  were  all  purchased  from  VWR 
International Ltd. Disodium hydrogen orthophosphate anhydrous (Na2HPO4; MW 
141.96) and sodium dihydrogen orthophosphate monohydrate (NaH2PO4H2O; MW 
137.99) were sourced from BDH. Sodium chloride 99+% was sourced from Aldrich. 
Ammonia solution 35% was sourced from Fisher Scientific. ZSGHB20 Clean Screen 
SPE column size 200 mg/10 mL were purchased from United Chemical Company Chapter 4    110 
UCT, USA. Distilled water came from the Millipore purification system within 
FMS.  
4.2.1.2  Preparation of Blank (Drug and Volatile-Free) Blood and Urine 
Prepared using expired packed red blood cell pouches and 1% saline solution as 
described  in  section  2.2.2.  Blank  urine  was  obtained  from  a  healthy  adult 
volunteer  with  no  history  of  alcohol consumption.  Triplicate  samples  of  each 
blood and urine were screened for BHB and the level was less than the LOD 
limits.  Preparation of Standards and Quality Controls 
Two  separate  stock  standard  solutions  (A)  and  (B)  were  prepared  at 
concentrations of 2 g/L. Stock standard solution (A) was used to prepare the 
standards for the calibration curve. The calibrator points were prepared in blood 
and urine as summarised in Table 4-1 from the stock standard to give final BHB 
concentrations of 0, 5, 10, 25, 50, 100, 200, 300, 400, 500 mg/L. 
Table 4-1:  Preparation of BHB Calibration Standards 
Calibrator 
Concentrations  
(mg/L) 
Calibration 
Level 
Volume of 
Stock A 
Added 
(µL) 
Final 
Volume 
Blood/Urine 
(mL) 
0  Level 1  0  5 
5  Level 2  12.5  5 
10  Level 3  25  5 
25  Level 4  62.5  5 
50  Level 5  125  5 
100  Level 6  250  5 
200  Level 7  500  5 
300  Level 8  750  5 
400  Level 9  1000  5 
500  Level 10  1250  5 
 
Stock  solution  (B)  was  used  for  preparing  the  quality  control  samples  as 
summarised in Table 4-2. Quality control material was prepared in blood and 
urine at concentrations of 50 and 300 mg/L and then aliquoted and transferred 
to 1.5mL polypropylene tubes and stored at -22±2°C.  Chapter 4    111 
Table 4-2:  Preparation of BHB Quality Control Samples 
Concentrations  
(mg/L) 
QC's 
level 
Volume of 
Stock B 
Added 
(µL) 
Final 
Volume 
Blood/Urine 
(mL) 
0  Level 1  0  5 
50  Level 5  125  5 
300  Level 8  750  5 
 
The working internal standard (GHB-D6) was prepared at 10 mg/L in methanol 
from a stock solution of (1 mg/mL). This was achieved by adding 1 mL of the 
stock internal standard solution (1 mg/mL) to a 100 mL volumetric flask and 
diluting with methanol.  
4.2.1.3  Preparation of Solutions 
0.1M  monobasic  sodium  phosphate  was  prepared  by  weighing  and  transfering  
2.76g  of  sodium  dihydrogen  orthophosphate  monohydrate  (NaH2PO4H2O;  MW 
137.99) to a 200 mL volumetric flask, dissolving in 100 mL deionized water and 
then  making  up  to  the  mark  with  water.  The  solution  was  mixed  and  then 
transferred to a labelled clean glass bottle to be stored for 1 month at 5±1ºC. 
0.1M dibasic sodium phosphate was prepared by weighing and transferring  2.84g 
of disodium hydrogen orthophosphate anhydrous (Na2HPO4; MW 141.96) to a 200 
mL volumetric flask, dissolving in 100 mL deionized water and then making up to 
the mark with water. The solution was mixed and then transferred to a labelled 
clean glass bottle to be stored for 1 month at 5±1ºC. 
0.1  M  phosphate  buffer  (pH  6)  was  prepared  by  dissolving  1.7g  disodium 
hydrogen  orthophosphate  anhydrous  (Na2HPO4)  and  12.14g  sodium  dihydrogen 
orthophosphate  monohydrate  (NaH2PO4H2O)  in  800  mL  of  water.  The  pH  was 
adjusted to pH 6±0.1 with 0.1M monobasis sodium phosphate (lowers pH) or 0.1M 
dibasic sodium phosphate (raises pH) and made up to 1 litre with water. The 
buffer was mixed and then transferred to a labelled clean glass bottle to be 
stored for 1 month at 5±1ºC. Chapter 4    112 
Methanol (CH3OH)/Ammonia NH4OH (99:1) was prepared by measuring 99 mL of 
methanol  using  a  measuring  cylinder  and  was  then  transferred  to  a  clean 
labelled reagent bottle and 1 mL of ammonia added and mixed. This solution 
was prepared fresh daily    
A solution of 0.025M H2SO4 was prepared by dissolving 0.695 mL of concentrated 
(18 M) sulphuric acid in approximately 200 mL of deionized water and then made 
up to the mark (500 mL volumetric flask) with water.  The solution was stored at 
room temperature after being transferred to a clean labelled bottle. 
4.2.2 Instrumentation 
Gas  chromatography-mass  spectrometry  (GC-MS)  was  carried  out  using  a 
Thermoquest, CE Instrument Trace GC with X-calibur software coupelled with 
Finnigan  Trace  MS  and  AS  800  autosampler  purchased  from  (Thermo  Fisher 
Scientific, UK). The column used was a DB-5 capillary column (5% phenyl/95% 
methylsiloxane, 30m x 0.25 mm I.D. 0.25 mm film thickness) purchased from 
Agilent Technologies Ltd, UK.  
4.2.2.1  GC/MS Conditions 
Optimization of the GC conditions was carried out by comparing two programs:  
Initial GC program - Initial oven temperature of 60ºC was held for two minutes 
and then ramped to 180ºC at 15ºC/min, followed by a further ramp to 300ºC at 
50ºC/min and held for 5 minutes. The total run time was 10 minutes. The source 
temperature was 200ºC; the transfer line temperature was 250ºC; the injector 
base temperature was 250ºC using splitless mode and the carrier gas flow rate 
was 1.2 mL/min. The mass detector multiplier voltage was 500 volts and the 
scan range was 40-300 amu.  
Final GC program - Initial oven temperature of 60ºC was held for two minutes 
and then ramped to 180ºC at 20ºC/min, followed by a further ramp to 250ºC at 
50ºC/min and held for 1 minute. The total run time was 10 minutes. The source 
temperature was 200ºC; the transfer line temperature was 250ºC; the injector 
base temperature was 250ºC using splitless mode and the carrier gas flow rate Chapter 4    113 
was 1.2 mL/min. The mass detector multiplier voltage was 500 volts and the 
scan range was 40-300.  
Data was collected in full scan mode and the ions monitored were: m/z 233, 
191, and 117 for BHB and m/z 239 and 240 for the internal standard GHB-d6. The 
bolded underlined ions were used for quantification. 
4.2.3 Method Evaluation 
Methods previously developed by other authors(179-181) were modified slightly, 
including  optimisation  of  the  extraction,  derivatization  and  GC-MS  conditions 
and were then applied to blood and urine samples. The three methods involved: 
(A) clean screen solid-phase extraction (SPE); (B) liquid-liquid extraction (LLE) 
and (C) protein precipitation. A summary of the methods are listed in Table 4-3. 
Table 4-3:  Methods Evaluated for the Determination of BHB in Blood and Urine.  
Method  Conditions  Extraction Solvent  Derivatization Conditions 
A (SPE)  Original(181) 
Acetone, pH 6 
Phosphate buffer  
MeOH: 
Ammonia 99:1 
100 µL EtOAc:100 µL of 
BSTFA+1%TMCS at 70ºC for 30 
minutes 
B (LLE) 
Original(179)  EtOAc  75 µL ACN: 25 µL BSTFA+1% TMCS at 
60ºC for 60 minutes 
Condition 1  EtOAc  75 µL ACN: 25 µL BSTFA+1% TMCS at 
60ºC for 60 minutes 
Condition 2   EtOAc  50 µL  EtOAc: 50 µL BSTFA+1% TMCS 
at 70ºC for 30 minutes 
Condition 3   EtOAc  25 µL  EtOAc: 75 µL BSTFA+1% TMCS 
at 70ºC for 30 minutes 
C (PP)  Original(180)  ACN  75 µL BSTFA+1% TMCS, at 90ºC for 10 
 
 
SPE - Solid Phase Extraction, LLE - Liquid-Liquid Extraction, PP - Protein Precipitation, 
EtOAc - Ethyl Acetate and ACN - Acetonitrile  
 
Two of the methods (A and C) were originally used for analysing GHB in different 
post-mortem matrices and were applied to the detection of BHB in blood and 
urine due to the similarity of their chemical structure.  Chapter 4    114 
Peak  shape,  reproducibility,  time  of  extraction,  linearity  range  and  the 
cleanliness  of  the  derivative  were  evaluated  when  comparing  the  above 
methods. The LLE extraction method (B) was also used to evaluate and optimize 
different derivatization conditions (incubation temperature and time and volume 
of derivatising agent) as summarised in Table 4-3.  
4.2.3.1  Method A – CLEAN SCREEN SPE 
The CLEAN SCREEN SPE is a mixed-mode cartridge packed with hydrophobic and 
phenyl/ propylsulfonic acid, which is a strong cationic exchange sorbent.(182) It 
was designed to be used for filtration and extraction of GHB. Isolation of BHB 
from  blood  and  urine  was  achieved  using  acetone,  after  adding  100  µL  of 
internal  standard  (GHB-D6)  as  follows;  after  vortexing  for  15  seconds  and 
centrifugation at 1500 rpm for 5 minutes, the upper layer was collected and 
transferred to a clean vial and evaporated at 70ºC to dryness with nitrogen. The 
dried extract was dissolved in 200 µL of 0.1M phosphate buffer (pH 6.0) and was 
vortex  mixed  for  10  seconds.  The  reconstituted  extract  of  the  samples  was 
applied to the conditioned SPE columns. Clean test tubes were added to the rack 
and then 1 mL of methanol/ammonia (99:1) was added to the original sample 
test tube, vortex mixed and then decanted onto the SPE column. The extract 
was collected, removed from the vacuum manifold and evaporated at 70ºC to 
dryness with nitrogen. For the derivatization step, 100 µL of ethyl acetate and 
100 µL of BSFTA +1% TCMS were added to all samples, mixed, and heated at 70ºC 
for 30 minutes. Samples were transferred to GC vials and 2 µL injected onto the 
GC-MS.  
4.2.3.2   Method B – Liquid-Liquid Extraction (LLE) 
A 100 µL aliquot of blood or urine was extracted by adding 100 µL of internal 
standard (GHB-d6), 1 mL ethyl acetate and 100 µL 0.025 M sulphuric acid. After 
mixing in the sample shaker for 10 minutes, the samples were centrifuged at 
1500 rpm for 5 minutes. The upper layer was collected and transferred to a 
clean vial and evaporated to dryness with nitrogen then derivatized with BSFTA 
+1%  TCMS.  Evaporation  and  derivatization  was  carried  out  at  different 
temperatures and using different ratio mixtures of ethyl acetate and BSFTA +1% Chapter 4    115 
TCMS as per Table 4-3. Samples were transferred to GC vials and 2 µL injected 
onto the GC-MS. 
4.2.4 Results and Discussion 
Good separation was achieved between BHB and the internal standard (GHB-D6) 
in  blood  and  urine  using  the  “Final  GC  Program”  conditions  as  illustrated  in 
Figures 4-1 and 4-2 respectively. 
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Figure 4-1:  Chromatogram and Spectra for BHB and GHB-D6 from a Blood Control (50 
mg/L) 
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Figure 4-2:  Chromatogram and Spectra for BHB and GHB-D6 in Post-Mortem Urine (300 
mg/L) 
 
Poor  peak  shape  was  observed  with  Method  B  (LLE)  using  derivatisation 
conditions (1): 75 µL ACN and 25 µL BSTFA+1% TMCS at 60ºC for 60 minutes as 
illustrated in Figure 4-3.  
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Figure 4-3:  BHB and GHB-D6 Extracted Ions for Spiked Blood using LLE and derivatization 
Conditions (1) 
 
 
This  may  be  due  to  the  long  derivatization  time  or  as  a  consequence  of 
incomplete derivatisation due to the low volume of  the derivatizing reagent. 
Symmetric peak shapes were observed when using derivatisation conditions (2) 
and (3). Figure 4-4 illustrates the excellent peak shapes achieved with the LLE 
method and derivatisation conditions (3). The derivatisation time was shorter 
and the volume of BSTFA+1%(TMCS) greater. Chapter 4    118 
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Figure 4-4:  BHB and GHB-D6 Extracted Ions for Spiked Blood using LLE Method and 
Derivatisation Conditions (3).  
 
 
The correlation coefficient (R
2) and linearity ranges are summarized in Table 4-
4. The linearity of BHB using the SPE method (A) was up to 200 mg/L and 100 
mg/L in blood and urine, respectively. The values were not always > 0.99 when 
the experiment was repeated and the sample preparation was found to be time-
consuming. The main limitations of the SPE method were: the number of steps 
involved with sample preparation and the linear range only extended to 200 and 
100  mg/L  in  blood  and  urine,  respectively.  The  upper  limit  of  quantification 
(ULOQ) was not high enough and would therefore require reanalysis and dilution 
of real case samples in order to achieve accurate quantitative results within the 
linear range. Also interference from uric acid is another problem and this is also 
observed by telepchak, et al. 2004.(183)  Chapter 4    119 
Table 4-4:  R
2 and Linear Range of BHB for Different Methods 
Method  Conditions  Matrix  BHB ( R
2)  Linear Range 
(mg/L) 
A (SPE)  Original 
Blood  0.9878   LOQ-200 
Urine  0.9335  LOQ-100 
B (LLE) 
Original  N/A  Poor peak shape 
Condition 1  N/A  Poor peak shape 
Condition 2 
Blood  0.9877  LOQ-500 
Urine  0.9877  LOQ-500 
Condition 3 
Blood  0.9991  LOQ-500 
Urine  0.9987  LOQ-500 
C (PP)  Original 
Blood  0.9994  LOQ-500 
Urine  0.9983  LOQ-400 
 
Although the linearity using the LLE method (B) was up to 500 mg/L using both 
derivatizing conditions 2 and 3, the value was better using conditions (3). The 
limitation  of  derivatisation  conditions  (2)  was  that  the  derivative,  following 
extraction of the blood sample, was brownish in colour and the presence of uric 
acid interfered with the urine extraction.  
Using the protein precipitation method (C) the linear ranges in blood and urine 
for BHB were LOQ-500 mg/L and LOQ-400 mg/L, respectively. The ULOQ in the 
published method was 300 mg/L for GHB. Interference with uric acid in urine 
samples was a problem with this method. Comparing the protein precipitation 
methods with LLE, the protein precipitation method in blood was more robust 
and  used  less  solvent.  The  final  derivatised  blood  extract  was  cleaner,  the 
sample preparation was faster due to fewer and shorter steps. However, using 
this method to extract urine was problematic, due to high interference with uric 
acid crystals in the final derivative.  
The SPE method (A) using clean screen SPE column was not selected due to the 
narrow linear range and the interference with uric acid which was also reported 
by Telepchak.(183) The LLE method (B) with condition 3 was selected for the Chapter 4    120 
extraction of BHB from urine as the final extract was cleaner than the protein 
precipitation  method  with  a  linear  range  up  to  500  mg/L.  The  protein 
precipitation method (C) was used for the extraction of BHB from post-mortem 
blood  because  it  was  more  robust,  the  final  derivatised  extract  was  cleaner 
compared with the LLE method and the linear range was up to 500 mg/L while 
using  less  solvent.  The  sample  preparation  was  fast  due  to  the  fact  that  it 
contained fewer and shorter steps. Method validation was carried out for both 
selected methods as summarised in Table 4-5.  
Table 4-5:  Summary of Blood and Urine Extraction Methods for the Analysis of BHB 
 
 
4.3 Method Validation 
4.3.1 Linearity 
Calibration standards were prepared by spiking blank blood and urine with BHB 
at concentrations ranging from 50-500 mg/L as detailed in section 4.2.1.3. The 
peak area ratio of the BHB to internal standard (GHB-D6) was calculated, and the 
calibration  curve  was  generated  by  plotting  the  area  ratio  against  the 
concentration.  The  equation  of  line  and  correlation  of  coefficient  (R
2)  was 
measured and should be greater than 0.99.  
Matrix 
Step 1  Step 2  Step 3  Step 4 
Sample 
 Volume 
GHB-d6 
(10 mg/L) 
Extraction  Derivatization 
Conditions 
Blood   100 µL    100 µL   
0.5 mL ACN 
 Vortex mix 30s 
Centrifuge @ 1500 rpm 
Evaporate @ 45ºC±1 to 
dryness 
75 µL BSTFA+1% TMCS, 
at 90ºC for 10 minutes 
Urine  100 µL    100 µL   
100 µL 0.025 M H2SO4  
+ 1 mL EtOAc 
Vortex 30s 
Centrifuge @ 1500 rpm 
Evaporate @ RTºC±1 to 
dryness 
25 µL  EtOAc: 75 µL 
BSTFA+1% TMCS at 
70ºC for 30 minutes Chapter 4    121 
4.3.2 Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The  LOD  and  LOQ  were  determined  by  diluting  the  spiked  samples  with 
decreasing concentrations of BHB within the expected range of the LODs (1.25–
25  mg/L).  Regression  analysis  was  undertaken  and  the  LOD  and  LOQ  were 
calculated was explained in chapter 2 section 2.2.9 in accordance with Miller 
and Miller.(168)  
Case samples for BHB at concentrations that are above or below the linear range 
(50-500 mg/L) were reported as less than the LOQ (<50 mg/L) or greater than 
the highest calibrator (>500 mg/L). 
4.3.3 Precision and Accuracy 
Intra-day precision (within-day precision) was evaluated with urine (N=6) and 
blood (N=8) spiked controls, prepared at two different concentrations (50 and 
300  mg/L)  and  extracted  in  a  batch  with  case  samples.  Inter-day  precision 
(between-day  precision)  was  evaluated  with  urine  and  blood  spiked  controls, 
prepared at two different concentrations (50 and 300 mg/L) and extracted in 
batches  with  case  samples  on  different  days  (N=8).  The  percentage  of 
coefficient  of  variance  (%CV)  acceptance  criteria  was  <20%.  Accuracy  was 
assessed by preparing and extracting triplicate spiked blood and urine control 
samples at concentrations of 50 and 300 mg/L. The accuracy was determined by 
comparing the calculated amount extracted to that of the theoretical expected 
concentration of both control levels.  
4.3.4 Recovery and Matrix Effect 
The  recovery  of  BHB  from  blood  and  urine  was  assessed  by  preparing  spiked 
blood and urine controls at concentrations of 50 and 300 mg/L. The controls 
were extracted as described above however, 100 µL of the internal standard 
(GHB-D6) at a concentration of 10 mg/L was added prior to evaporation after 
extraction. The recovery was determined by comparing the extracted BHB:GHB-
D6  ratio to that of the unextracted  standards  at  the  same concentration.  All 
analyses were carried out in triplicate and the average calculated. The absolute 
recovery was calculated by comparing the peak area ratio of extracted sample Chapter 4    122 
when the internal standard was added at the beginning of the extraction versus 
the unextracted standards at the same concentration. 
The relative recovery was obtained by extracting water spiked at concentrations 
of 50 and 300 mg/L, calculating the BHB: GHB- D6 ratio and comparing that to 
the ratio calculated for blood and urine, expressed as a percentage. All analyses 
were carried out in triplicate and the average calculated. The relative recovery 
was carried out to check the matrix effect and the absolute recovery to check 
the efficiency of the method. 
4.3.5 Stability  
Two  small  studies  were  carried  out  to  assess  the  stability  of  the  derivatized 
extracts  and  to  assess  the  stability  of  BHB  in  blood.  The  stability  of  the 
derivatized extract was evaluated by repeatedly injecting the same two levels 
(50 and 300 mg/L) of processed samples for 4 days following derivatization and 
storage at room temperature (22±2°C).  
The stability of BHB in blood was assessed by extracting replicate spiked samples 
(50  and  300  mg/L)  from  the  same  quality  control  lot  stored  at  2-5ºC  and 
analysed at time intervals of days 1, 3, 11, 13 and 15. The percentage recovery 
was calculated from the mean concentration of QC samples injected in days 3, 
11, 13 and 15 and compared as a percentage to day one (normalised as 100%). 
The 95% confidence interval (CI) from the mean concentration (n=6) for day one 
was calculated and stability was assumed when the percentage of the mean of 
the QC samples was within 80-120%.(169)  
4.3.6  Case samples  
Post-mortem blood (N=13) and urine (N=12) were selected from fourteen cases 
where the cause of death was not known and there was a history of alcohol 
abuse. Preserved samples (0.2% sodium fluoride) were analysed in preference to 
unpreserved samples but these were not available for all cases. All unpreserved 
and preserved samples were stored at 4±1ºC until analysis.   
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4.3.7 Results and Discussion 
Both methods for blood and urine were linear over the range of 50-500 mg/L and 
resulted in average coefficients of correlation (R
2) > 0.99 as illustrated in Figure 
4-5). The LOD was 2 mg/L in blood and urine, while the LOQ was 6 and 7 mg/L 
respectively  for  urine  and  blood.  Although  the  LOQ  is  lower  than  the  first 
calibrator point (50 mg/L), this point was used as a cut-off point to distinguish 
between positive and negative results. The endogenous level in serum has been 
reported in healthy adults as being 30-60 mg/L.(133) Urinary endogenous levels 
of BHB in healthy humans ranged 8.51-34.7 mg/L (mean is 18.4 mg/L), it has 
been also observed that the urinary endogenous levels of BHB is approximately 
20 times higher than its related compounds such as GHB.(134) Triplicate samples 
of blood and urine were screened for BHB to be used to spike quality conrol 
samples and the results were less than LOD of the method also they very low 
compared to the cut-off points (50 mg/L). Urine and blood blanks were included 
in each calibration curve to take into account any endogenous BHB.   
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Figure 4-5:  Calibration Curves for BHB in Blood (A) and Urine (B) 
 
 
The inter-day and intra-day precision was measured by coefficients of variation 
(%CV) for blood and urine and ranged from 1.40 to 12.41% for quality control 
samples spiked at level of 50 and 300 mg/L as summarised in Table 4-6. Chapter 4    124 
Table 4-6:  BHB Intra day and Interday Precision in Blood and Urine 
Matrix 
Intraday Precision 
(%CV) 
Interday Precision 
(%CV) 
Accuracy 
(%) 
50 mg/L  300 mg/L  50 mg/L  300 mg/L  50 mg/L  300 mg/L 
Urine  6.75 
(N=6) 
5.23 
(N=6) 
12.16 
(N=8) 
6.03 
(N=8) 
111 
(N=3) 
100 
(N=3) 
Blood  4.94 
(N=8) 
1.40 
(N=8) 
12.41 
(N=8) 
6.79 
(N=8) 
97 
(N=3) 
99 
(N=3) 
 
Table 4-7 summarises the recovery of BHB from blood and urine. The recovery of 
BHB from blood was greater than or equal to 82% while the relative recovery 
(matrix  effect)  was  129%  and  106%  at  concentrations  of  50  and  300  mg/L, 
respectively.  The  recovery  of  BHB  from  urine  was  134  and  105%  at 
concentrations  of  50  and  300  mg/L,  respectively.    The  efficiency  (Absolute 
recovery) for both urine and blood were all within the range of 88-106% at both 
concentrations except in urine at 50 mg/L (135%). The high % recoveries may be 
explained by matrix effects, e.g. interference from uric acid in urine, but can 
also be affected by poor extraction or the fact that the internal standard, (GHB-
D6) although structurally related to BHB is not the same. 
Table 4-7:  BHB Recovery and Matrix Effect Data 
Method 
Matrix effect 
(Relative Recovery) % 
Efficiency 
(Absolute Recovery) %  Recovery % 
50 mg/L  300 mg/L  50 mg/L  300 mg/L  50 mg/L  300 mg/L 
Urine  101  131  135  89  134  105 
Blood  129  106  106  88  82  83 
 
 
 
Table 4-8 summaries the stability data for BHB in blood over a period of 15 days 
and a separate study following derivatization and storage for 4 days.  Chapter 4    125 
Table 4-8:  BHB Stability Data for Spiked Blood Stored at 2-5ºC for 15 Days 
 (A) BHB stability in spiked blood stored at 2-
5º for 15 days 
n=3  Recovery %[Measured value mg/L] 
Day  50 mg/L  300 mg/L 
1  100 [55]  100 [297] 
3  103 [56]  117 [348] 
11  106 [58]  105 [313] 
13  98  [53]  106 [315] 
15  77  [42]  100 [298] 
Range 
[Mean of 
day 1±SD 
52-57  262-332 
 
  (B) BHB stability in processed samples 
stored at room temperature for 4 days 
n=3  Recovery % Measured value mg/L] 
Day  50 mg/L  300 mg/L 
1  100 [61]  100  [330] 
2  109 [66]  112  [369] 
3  102 [62]  99   [327] 
4  113 [69]  99   [326] 
Range 
[Mean of 
day 1±SD 
56-66  283-378 
 
(A) and (B) for Derivatised Extracts Stored at Room temperature for 4 Days 
 
Although there was some variation in the measured concentrations, BHB remains 
stable in blood spiked at a concentration of 300 mg/L for 15 days when stored 
within a refrigerator (2-5°C). There was some loss of BHB in the control samples 
spiked  at  50  mg/L  on  day  15  and  a  longer  stability  study  is  required  to 
investigate this further. BHB remains stable for approximately four days at room 
temperature after derivatization.  
Fourteen  case  samples(details  summarised  in  Table  4-9)  consisting  of  blood 
(N=13), urine (N=12) and vitreous humour (N=1) samples were analysed for BHB. 
The cause of death as reported by the pathologist is also included. Chapter 4    126 
Table 4-9:  BHB Summary of Case Results  
No. 
BHB mg/L  Acetone mg/L  Ethanol mg/dL 
History /Cause of Death 
Blood  Urine  VH  Blood  Urine  VH  Blood  Urine  VH 
1  205  >500    145*  431  152  19*  81  30  Alcoholic/fatty liver, cause of 
death undetermined 
2  343  >500    35*  452  41  NEG*  NEG  NEG  Fatty liver 
3  239  429    694*  780    30*  NEG    Diabetic/possible ketoacidosis or 
drug/alcohol related 
4    >500      201  325    12  25  Known alcohol abuse 
5  <50  >500    20*  164    12*  58    Chronic alcohol abuse 
6  203  >500    40*  54    NEG*  NEG    Fatty liver 
7  328      387*      NEG*      Diabetic/possible ketoacidosis or 
drug/alcohol related 
8  214*  >500    19*  89    NEG*  NEG    Alcoholic/Fatty liver, cause of 
death undetermined 
9  198*  432    194*  342    12*  NEG    Alcohol abuse 
10  138*  323  341  76*  103  71  67*  88  72  Undetermined cause of death, 
fibrosis 
11  233  307    157*  225    340*  538   
Liver failure, known alcoholic, 
smell of alcohol, micronodular 
cirrhosis, heart disease 
12  211      311*      NEG*     
Suspected drug related 
death/alcohol abuse but no smell 
of alcohol 
13  246  252    50*  76    297*  347    Found dead in his room 
14  267*  >500    250*  314    NEG*  NEG    Fatty degeneration of the liver, 
chronic alcohol abuse, fatty liver 
*Indicates preserved samples. 
 
BHB  and  acetone  are  reported  in  mg/L  while  ethanol  is  reported  in  mg/dL. 
Results are reported with no decimal places. Blood BHB results for alcoholics 
above 260 mg/L or 2500 µmol/L are considered to be consistent with alcoholic 
ketoacidosis (AKA).  
The cases were selected on the basis of high acetone levels and the cause of 
death was either undetermined or the deceased had a history of chronic alcohol 
abuse. Two of the fourteen cases were known diabetics (Cases #3 and #7), but in 
all cases the deceased had a history of alcohol abuse and post-mortem findings 
included fatty degeneration or fibrosis of the liver. Chapter 4    127 
BHB levels in post-mortem blood ≥260 mg/L have been associated with fatalities 
attributed to alcoholic ketoacidosis.(127) BHB was elevated within the toxic or 
fatal ranges in blood for all the cases investigated except one (case sample #5) 
where the BHB level was normal <50 mg/L. The range of BHB in urine in all 12 
cases was between 252 to >500 mg/L. 
Figures  4-6  illustrates  a  chromatogram  and  spectra  for  BHB  and  the  internal 
standard GHB- D6 extracted from a case with both blood and urine samples. 
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Figure 4-6:  Post-mortem Case Samples with BHB in (A) Blood (343 mg/L) and (B) Urine 
(>500 mg/L) 
 
 
Blood acetone levels were elevated in all cases although, in five cases, acetone 
levels were ≤ 50 mg/L. Ethanol levels in all case samples were low or less than 
the LOD, except for case samples # 11 and 13, where the ethanol level for both 
urine and blood samples was high. 
The  relationship  between  BHB,  acetone  and  ethanol  levels  requires  further 
investigation with a larger data set. Chapter 4    129 
4.4 Study  Investigating  the  Relationship  between  β β β β-
hydroxybutyrate (BHB), Acetone and Ethanol in Post-
Mortem Cases 
4.4.1 Introduction 
A reduced blood pH (ketoacidosis) from the production of ketone bodies as a 
result of alcoholic ketoacidosis (AKA) or diabetic ketoacidosis (DKA) can feature 
in many fatalities and analytical evidence can be used to support a pathological 
diagnosis,  or  provide  a  possible  cause  of  death  in  the  absence  of  other 
pathologically significant findings. Existing beliefs concerning the relationship of 
BHB  concentrations,  acetone  and  ethanol  needs  to  be  re-examined  by  the 
analysis  of  these  analytes  in  a  range  of  different  post-mortem  cases.  BHB, 
acetone  and  ethanol  concentrations  measured  in  post-mortem  blood  will  be 
grouped according to whether or not the deceased had a history of alcohol abuse 
or diabetes. 
The  method  developed  and  described  earlier  in  the  chapter  for  the 
determination  of  BHB  in  blood  was  adapted  and  revalidated  using  a  newer 
instrument from a different manufacturer. Acetone and ethanol were analysed 
with a dual–column head space gas chromatography flame ionisation detector 
(HS-GC-FID) in accordance with the FMS ISO/IEC 17025 accredited method.(132)  
The existing belief that in cases of AKA, ethanol is always low (<10 mg/dL) or 
absent  will  be  evaluated in addition  to  whether the  absence  of  acetone  will 
preclude a high BHB (>250 mg/L). The levels of BHB measured in this study will 
be categorised according to the published data indicating endogenous levels are 
<50 mg/L, toxic levels are within the range of 51–249 mg/L and pathologically 
significant levels are >250 mg/L. 
4.4.2 Methodology 
4.4.2.1  Instrumentation 
GC-MS analysis was carried out using an Agilent 7890A GC system coupled with a 
5975 mass spectrometry detector (MSD) and ChemStation software (Agilent, UK). Chapter 4    130 
A DB-5+ DG capillary column (30m x 0.25 mm I.D., 0.25 µm film thickness) was 
purchased from Agilent Technologies Ltd., UK.  
The conditions optimised using the Thermo instrument and described in 4.2.2 
were  used  on  the  Agilent  instrument  with  only  one  alteration.  Due  to  the 
sensitivity of the newer Agilent instrument the samples were injected in split 
mode as opposed to splitless mode.  
4.4.2.2  Summary of Validation 
The validation was carried out as described in sections 4.3.1 to 4.3.4 above. In 
summary, BHB in both blood and urine was found to have a linear response over 
the concentration range of 10-500 mg/L as illustrated in Figure 4-7.  
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Figure 4-7:  BHB Calibration Curves for Blood (A) and Urine (B) using the Agilent GC-MS. 
 
 
The  LOD  and  LOQ  was  2  and  6  mg/L  respectively  for  blood  and  1  and  2 
respectively for urine. An overlay of chromatograms for BHB in samples of spiked 
blood and urine at concentrations of 2, 5, 10, and 50 mg/L in comparison to a 
blank sample is illustrated in Figure 4-8. Chapter 4    131 
7.55 7.60 7.65 7.70 7.75 7.80 7.85 7.90 7.95 8.00 8.05 8.10 8.15
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
Tim e-->
A bundance
Ion 233.00 (232.70 to 233.70): 2009-06-14-006.D\data.m s
Ion 233.00 (232.70 to 233.70): 2009-06-14-011.D\data.m s
Ion 233.00 (232.70 to 233.70): 2009-06-14-012.D\data.m s
Ion 233.00 (232.70 to 233.70): 2009-06-14-014.D\data.m s
Ion 233.00 (232.70 to 233.70): 2009-06-14-016.D\data.m s
 
 
7.56 7.58 7.60 7.62 7.64 7.66 7.68 7.70 7.72 7.74 7.76 7.78 7.80
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
220000
240000
260000
280000
300000
320000
340000
360000
Time-->
Abundance
Ion 233.00 (232.70 to 233.70): 2009-06-14-029.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-032.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-034.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-036.D\data.ms
Ion 233.00 (232.70 to 233.70): 2009-06-14-038.D\data.ms
 
Figure 4-8:  BHB Overlaid Chromatograms for Spiked Blood (A) and Spiked Urine (B) at 
Different Concentrations. 
 
 
The intra and inter-day precision was less than 20%. Although the recovery was 
between 50-61% for BHB in blood and urine, the efficiency of the method was 
between 93-137% and its accuracy between 84-98%. Table 4-10 summarises the 
validation data for BHB in blood and urine.  
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Table 4-10:  BHB Intraday, Interday Precision, Accuracy and Recovery  Data 
 
 
Intraday 
precision 
CV%  (n=6) 
Interday 
precision 
CV% (n=10) 
 
Accuracy % 
 
Recovery % 
 
Efficiency % 
Matrix  50 
mg/L 
300 
mg/L 
50 
mg/L 
300 
mg/L 
50 
mg/L 
300 
mg/L 
50 
mg/L 
300 
 mg/L 
50 
mg/L 
300  
mg/L 
Urine   7.5  4. 6  13.2  5.8  84  98  61  50  137  105 
Blood   1. 3  1. 4  2.8  5.3  95  97  56  60  100  93 
 
Quality control samples (QC’s) were prepared at two different concentrations 
(50 and 300 mg/L) and were then extracted with each batch and injected on 
different days. QC’s were evaluated according to the acceptable range which is 
the mean ± 2 standard deviations. Quality control charts were used to record 
and monitor the acceptability of each batch and are included in Appendix 4-1. 
QC results were within the acceptable range for all batches. 
4.4.2.3  Case Samples 
Post-mortem  blood  (N=120)  and  urine  (N=82)  from  122  cases  were  identified 
within the FMS in-house database to be tested for BHB. The cases had already 
been analysed for volatiles and had varying causes of death recorded. BHB had 
not been tested routinely within FMS prior to this study and as such the cause of 
death  was  determined  by  the  pathologist  without  knowledge  of  the  BHB 
concentrations.  Preserved  case  samples  were  analysed  in  preference  to 
unpreserved samples but were not available for all cases; namely case numbers 
99,  101,  102,  104,  105,  108  and  109.  Full  details  of  each  case  are  listed  in 
Appendix  4-2.  “Preserved”  blood  samples  were  blood  samples  collected  and 
stored in  commercially  available  vials  containing  a preservative  (0.2%  sodium 
fluoride). All unpreserved and preserved samples were stored at 4ºC ±1 until 
analysis.  
4.4.3 Results and Discussion 
The majority of the cases (72%, N=79) have blood BHB levels between 0 and 50 
mg/L  with  10%  of  cases  having  blood  BHB  levels  >250  mg/L  as  illustrated  in 
Figure 4-9.   Chapter 4    133 
13%
10%
5%
72%
BHB 0-50 BHB 51-150 BHB 151-250 BHB >250
 
Figure 4-9:  Prevalence of BHB at Different Concentrations in Post-Mortem Blood 
 
The cases were grouped according to the cause of death and the level of BHB 
present in blood. Twelve cases were excluded on the basis that the cause of 
death was not known (N=11), as these were carried out by external pathologists 
or  only  urine  was  available  (N=1).  Table  4-11  summarises  the  number  cases 
categorised by cause of death and blood BHB concentration, while Figure 4-10 
illustrates the percentage of cases at each blood BHB concentration by cause of 
death.  
Table 4-11:  Post-Mortem Cases Classified by Cause of Death and Blood BHB Level   
    Cause of Death 
BHB  N  Natural  Alc  Drug  Accident  Suicide  Homicide  Unasc. 
0-50  79  18  6  23  9  16  3  4 
51-150  16  6  5  1  3  0  0  1 
151-250  6  3  2  1  0  0  0  0 
>250  9  3  6  0  0  0  0  0 
Alc: alcohol-related; Drug: drug-related; Unasc.: unascertained/undetermined Chapter 4    134 
Of the 79 cases with blood BHB levels at 50 mg/L or below, 27 cases (34%) were 
negative (<10 mg/L) for BHB in blood. The positive blood samples ranged from 
10 to 48 mg/L with a mean and median of 22 and 19 mg/L respectively. The 
cause of death in these cases was predominantly un-related to alcohol (92%) but 
it was not possible to determine from the case files whether there was a history 
of alcohol misuse or diabetes in these cases. 
Although the number of cases with blood BHB levels  ranging between 51-150 
mg/L,  was  considerable  smaller,  there  was  observed,  an  increase  in  the 
percentage of alcohol-related deaths in this group. 
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Figure 4-10:  Percentage of Cases with Varying Blood BHB Concentrations by Cause Death  
 
 
Table  4-12  summarises  details  of  the  six  cases  with  elevated  levels  of  BHB 
ranging  from  165  -  249  mg/L.  The  cause of  death  in  two  cases  was  alcohol-
related.  A  history  of  alcohol  misuse  was  recorded  for  one  of  the  four  cases 
where the cause of death was not related to alcohol.  Chapter 4    135 
Table 4-12:  Post-Mortem Cases with Blood BHB Concentrations Between 151-250 mg/L 
 
Case 
# 
 
Gender  Age 
BHB          
(mg/L) 
Acetone    
(mg/L) 
Ethanol   
(mg/dL)  Cause of Death 
Blood  Urine  Blood  Urine  Blood  Urine 
16  M  73  195    50  56  NEG  NEG 
1a- Ischaemic heart 
disease 
1b- Coronary artery 
atheroma 
30  F  66  237  452  15  26  NEG  NEG 
1a- Acute hepatic 
necrosis; 
 1b- paracetamol Toxicity 
73  M  71  208  308  67  84  NEG  NEG  1a- Acute pyelonephritis; 
1b- Possible hypothermia 
81  F  40  249  498  121  145  NEG  66 
1a- Fatty degeneration of 
the liver                                    
1b- Chronic alcoholic 
abuse 
100  M  80  215  497  82  111  23  14  1a-Hypothermia 
113  F  36  165    40    NEG   
1a. Fatty  degeneration of 
the Liver;  
1b. Chronic Alcohol 
Abuse 
F: female, M: male, NEG: negative 
 
Table 4-13 summarises the cases where blood BHB concentrations are >250 mg/L 
which  is  associated  with  pathological  findings  and  considered  a  marker  for 
ketoacidosis.  Three deaths (#17, 89, 112) were categorised as natural and the 
cause  of  death  in  each  of  these  was  related  to  insulin  dependent  diabetes 
mellitus  (IDDM)  and  was  specifically  recorded  as  diabetic  ketoacidosis  in  two 
cases (#17. 89). In both cases, the pathologist had requested BHB analysis, while 
in  the  third  case  (#112)  BHB  analysis  was  not  requested  even  though  the 
individual had a history of diabetes and alcohol misuse. 
The remaining six cases were all alcohol-related and in all cases the individual 
had a history of chronic alcohol misuse. However, alcoholic ketoacidosis was not 
recorded as a contributing factor to the cause of death. The role of alcoholic 
ketoacidosis should be considered in these cases and those listed in Table 4-12 in 
light of the elevated blood BHB concentrations. Chapter 4    136 
Table 4-13:  Post-Mortem Cases with Blood BHB Concentrations >250 mg/L 
 
Case 
# 
 
Gender  Age 
BHB          
(mg/L) 
Acetone     
(mg/L) 
Ethanol   
(mg/dL)  Cause of Death 
Blood  Urine  Blood  Urine  Blood  Urine 
5  F  44  >500  >500  167  224  NEG  16 
1a- Fatty degeneration of 
the liver                                    
1b- Chronic alcoholic 
17  F  18  >500  >500  >400  >400  NEG  NEG 
1a- Diabetic ketoacidosis; 
1b. Insulin Dependent 
Diabetic Mellitus 
89  M  34  >500  >500  297  >400  NEG  NEG 
1a- Drowning ; 1b- Diabetic 
ketoacidosis;  
1c. Insulin Dependent 
Diabetic Mellitus 
98  M  67  383  358  72  85  338  392  1a. Alcohol related death 
104  M  61  263  >500  42  147  193  286 
1a. Ischaemic heart 
disease and gastro 
intestinal haemorrhage 
from erosive oesophagitis.  
2a. Fatty degeneration of 
the liver 
105  F  56  396    177    34   
1a. Fatty degeneration of 
the liver due to;  
1b. chronic alcohol abuse. 
110  F  57  >500  >500  399  620  NEG  NEG 
1a-Alcoholic Stetosis  and 
Ischaemic heart disease; 
1b Fatty degeneration of 
the liver;  
1c- Chronic Alcoholic 
112  M  42  >500    469    30  NEG 
1a-Ischaemic heart disease  
1b- Coronary artery 
atheroma  
2a- Insulin dependent 
diabetes mellitus 
122      >500    169  247  NEG  NEG 
1a. Fatty  degeneration of 
the Liver;  
1b. Chronic Alcohol Abuse 
F: female, M: male, NEG: negative 
 
Alcoholic  ketoacidosis  is  commonly  associated  with  high  blood  BHB 
concentrations,  elevated  blood  acetone  concentrations  and  low  alcohol 
concentrations. 
Figure 4-11 illustrates the concentrations of acetone found relative to the blood 
BHB concentration. In all cases with blood BHB >250 mg/L, acetone was >10 
mg/L. In two cases (# 98, 104) the acetone concentrations were below 100 mg/L 
(42 and 72 mg/L respectively) with corresponding BHB >250mg/L. Chapter 4    137 
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Figure 4-11:  Acetone Concentrations in Post-Mortem Blood Relative to BHB Levels  
Note: The scale of y axis has been reduced to 15 instead 100 to show the case number in 
lower scale  
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Figure 4-12:  Ethanol Concentrations in Post-Mortem Blood Relative to BHB Levels 
 
 
In five of the nine cases with blood BHB >250 mg/L, no ethanol was detected. 
Two cases had low ethanol concentrations of 30 and 34 mg/dL, however the 
remaining two cases had high ethanol concentrations of 193 and 338 mg/dL, as 
illustrated in Figure 4-12. Chapter 4    138 
4.5 Conclusion 
A robust and sensitive method for the analysis of BHB in postmortem blood and 
urine was validated. The method was utilised to investigate the stability of BHB 
in blood and to investigate the potential of BHB as a biomarker for AKA. BHB was 
found to be stable in blood for 15 days when stored in the refrigerator and initial 
findings support the use of BHB as a biomarker for AKA. The majority of samples 
analysed were preserved, there were not enough unpreserved results to evaluate 
the  affect  of  preservative  on  BHB.    AKA  does  not  always  equate  to  low  or 
negative ethanol levels. High levels of ethanol were reported in case samples 
with  blood  BHB  levels  >250  mg/L,  which  is  in  agreement  to  other 
studies.(55;184) In all case samples with high blood BHB level (>250 mg/L), the 
acetone concentration was high. Acetone can be used as an initial biomarker for 
AKA but the concentrations measured are not well correlated to BHB. Acetone is 
volatile and may be unstable in the blood and the production of other volatiles 
may interfere with it due to putrefaction, (55;127) therfore, its  absence does 
not  preclude    a  pathologically  significant  ketoacidosis  (BHB  >250  mg/L). 
Therefore, BHB should still be analysed in case samples associated with a history 
of chronic alcoholism, even if acetone is low or absent. From the literature, 
vitreous humour could be an alternative substitute for blood.(125) 139 
Chapter 5 - Application of the Method Validated for 
the Analysis of β β β β-Hydroxybutyrate (BHB) to the 
Analysis of γ γ γ γ-Hydroxy-butyrate (GHB) and β β β β-
Hydroxy-β β β β-Methylbutyrate (HMB) 
5.1 Introduction 
Due to the similarity of the structures of β-hydroxy-β-methylbutyrate (HMB) and 
γ-hydroxybutyrate (GHB) to β-hydroxybutyrate (BHB), as illustrated in Figure 5-
1, the method validated for the analysis of BHB (as described in Chapter 4) was 
applied to the analysis of GHB in blood and urine, and the analysis of HMB in 
plasma and urine.  
C H3 O
OH OH
            O H
O
C H 3
C H 3 O H
         
O H
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β-hydroxybutyrate     β-hydroxy-β-methylbutyrate     γ-hydroxybutyrate 
(BHB)               (HMB)                      (GHB) 
 
 
Deuterated γ-hydroxybutyrate sodium salt 
(GHB-D6) 
Figure 5-1:  Chemical Structures of BHB, HMB, GHB and GHB-D6 
 
This chapter has two parts, the first part will summarise the validation of the 
BHB method for the analysis of GHB in postmortem blood and urine. The aims of 
this study are to develop a robust method for the determination of GHB in post-
mortem blood and urine, to identify GHB-related fatalities, and to evaluate the 
level of GHB in post-mortem bodies that are not associated with a history of GHB 
intoxication. These results will then be compared with the published data. 
The second part of the chapter will summarise the validation for the analysis of 
all three analytes (BHB, GHB & HMB) in plasma and urine. The aims of this study Chapter 5    140 
were to develop and validate a method for the determination of HMB in plasma 
and urine in normal individuals at baseline and after oral administration of a 
dose of 3 grams of HMB. 
5.2 Determination of GHB in Post-Mortem Blood and 
Urine using GC-MS 
5.2.1 Introduction 
GHB is a minor metabolite of γ-aminobutyric acid (GABA) which is an inhibitory 
neurotransmitter,  and  is  a  central  nervous  system  depressant.  The  two  main 
metabolic  precursors  of  GHB  are  γ-butyrolactone  (GBL)  and  1,4-butanediol 
(1,4B) Figure 5-2. 
 
Figure 5-2: In vivo metabolism of GHB, GABA, GBL and 1,4BD 
[Redraw from Marinetti(185)] 
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GHB  was  therapeutically  used  as  an  anaesthetic  and  antidepressant  agent.  It 
causes relaxation and has the capacity to induce euphoria, short-term amnesia, 
and sedation at high concentrations.(185)  In the USA, has been used in the form 
of a sodium oxybate under the name of Xyrem to treat narcolepsy. It is also used 
in  the  treatment  of  alcohol  withdrawal  syndrome.  (185)  Misuse  of  GHB  is 
common among body builders, as it is believed that GHB stimulates the release 
of the growth hormone; it is also used by dance club attendees, for its sedative 
and  muscle  relaxant effects  and has  been  detected in drivers and  victims of 
drug-facilitated sexual assault.(186) The use of GHB has been associated with 
fatalities when administered alone or in combination with other drugs. GHB is 
commonly referred to as a "date-rape drug", with street/slang names for GHB 
including  "scoops,"  "liquid  ecstasy,"  "easy  lay,"  "salt  water,"  "vita  G,"  "Georgia 
home boy," "grievous bodily harm" and "great hormones at bedtime." (185) 
The  slang  name  "liquid  ecstasy"  used  for  GHB  is  often  confused  with  MDMA. 
"Ecstacy,"  or  “XTC”  is  the  slang  name  commonly  associated  with  methylene-
dioxymethamphetamine (MDMA), which is not in the same classification as GHB. 
(185)  MDMA scheduled as class A and GHB as Class C.(187)  
5.2.2 Prevalence of GHB in Biological Matrices 
GHB  is  a  small  molecule.  It  behaves  similar  to  ethanol  due  to  being  highly 
solubility in water and lacking the ability to bind to plasma protein. As expected 
GHB concentrations are higher in plasma than blood due to a higher percentage 
of water in plasma than blood. The distribution ratio between blood and serum 
is probably similar to ethanol which is 1.6:1. The fatal concentration of GHB in 
plasma ranged between 250-280 mg/L and therefore it is expected that whole 
blood  GHB  concentration  will  be  around  16%  lower  in  plasma.  [Cited  by 
Kugelberg, et al. 2008 (188) from Iffland et al 1999]. Due to the endogenous 
nature  of  GHB,  the  interpretation  of  GHB  levels  in  biological  matrices  is  a 
challenge in forensic toxicology.(188) 
In living individuals, toxicological analysis of exogenous GHB in body fluids is 
time critical, since GHB disappears very quickly from the body after ingestion. Chapter 5    142 
The cut-off time for detection in blood is approximately 8 hours post-ingestion 
and 12 hours and not more than 48 hours after offence in the urine.(189) 
An elevation of the urinary levels of GHB has been reported in the case of a 
genetic  disorder  called  GHB  aciduria,  due  to  a  deficiency  of  succinic 
semialdehyde dehydrogenase. This leads to an accumulation of GHB in the urine. 
The  reported  level  of  GHB  in  this  type  of  disorder  was  around  200  mg/L  in 
urine.(184;190-192)  
Characteristics of GHB toxicity include euphoria, dizziness, visual disturbances, 
vomiting, nausea, bradycardia, hypotension, confusion, agitation, hypothermia, 
coma, respiratory depression, and death.(185)  
In postmortem blood samples, GHB is frequently detected at levels that range 
from physiological to pharmacological concentrations, even in cases when GHB 
use is not suspected. Stephens et al. (1999) (193) observed a relatively minimal 
formation  of  GHB  in  blood  samples  stored  in  a  refrigerator  without  sodium 
fluoride. It has been reported GHB detected in the blood of corpses could be due 
to production during the interval between death and autopsy, rather than during 
sample storage at 4°C.(194)   
GHB  concentrations  may  increase  after  death  in  the  case  of  advanced 
decomposition or when the sample is heart blood. The common cut-off level of 
urinary GHB used in several studies to differentiate endogenous from exogenous 
is 10 mg/L. This can be applied to the samples that were properly stored but 
excludes cases of GHB aciduria.(134;192;195) Some laboratories use a cut-off 
concentration  of  50  mg/L  in  the  case  of  post-mortem  cardiac  blood.(186)  In 
another study, the cut-off concentration of GHB for reporting positive results in 
post-mortem femoral blood and urine was 30 mg/L.(188)  
It is expected that the concentrations of GHB produced in vitro during storage 
will be more prevalent in post-mortem than in antemortem material. No levels 
of GHB above 3 mg/L were found in antemortem serum specimens, whereas in 
post-mortem blood, GHB levels up to 100 mg/L were reported, followed by a 
subsequent drop to unmeasurable values. (196) GHB production is less likely in Chapter 5    143 
post-mortem urine samples and therefore collection and analysis of urine could 
provide an ideal control for the analysis of GHB in suspected drug related death. 
Freezing  or  preservation  of  specimens  with  sodium  fluoride  may  improve 
stability of GHB from the time of the collection until the time of analysis.(196)  
It  has  been  suggested  that  enzymatic  conversion  of  succinic  acid,  GABA  and 
putrescine are probably responsible for endogenous GHB production. In addition, 
glycolysis by bacteria may enhance endogenous GHB production.(185) Bacteria 
can  metabolize  glucose  to  succinic  acid  via  phosphoenolpyruvate  and 
oxaloacetate. Succinic acid is converted to succinic semialdehyde that can be 
reduced to GHB by succinic semialdehyde reductase.(185) Table 5-1 summarises 
published GHB levels in both living and post-mortem samples. 
Table 5-1:  GHB Published Levels in the Living and Post-Mortem 
Reference  Matrix  Population/Status  GHB  (mg/L)  N 
Endogenous GHB 
Elian, 2002.(197)  Urine  Ante mortem urine  0.34-5.75  670 
Fieler, Coleman and Baselt,  
1998.(198)  Blood  Postmortem  3.2-168  20 
Rahbeeni et al. 1994; Divry  
 et al. 1983; Elliott, 2003. 
(190-192) 
Urine  Patients with GHB aciduria  200  6 
Exogenous GHB 
Kavanagh, Kenny and Feely, 
2001(199)  Urine 
Volunteers  after 10 
hours after administration 
of 1 gram GHB 
 
4  1 
Jones, Holmgren and 
Kugelberg, 2008. (200)  Blood 
People arrested for 
driving under the 
influence of GHB 
Mean=89, 
highest 340 
548 
Fatal GHB level 
Kugelberg et al. 2010. (188)  Blood  Postmortem  In excess 
of 300  49 
 
5.2.3 Analysis of GHB 
Several techniques have been used to analyse GHB in biological samples, such as 
GC-MS, high performance liquid chromatography with UV detection (HPLC-UV) 
and liquid chromatography tandem mass spectrometry (LC/MS/MS). Appendix 5-1 Chapter 5    144 
lists a summary of the published methods for the analysis of GHB and related 
compounds in different biological matrices. 
The method originally developed and validated for the analysis of BHB in post-
mortem  blood  and  urine(138)  as  described  in  Chapter  4,  was  adapted  and 
revalidated for the determination of GHB in post-mortem blood and urine and 
this validation is described below.  
5.2.4 Materials 
The  internal  standard  used  was  deuterated  gamma  hydroxybutyrate  (GHB-D6      
1 mg/mL), purchased from Cerilliant Corporation (Round Rock, TX) and gamma-
hydroxybutyrate (GHB) was obtained from Sigma-Aldrich Co. Ltd. (Basingstoke, 
England). All other materials used are as described in sections 4.2.1.1 – 4.2.1.4. 
Drug and volatile-free blood and urine blanks used for preparing quality controls 
and calibrators were tested for endogenous interference.  
Post-mortem blood (N=120) and urine (N =64) samples selected from the same 
cases analysed for BHB (as described in section 4.5.2.3) were also analysed for 
GHB.  Basic  demographic  information  is  also  summarised  in  Appendix  5-2  for 
these cases, including gender, age, other drugs detected at post-mortem and 
the cause of death. This information was not always available for every case as 
the post-mortem was carried out for some cases by a forensic pathologist who 
was not based within Forensic Medicine and Science. These cases are indicated 
as “External Case”. 
5.2.5 Methodology 
The instrumentation, GC conditions utilised and extraction methods developed 
and validated in Chapter 4 for the analysis of BHB were also used for the analysis 
of GHB in blood and urine. Data was collected in full scan mode and the ions 
monitored were m/z 233, 117, and 204 for GHB and m/z 239 and 240 for the 
internal standard GHB-D6. The underlined ions were used for quantification. Chapter 5    145 
5.2.6 Method Validation 
Method validation for GHB in post-mortem blood and urine was carried out as 
previously described in Section 4.3 for the validation of BHB in blood and urine. 
5.2.7 Results and Discussion 
Figures 5-3 and 5-4 illustrate typical chromatograms and spectra for GHB and the 
internal standard GHB- D6 extracted from blood and urine, respectively. Chapter 5    146 
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Figure 5-3:  Chromatogram and Full-Scan Spectrum of GHB extracted from spiked blood 
(50 mg/L). 
[(A) GHB-TMS extracted ion chromatogram, (B) GHB-TMS and GHB-d6-TMS overlaid 
extracted ions chromatogram. (C) and (D) Full-scan spectra of GHB-TMS and GHB-D6 TMS, 
respectively] 
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Figure 5-4:  Chromatogram and Full-Scan Spectrum of GHB extracted from spiked urine 
(50 mg/L). 
[(A) GHB-TMS extracted ion chromatogram, (B) GHB-TMS and GHB-d6-TMS overlaid 
extracted ions chromatogram. (C) and (D) Full-scan spectra of GHB-TMS and GHB-D6 TMS, 
respectively] 
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GHB was linear over the concentration range of 10-500 mg/L in both blood and 
urine as illustrated in Figure 5-5. 
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Figure 5-5:  GHB Calibration Curves for Blood and Urine 
 
The LOD of GHB in urine and blood was 1 mg/L and the LOQ was 2 and 4 mg/L 
respectively.  Figure  5-6  involves  a  series  of  overlaid  chromatograms  for  GHB 
spiked in blood and urine at low concentrations (blank, 2, 5 and 10 mg/L) to 
demonstrate that there was no interference from the matrix due to endogenous 
GHB. GHB levels in the blank samples were less than the LOD in both matrices. 
The intra-day and inter-day precision were less than 10% as summarised in Table 
5-2. QC results were within the acceptable ranges as illustrated in Appendix 5-3.  
    Table 5-2:  GHB Intra-day and Inter-day Precision for Blood and Urine 
 
 
 
 
 
Intra-day 
precision %CV 
(n=6) 
Inter-day 
precision %CV 
(n=10) 
Matrix  50 
(mg/L) 
300 
(mg/L) 
50 
(mg/L) 
300 
(mg/L) 
Urine  1.7  1.5  2.9  2.7 
Blood  2.3  3.1  3.3  5.6 Chapter 5    149 
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Figure 5-6:  GHB Extracted Ion Chromatograms for Blank Blood (A) and Urine (B)  
[Spiked at Concentrations of 2, 5 and 10 mg/L] 
 
Recovery  of  GHB  ranged  from  40-50%  in  blood  and  urine.  The  efficiency 
(absolute recovery) of the method was between 83 and 99% and the accuracy 
was between 89 and 104%, as summarised in Table 5-3.  
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Table 5-3:  Recovery, Efficiency and Accuracy of GHB  
  Recovery (%)  Efficiency (%)  Accuracy (%) 
Matrix  50     
(mg/L) 
300     
(mg/L) 
50 
(mg/L) 
300 
(mg/L) 
50 
(mg/L) 
300 
(mg/L) 
Urine  40  41  99  96  95  89 
Blood  47  50  86  83  95  104 
 
Although the recovery of GHB was low (40 and 50%) in blood and urine, the 
efficiency (absolute recovery) of the method was between 83 and 99%, and the 
accuracy was between 89 and 104%.  
Appendix 5-2 summarises the 120 cases tested for GHB and included five cases 
(case # 36, 103, 106, 108 and 118) with high levels of GHB in post-mortem blood 
and urine (where available). These five specific cases are summarised in Table 5-
4 and Figure 5-7 illustrates the chromatograms and spectra for the high levels 
GHB detected in blood and urine samples from Case number 36. 
Table 5-4:  Case Samples with High/Toxic Levels of GHB in Post-Mortem Blood and Urine  
Case No.  Gender  Age 
GHB (mg/L)  Background/ 
Cause of Death  Blood  Urine 
36  Male  34  >500  >500  1a- GHB intoxication 
103  Male    369    Suspected GHB/GBL 
intoxication (External Case) 
106  Male    300    Suspected GHB/GBL 
intoxication (External Case) 
108  Female    >500  >500  Suspected GHB/GBL 
intoxication (External Case) 
118  Female  37  264    Suspected GHB/GBL 
intoxication (External Case) 
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Figure 5-7:  Chromatograms (A) and (C) and Full-Scan Spectra (B) and (D) for GHB Extracted 
from Blood and Urine, respectively, from Case # 36 at Levels >500 mg/L. 
 
The mean, median and 95% confidence interval (95% CI) of GHB in post-mortem 
blood and urine were calculated from table of results for GHB in Appendix 5-2, 
with no history of misuse of GHB or its precursor and excluding the five cases 
listed in Table 5-4. The mean GHB concentration in blood case samples where 
there was no history of GHB intoxication, was 20 mg/L, the median was 19 and 
the 95% CI range 17-23 mg/L.  In urine the mean was 4 mg/L, the median was 0 
and the 95% CI range 2-8 mg/L in urine. The majority of the urine samples were 
negative (<10 mg/L), while the majority of blood samples (83%) were positive for 
GHB at concentrations ranging from 10-50 mg/L as illustrated in Figure 5-8.  
Significant variations in the GHB levels in postmortem blood have been noted, 
even in cases when GHB use is not suspected. Table 5-1 summarises published 
studies  reporting endogenous  GHB  levels  in  living  individuals  and  in different 
postmortem biological matrices. The broad range of GHB levels in postmortem 
blood could be due to formation of GHB between death and sample collection, 
from enzymatic or bacterial actions as reported earlier. The mean concentration 
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of  GHB  in  urine  was  4  mg/L,  the  majority  of  the  results  were  negative. 
Concentrations of 50 mg/L in postmortem blood and less than 10 mg/L in urine 
may be due to endogenous levels of GHB, but this is not sufficient by itself to 
distinguish between natural endogenous levels and exogenous use. 
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Figure 5-8:  GHB Levels in Post-Mortem Blood and Urine in Cases with no History of GHB 
and/or GBL Misuse. 
 
Earlier  observations  suggested  that  GHB  was  present  in  postmortem  blood  of 
non-GHB related fatalities, it was therefore suggested that the presence of GHB 
in  urine  could  indicate  the  exogenous  ingestion  of  GHB  before death.(198)  A 
study detected GHB in postmortem blood and urine in non GHB related fatalities 
with higher levels in blood than urine.(193) The exact source of the GHB in such 
instances has not as yet been identified. 
Although some studies indicated that the GHB concentration due to formation 
postmortem may reach 409 mg/L(186) and 168 mg/L,(198) Berankova et al.(196) 
found levels up to 100 mg/L of GHB concentration in postmortem blood. The 
exogenous  increase  of  GHB  levels  in  post-mortem  blood  was  only  temporary, 
reaching the maximum with a subsequent drop to immeasurable values. Another Chapter 5    153 
study  reported  that  43  mg/L  was  the  highest  GHB  level  in  postmortem 
blood.(194) 
The  levels  of  GHB  in  postmortem  blood  and  urine  that  were  associated  with 
GHB/GBL intoxication in this study had high or fatal levels of GHB ranging from 
264 to >500 mg/L. A high GHB concentration ranging from( was also reported in 
case samples where there was no evidence of GHB and or GBL exposure.Fieler et 
al.1998 reported that GHB post-mortem blood can be detected at concentration 
ranges  between  (3.2-168  mg/L)in post-mortem  femoral  blood.  According  to  a 
study carried out by Kintz  et al. 2004 (186) seventy one autopsy cases were 
reported where cardiac blood GHB concentrations were >50 mg/L with range of 
(0.4-409  mg/L).This  makes  the  interpretation  more  difficult  to  distinguish 
between endogenous and exogenous levels of GHB. Analysis of other biological 
fluids postmortem, such as vitreous humour or femoral blood, in addition to the 
knowledge of the circumstances surrounding the death may help in interpreting 
the results.  Additionaly information relating to the post-mortem interval, the 
time of sample collection and the condition of storage of the corpse may also 
provide supportive information for result interpretation. Elliott, 2001(184;201) 
reported  that  GHB  in  urine  was  elevated  in  GHB  unrelated  fatalities  and 
suggested that the presence of GHB in urine does not necessarily indicate GHB 
ingestion.  Furthermore  in  living  subjects  although  urine  was  an  accepted 
specimen in most of drug-facilated sexual abuse (DFSA) at a cut off 10 mg/L, it 
has been reported by Le Beau et al. 2006.(202) that there is potential for an 
artificial increase in GHB concentrations in urine and reported results from 31 
volunteers who never used GHB thought to occur during storage in refrigerator at 
5ºC without preservative for a period over 6 months.   
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5.3 Simultaneous Determination of HMB, BHB and GHB 
in Plasma and Urine using GC/MS 
5.3.1 Introduction 
β-Hydroxy-β-methylbutyrate  (HMB),  or  β-hydroxyisovaleric  acid  (β-HIV),  has 
recently been considered a promising dietary supplement; the claim is that it 
increases strength and muscle mass and that it is the sixth most commonly used 
supplement. In 1999, the International Olympic Committee’s medical advisory 
board categorized HMB as a legal substance.(203) It was patented by Iowa State 
University Research Foundation in 2000. HMB has been found useful for reducing 
cholesterol levels and improving low lipoprotein density (LDL), enhancing the 
immune response of mammals (204), and it may lead to increase muscle mass 
and  decrease  muscle  break  down  and  proteolysis.  It  is  considered  an 
anticatabolic  agent(204).  It  has  been  proposed  that  the  HMB  nutritional 
supplement  may  increase  the  strength  and  lean  mass  in  humans  involved  in 
resistance training programs.(205) HMB can be synthesised through oxidation of 
diacetone alcohol in a free acid form which is then converted to the salt.(204) 
Other studies indicate that HMB can be produced through the conversion of β—
methylbutyric acid by the action of bacteria (Galactomyces reesii). (205)  HMB 
doses used in research was between 1.5 to 3.0 grams per day. (206) It has been 
concluded from review studies carried out by Slater and Jenkins, 2000 (203) that 
supplementation  of  HMB  at  doses  of  1.5  to  3  g/day  may  enhance  gains  in 
strenghth and lean body associated with resistance training and there may be a 
reduction in skeletal muscle damage. The mechanism by which this may occur is 
unknown. It has been suggested that the further controlled studies to confirm 
this finding.  
HMB is a metabolite of the essential amino acid (leucine). Transamination of 
leucine  is  through  branched  chain  acid  transaminase  to  produce  alpha-
ketoisocaptoate (KIC). KIC is involved in the formation of β-hydroxyisovalorate 
(β-HIV  or  HMB)  in  3  different  ways.  The  first  way  is  through  the  action  of 
cytosolic  α-ketoisocaproate  oxygenase.  The  second  way  is  through 
decarboxylation  of  the  branched  chain  ketoacid  dehydrogenase  to  isovaleryl-
CoA, which is partially hydrolyzed to isovalerate and then oxidized to HMB. The Chapter 5    155 
third way is through further oxidization of isovaleryl-CoA to β-methyl crotonyl-
CoA by isovaleryl-CoA-dehydrogenase and by hydration, followed by enoyl-CoA 
hydratase, followed by hydrolysis of β-hydroxyisovaleryl-CoA. β-methyl crotonyl-
CoA is metabolized to acetyl CoA and ketone bodies via β-methylglutaconyl-CoA 
and  β-hydroxy-β-methylglutaryl-CoA(206).as  illustrated  in  Figure  5-9. 
Approximately 2–10% of leucine oxidation is converted to HMB.(207) 
 
 
Figure 5-9:  Leucine Metabolism and Formation of β-hydroxy-β-methylbutyrate (HMB) 
[(A) Branched chain amino acid transaminase, (B) branched chain ketoacid dehydrogenase, 
(C) isovaleryl-CoA, (D) enoyl-CoA hydratase, (E) β-methylcrotonyl-CoA carboxylase,(F) β-
methylglutaconyl-CoA hydratase, (G) cytolic α-ketoisocaporate oxygenate, (H) β–hydroxy 
butyric acid dehydrogenase.  [Redraw from Yu et al  (206)and Landaas(208)] 
 
Leucine hypoglycaemia and maple-syrup urine disease (MSUD) are known to be 
the only inborn error disease related to leucine metabolism. Several studies have 
indicated that a new genetic disorder related to leucine metabolism has been 
discovered  in  which  the  defect  of  leucine  metabolism  results  in  the 
accumulation of isovaleric acid, HMB and β-methylcrotonyl aciduria.  (206;209-
212) It was reported that the urinary increase of HMB in the inborn error disease 
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could  be  due  to  the  defect  of  enzymes  involve  in  the  degradation  of 
leucine.(209) 
In  ketoacidosis,  usually  characterized  by  the  accumulation  of  ketone  bodies 
(acetone, acetoacetate and BHB), this may occur with several clinical disorders 
in which fatty acids replace glucose for energy. Production of acetyl CoA is as a 
result  of  fatty  acid  oxidation.  Acetyl  CoA  has  an  important  role  in 
ketogeneis.(208)  Landaas  reported  the  urinary  increase  of  HMB  in  all  ketotic 
patients and a positive correlation between HMB and BHB. High levels of BHB 
and  acetoacetate  and  increased  oxidation  of  fatty  acids  may  influence  the 
degradation of leucine, which may lead to increased HMB levels.(208) 
In  1975,  Landaas(213)  reported  that  in  ketoacidosis,  a  close  relationship  was 
demonstrated  between  the  excretion  of  HMB  in  urine  and  the  degree  of 
ketoacidosis.  He  also  indicated  that  another  two  hydroxy  acids  (β-
hydroxyisobutyric  acid  and  2-methyl-3-hydroxybutyric  acid)  increased,  in 
addition  to  HMB.  Two  possibilities  have  been  considered  in  relation  to  the 
formation of HMB during ketoacidosis. The first one indicates that either the 
leucine  might  be  the  precursor  or  the  increased  pool  of  3-hydroxy-3-
methylglutaryl-CoA(3-HMG-CoA) might give rise to metabolites.(213) 
According  to  the  study  of  Weimin,  et  al.(206),  it  is  also  known  that  type  1 
diabetes mellitus (insulin deficiency) may accelerate the breakdown of proteins, 
leading to enhanced leucine metabolism, and the same effect might occur in 
cases of diabetes melitus type 2 (insulin resistance). It was also reported that 
urinary levels of HMB and serum leucine were higher in ketotic patients than in 
nonketotic  patients.  The  amount  that  HMB  increases  in  nonketotic  patients 
depends on the degree of hyperglycemia. It has also been observed that the 
leucine  levels  in  nonketotic  patients  was  almost  the  same  as  in  the  control 
group. This study leads to the conclusion that urinary HMB levels in diabetes 
mellitus might be useful in the evaluation of protein metabolism even in the 
absence of ketosis and marked hyperglycemia. 
Weimin, et al.(206) calculated the HMB and BHB urinary concentrations listed in 
Table 5-5 were from the ratio of the HMB peak area  to that of the internal Chapter 5    157 
standard  and  expressed  as  µg  per  mg  creatinine  as  a  correction  for  urinary 
dilution  or  concentration  by  kidneys  which  may  affect  endogenous  HMB 
concentrations.  
Table 5-5:  Urinary Levels of HMB, BHB and Serum Leucine in Diabetic and Non-Diabetic 
Patients(206) 
Group  Urinary HMB  Urinary BHB 
Serum leucine 
µmol/L  N 
Diabetic with 
ketosis 
27.1-87.5 ug/mg 
creatinine 
0-1274 ug/mg 
creatinine 
212-260  9 
Diabetic without 
ketosis 
21.7-51.3 ug/mg 
creatinine 
undetectable  141-187  12 
Control Group 
4.1-16.3 ug/mg 
creatinine 
undetectable  135-168  21 
 
5.3.2 Analysis of HMB  
Analysis  of  HMB  has  been  conducted  using  a  variety  of  different  analytical 
techniques such as GC/MS and LC/MS/MS as summarised in Table 5-6.  
Table 5-6:  Summary of the Published Methods for the Analysis of HMB. 
Ref.  Analyte  Matrix 
Extraction and 
Internal Standard 
Technique  Ions/identification 
(206)  HMB, BHB, MMA  Urine 
serum 
PP for serum 
(n-heptadecanoic acid). 
LLE for urine then SPE 
(MMA D3) 
GC/MS-SIM 
HMB (247) 
MMAD3 (250) 
 
 
(208)  HMB, BHB and 
Lactate 
Urine 
serum 
PP for serum 
LLE for urine 
(2-HIV). 
 
GLC/MS  Retention Time/Mass 
spectra 
(214)  HMB  Plasma 
LLE 
(MMA D3) 98% pure 
synthesized from 
acetone D6 and acetic 
acid 
GC/MS 
HMB (117,175, 217) 
HMB-D6 (181) 
 
 
(162) 
Amino acid, Fatty 
acids Organic 
acids 
Blood 
Sample dissolve in 
water and organic 
solvent then 
derivatized. 
LC/MS/MS  Different scan mode 
depends on analytes 
PP (Protein precipitation), LLE (Liquid Liquid Extraction), MMA D3 (Deuterated methyl malonic acid), 2-
HIV (2- Hydroxy isovaleric acid), HMB-D6 (Deuterated HMB) 
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The method originally developed and validated for the analysis of BHB and GHB 
in post-mortem blood and urine,(212) as described in Chapter 5, was further 
adapted and revalidated for the determination of HMB in plasma and urine as 
described below.  
5.3.3 Materials 
β-hydroxyisovaleric acid (HMB), liquid form, purity, ≥97% was purchased from 
Sigma Aldrich Co. (St Louis, USA). Blank plasma was obtained from the blood 
bank at the Western Infirmary Hospital, Glasgow. Blank urine was obtained from 
a healthy adult volunteer. Both blank plasma and urine were tested in triplicate 
for  the  presence  of  HMB,  BHB  and  GHB.  The  internal  standard  used  was 
deuterated  gamma  hydroxybutyrate  (GHB-d6,  1  mg/mL),  purchased  from 
Cerilliant  Corporation  (Round  Rock,  TX).  All  other  materials  used  are  as 
described in Sections 4.2.1.1 – 4.2.1.4. Drug and volatile-free plasma and urine 
blanks  used  for  preparing  quality  controls  and  calibrators  were  tested  for 
endogenous interference.   
One hundred and forty five plasma and 201 urine samples were received from 
the  Center  for  Human  Toxicology,  University  of  Utah,  USA  as  part  of 
collaboration.  The  samples  were  collected  from  subjects  (N=8)  as  part  of  a 
clinical study, at time zero (baseline), and after 2 hours for plasma and between 
0–4 hours for urine after oral administration of 3 grams of HMB. All samples were 
tested for HMB, BHB and GHB. Results less than the LOQ were reported as <LOQ. 
Samples  greater  than  the  ULOQ  were  diluted  in  water  and  reanalysed,  then 
multiplied  by  the  dilution  factor  after analysis.  All  samples  were  stored  at  -
20±2ºC during the time of analysis. 
A  statistical  calculation  of  mean,  standard  deviation  and  95%  confidence 
intervals (CI%) was calculated at baseline and after 2 hours for plasma and at 0–4 
hours for urine for all analytes (HMB, BHB and GHB). 
The method was applied to two post-mortem cases in which the results of initial 
analysis using the previous method indicated a high BHB level in one case and Chapter 5    159 
high GHB level in the other case. Whole blood and urine for both cases were 
analysed using this method.  
5.3.4 Methodology 
The instrumentation, GC conditions utilised and extraction methods developed 
and validated in Chapter 4 and section 5.2 for the analysis of BHB and GHB were 
also used for the analysis of HMB in plasma and urine. Data was collected in full-
scan mode and the ions monitored were: for HMB m/z 247, 131 and 205; BHB 
m/z 233, 117 and 191; GHB m/z 233,117 and 204 and m/z 239 and 241 for the 
internal standard GHB-d6. The bold underlined ions were used for quantification. 
A 50µL aliquot of plasma or urine calibrators, QCs and samples were transferred 
to 2 mL snap top polypropylene microcentrifuge tubes and extracted using the 
same blood method described in section 4.2.4 and Table 4-5.  
5.3.5 Method Validation 
Method validation for HMB, BHB and GHB in plasma and urine was carried out as 
previously described in Section 4.3 for the validation of BHB in blood and urine, 
with the exception of the assessment of stability which is summarised below. 
The assessment of the long-term stability of HMB, BHB and GHB in plasma and 
urine at two concentrations (50 and 300 mg/L) was carried out by re-analysing 
three  sets  of  QC  samples  stored  for  12  months  at  -20±2ºC.  The  percentage 
recovery was calculated by dividing the mean peak area ratio of the extracted 
QC samples versus the mean peak area ratio of the same spiked QC samples 
extracted  and  analysed  12  months  previously.  Analytes  were  considered  as 
stable when the percentage recovery was between 90-110% of control samples 
and the 95% confidence interval (CI) was within 80-120% of the mean of the 
control samples.(169)  
5.3.6 Results and Discussion 
Figure 5-10 illustrates a typical chromatogram and  spectra of an unextracted 
derivatized standard for HMB, BHB, GHB and internal standard GHB-D6. Chapter 5    160 
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Figure 5-10:  (A) HMB, (B) BHB, (C) GHB and (D) GHB-D6Chromatograms  and Full-Scan 
Spectra of Unextracted Derivatized Standards (100 mg/L). 
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analytes in plasma and urine respectively. The retention time of all analytes, 
including the internal standards was between 6-8 minutes.  
6.90 7.00 7.10 7.20 7.30 7.40 7.50 7.60 7.70 7.80 7.90 8.00
0
100000
200000
300000
400000
500000
600000
Time-->
Abundance
Ion 233.00 (232.70 to 233.70): 2010-18-06-006.D\data.m s
6.90 7.00 7.10 7.20 7.30 7.40 7.50 7.60 7.70 7.80 7.90 8.00
0
50000
100000
150000
200000
Time-->
Abundance
Ion 247.00 (246.70 to 247.70): 2010-18-06-006.D\data.m s
6.90 7.00 7.10 7.20 7.30 7.40 7.50 7.60 7.70 7.80 7.90 8.00 0
100000
200000
300000
400000
Time-->
Abundance
Ion 239.00 (238.70 to 239.70): 2010-18-06-006.D\data.m s
 
 
40 60 80 100 120 140 160 180 200 220 240 260 280 300
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
2200000
2400000
2600000
2800000
3000000
3200000
m/z-->
Abundance
S can 615 (7.064 m in): 2010-18-06-006.D\data.m s
147
73
117
191
233
88 130 45
59 204 101
217 177 163 247 299 260 284  
 
40 60 80 100 120 140 160 180 200 220 240 260 280 300
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
2200000
2400000
2600000
2800000
3000000
m/z-->
Abundance
S can 800 (7.659 m in): 2010-18-06-006.D\data.m s
147
73
233
117
204 45 133 103 59 189 85 159171 218 261 276 245 299  
 
40 60 80 100 120 140 160 180 200 220 240 260 280 300
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
1100000
1200000
m/z-->
Abundance
S can 741 (7.469 m in): 2010-18-06-006.D\data.m s
147
131
73
247
115 95 205 45
189 59
163 231 217 299 175 266 283
 
 
40 60 80 100 120 140 160 180 200 220 240 260 280 300
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
m/z-->
Abundance
S can 791 (7.630 m in): 2010-18-06-006.D\data.m s
147
73 239
120133 45 206 58 105 90 189 165 222 299 261 276 177
 
 
Figure 5-11:  Chromatogram and Full-Scan Spectrum for HMB, BHB and GHB 
         Extracted from Spiked Plasma (50 mg/L). 
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Figure 5-12:  Chromatogram and Full-Scan Spectrum for HMB, BHB and GHB 
Extracted from Spiked Urine (50 mg/L).  
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The correlation coefficients (R
2) were >0.99 for HMB, BHB and GHB over the 
linear range of 10–500 mg/L as illustrated in figure 5-13. Table 5-7 summarises 
the linearity data for each analyte in both matrices and also includes the LOD 
and LOQ. Due to the endogenous nature of HMB (212), BHB and GHB, the first 
point of the calibration curve was used as the lower limit of quantitation (LLOQ). 
Results less than 10 mg/L were reported as negative and results above 500 mg/L 
were reported as >500 mg/L. 
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Figure 5-13:  HMB, GHB and BHB Calibration Curves for Urine (A) and Plasma (B) Chapter 5    164 
 
Table 5-7:  LOD, LOQ and Linearity for HMB, BHB and GHB 
Matrix  Analyte  LOD 
(mg/L) 
LOQ 
(mg/L) 
Linearity 
(mg/L)  R
2 
Urine 
HMB  2.3  7.7  10-500  0.994 
GHB  1.0  3.3  10-500  0.999 
BHB  2.2  7.3  10-500  0.999 
Plasma 
HMB  2.3  7.8  10-500  0.990 
GHB  1.5  5.1  10-500  0.999 
BHB  0.9  2.9  10-500  0.998 
 
Inter-day and intra-day precision was less than 10% for all three analytes in both 
matrices. The average accuracy ranged from 98-102% and recovery from 42-77% 
in spiked controls as summarized in Table 5-8. 
Table 5-8:  HMB, BHB and GHB, Intraday and Interday Precision, Recovery and Accuracy  
 
 
The quality control samples were analysed on several occasions as illustrated in 
Appendix 5-4 and although some variation was noted, specifically in the lowest 
QC level of 10 mg/L, the majority of the QC results were within the acceptable 
limit of the mean ± 2 standard deviations (±2SD).  
Matrix  Analyte  QC conc. 
(mg/L) 
Intraday 
%CV 
(n=5) 
Interday 
%CV 
(n=12) 
Accuracy 
(%) 
Recovery 
(%) 
 
Urine 
HMB  50 
(300) 
3.7 
(1.7) 
12.4 
(8.5) 
120 
(102) 
75 
(77) 
GHB  50 
(300) 
3.2 
(1.8) 
5.5 
(5.2) 
98 
(100) 
67 
(74) 
BHB  50 
(300) 
1.8 
(1.5) 
11.1 
(5.3) 
100 
(99) 
64 
(68) 
 
Plasma 
HMB  50 
(300) 
6.2 
(9.2) 
9.5 
(7.9) 
100 
(101) 
42 
(53) 
GHB  50 
(300) 
0.9 
(3.6) 
2.9 
(4.0) 
100 
(102) 
73 
(74) 
BHB  50 
(300) 
8.9 
(2.8) 
3.4 
(4.4) 
98 
(101) 
57 
(66) Chapter 5    165 
HMB, GHB and BHB were all stable when stored for over 12 months at -20±2ºC 
with recoveries of greater than 91% achieved for the 300 mg/L QC as summarised 
in Table 5-9.  
Table 5-9:  HMB, GHB and BHB Concentrations Measured in Spiked Plasma and Urine 
[following (A) Initial tests and (B) after 12 months storage at -20° ° ° °C].  
 
GHB  concentrations  increased  across  both  matrices  and  at  the  two 
concentrations investigated. The recoveries for BHB were lower for the 50 mg/L 
QC in both plasma and urine although still greater than 85% after 12 months. The 
%CV was much higher for the 50 mg/L QC when retested for both plasma and 
urine and may account for this variability. However, this does not explain the 
considerable decrease in HMB concentration for the 50 mg/L spiked urine QC 
sample (56%) however this is not reflected in the recoveries at 300 mg/L urine 
QC sample or either of the plasma samples which are all greater than 91%.  
Figures 5-14 and 5-15 provide examples of HMB identified in plasma and urine 
respectively in both spiked and real case scenarios when compared with blank 
matrices. Full scan spectra are also provided.  
The method was applied to two post-mortem cases where both whole blood and 
urine were analysed. The first case (Figure 5-16) had high concentrations of BHB 
in blood and urine and elevated levels of GHB, while the second case (Figure 5-
     
PLASMA  
(mg/L) 
URINE  
(mg/L) 
 Sample 
Conditions 
Conc. 
(mg/L)     HMB  GHB  BHB  HMB  GHB  BHB 
A 
50                    
(n=12) 
Mean  50  50  49  60  49  50 
SD  4.26  1.78  2.54  8.14  2.96  5.03 
%CV  8.51  3.54  5.17  13.59  6.05  10.02 
300                 
(n=12) 
Mean  304  305  304  307  299  296 
SD  26.96  13.71  14.26  44.53  10.34  10.97 
%CV  8.87  4.49  4.68  14.51  3.46  3.71 
B 
50                 
(n=6) 
Mean  47  56  43  33  54  43 
SD  6.53  1.62  6.78  4.90  1.70  5.77 
%CV  13.77  2.90  15.61  14.73  3.16  13.54 
300                 
(n=6) 
Mean  282  334  296  279  358  316 
SD  21.68  14.83  18.35  14.09  9.91  7.40 
%CV  7.68  4.44  6.20  5.06  2.77  2.34 
                 
% 
Recovery 
50    95  111  88  56  110  85 
300    93  109  97  91  120  107 Chapter 5    166 
17) had high concentrations of GHB in blood and urine and low levels of BHB. In 
both cases HMB was less than the LOQ.  
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Figure 5-14:  Chromatogram and Full-Scan Spectrum for HMB Extracted from a Plasma Case 
Sample (37 mg/L) Versus the Spiked Plasma Control at 50 mg/L and Blank Plasma.  
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Figure 5-15:  Chromatogram and Full-Scan Spectrum for HMB extracted from a Urine Case 
Sample (500 mg/L) versus the Spiked Urine Control at 50 mg/L and Blank Urine.  
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Figure 5-16:  (A) Chromatogram and (B) Full-Scan Spectrum for BHB 
[Extracted from Urine Case Sample (>500 mg/L), HMB (< LOQ) and GHB (13 mg/L). (C) 
Chromatogram and (D) Full-Scan Spectrum for BHB extracted from Blood Base Sample 
(>500 mg/L), HMB (< LOQ) and GHB (18 mg/L)]. 
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Figure 5-17:  (A) Chromatogram and (B) Full-Fcan Spectrum of GHB  
[Extracted from Urine Case Sample (>500 mg/L), HMB (< LOQ) and BHB (12 mg/L). (C) 
Chromatogram and (D)Full-Scan Spectrum for GHB Extracted from Blood Case  Sample 
(>500 mg/L), HMB (14 mg/L) and BHB (12 mg/L)]. 
 
The use of GC-MS provides a specific and selective technique for determining 
HMB  and  structurally  related  compounds  such  as  BHB  and  GHB  in  biological 
samples. Modification of the method used for the determination of BHB and GHB 
in  postmortem  samples  did  not  present  any  challenges.  The  reason  for  using 
blank  plasma  to  dilute  the  urine  and  plasma  samples  is  to  obtain  a  cleaner 
extraction as interference with urea is a problem in this method. The recovery 
GBH
BHB GBH
HMB
GHB-D6 
GHB-D6 
HMB
BHB Chapter 5    169 
of HMB at a concentration of 50 mg/L was less than 50%, but the accuracy was 
between 98% and 102%. 
Table 5-10 summarises the mean and range of HMB, GHB and BHB at baseline 
and  after  administration  of  3  g  of  HMB.  Baseline  concentrations  for  HMB  in 
plasma and urine were less than the LOQ (<10 mg/L) before drug administration.  
Following administration of the 3g dose of HMB, plasma and urine were positive 
respectively. 
Table 5-10:  HMB, GHB and BHB level in urine and plasma at baseline and after 0-4  
hours(urine) and 2hours(plasma) following 3g  dose of HMB   
 
 
5.4 Conclusion 
A robust and sensitive method for the analysis of gamma-hydroxybutyrate (GHB) 
in  postmortem  blood  and  urine  was  validated.  The  method  was  utilised  to 
investigate GHB intoxication in postmortem case samples. In all case samples, 
there are no data to support GHB exposure with the exception of five cases. 
Concentrations of GHB less than the proposed published cut-off point of 50 mg/L 
in postmortem blood may be due to endogenous levels of GHB, but this is not 
sufficient  by  itself  to  distinguish  between  natural  endogenous  levels  and 
exogenous use. Other matrices, such as vitreous humour, femoral blood, urine 
and hair, must also be considered when interpreting postmortem GHB levels, as 
recommended  by  Kintz  et  al.  (186)Knowledge  of  the  time  intervals  from  the 
Matrix  Analyte 
Baseline 
(mg/L) 
0-4 hours (urine) or 2 hours 
(plasma) after 3g oral HMB 
(mg/L) 
Mean  Median  95% CI  Mean  Median  95% CI 
Urine 
(n=8) 
HMB  4  4  1-7  123  111  52-194 
GHB  0  0  0-1  0  0  0-1 
BHB  5  4  1-9  1  0  0-3 
Plasma 
(n=7) 
HMB  0  0  0  20  23  17-24 
GHB  0  0  0  0  0  0 
BHB  6  0  0-15  0  0  0-1 Chapter 5    170 
time  of  death  until  the  time  of  sample  collection  and  the  condition  of  the 
storage of the corpse before collection of the samples might also provide some 
information for better interpretation of the results. 
It is important to evaluate the effect of HMB on the body because it is the sixth
 
most commonly used dietary supplement and because it is legal.(203) There was 
a significant increase of HMB levels in urine and plasma 20–30 times more than 
the baseline level after consumption of 3 grams of HMB. No increase of BHB and 
GHB was observed. There was no correlation between the HMB levels and BHB or 
GHB in plasma and urine after administration of the HMB drug. 
The use of GC-MS provides a specific and selective technique for determining 
HMB  and  structurally  related  compounds  such  as  BHB  and  GHB  in  biological 
samples. Dilution of the urine and plasma samples with blank plasma provided a 
cleaner extract minimising the interference from urea in urine samples. A rapid, 
specific and robust method was developed for the simultaneous determination of 
HMB, BHB and GHB in plasma and urine. This method was successfully applied to 
post-mortem blood and urine, and plasma and urine from healthy subjects. For 
long-term storage, samples should be stored at -20±2ºC to minimise degradation 
of HMB, BHB or GHB.  171 
Chapter 6 - Fatty Acid Ethyl Esters 
6.1 Introduction 
 
Fatty acid ethyl esters (FAEEs) are non-oxidative metabolites of ethanol which 
are  currently  used  as  biomarkers  for  direct  ethanol  consumption  in  different 
biological matrices including, hair, blood and skin surface lipids. Elevated FAEEs 
in meconium, the infant’s first bowel movement, have also been reported as a 
biomarker for the detection of heavy prenatal ethanol exposure.  The aim of this 
project was to develop and validate a method for the determination of FAEEs in 
meconium using liquid chromatography tandem mass spectrometry (LC-MS/MS). 
Commercially  available  deuterated  internal  standards  were  used  for  the  first 
time for the detection of FAEEs using LC/MS/MS. The validated method was then 
applied to the analysis of eighty- four meconium case samples collected from 
babies  born  at  the  Princess  Royal  Maternity  Hospital,  Glasgow  to  investigate 
neonatal exposure to alcohol in the absence of maternal drinking history.  
6.2 Materials and Methods  
6.2.1 Chemicals and Reagents 
Ethyl  laurate  99.5%  GC  grade  (E12:0),  ethyl  myristate  (E14:0)  99%  GC  grade, 
ethyl palmitate 99% GC grade (E16:0), ethyl stearate (E18:0) 99% GC grade, ethyl 
oleate  98%  GC  grade  (E18:1),  ethyl  linoleate  99%  GC  grade  (E18:2),  ethyl 
linolenate (E18:3) minimum 98%, and ethyl arachidonate 99% (E20:4) esters were 
obtained from Sigma Aldrich Company Ltd., Dorset, UK. The deuterated internal 
standards (IS) ethyl myristate-D5 99%, ethyl palmitate– D5 99%, ethyl oleate– D5, 
and ethyl stearate-D5 were obtained from LGC Standards, Teddington,UK. Ethyl 
heptadecanoate (E:17) >97 % GC, ethyl palmitoleate (16:1) >99%, and the methyl 
esters standards were all obtained from Sigma Aldrich Company Ltd., Dorset, 
UK. The methyl esters included, methyl arachidonate (99% GC grade), methyl 
heptadecanoate  (99%  GC  grade),  methyl  linoleate  (minimum  99%),  methyl 
lenolenate, methyl myristate (99% GC grade), methyl oleate (≥ 99% GC grade), 
methyl palmitate (≥ 99% GC grade), methyl palmitoleate (99% GC grade), methyl 
stearate (99%) and methyl laurate (99.5% GC grade).  Chapter 6    172 
The  deuterated  internal  standards  purchased  from  LGC  Standards  were  not 
available at the start of this project and so deuterated internal standards were 
initially prepared in-house, the details of which are summarised in Appendix 6-1. 
Cyclohexane, acetone, acetonitrile and 2-propanol were all purchased from VWR 
International  Ltd;  ultrapure  water  was  obtained  from  the  in-house  Millipore 
purification  system.  Amino  propyl-silica  solid  phase  extraction  (SPE)  columns 
(100 mg sorbent amount, 1 mL volume, 40µm particle size) were obtained from 
Sigma Aldrich Company Ltd., Dorset,UK. 
6.2.2 Instrumentation  
Analysis  was  carried  out  using  an  Agilent  6410  LC/MS/MS  triple  quadropole 
(Agilent,  USA)  coupled  with  an  Agilent  1200-series  binary  pump,  high 
performance  autosampler,  and  thermostated  column  compartment.  An 
electrospray ionization (ESI) source was used in positive ionization mode. The 
column  used  was  Eclipse  XDB-C8  column  (150  x  4.6mm,  5µm)  with  a  guard 
column of the same packing material (4.6 x 12.5) from Agilent Technologies, 
USA. An LC/MS/MS LCQ DECA XP Plus ion trap instrument from Thermo Finnigan 
(San Jose, CA) was used to tune the analytes of interest for collision energy 
optimization and product ion optimization to compare with the triple quadropole 
LC/MS/MS instrument. 
6.2.3 LC-MS-MS Operating Conditions 
Isocratic  elution  was  chosen  using  a  mobile  phase  with  the  ratio  of  water: 
isopropanol: acetonitrile of 20:40:40, v/v/v, at a flow rate of 0.7 mL/min. The 
total run time was 25 minutes with a column temperature maintained at 30ºC. 
The source parameters to obtain optimum sensitivity and specificity were the as 
follows  capillary  voltage,  4500v,  source  temperature  120ºC,  gas  temperature 
300ºC,  gas  flow  8  L/min,  and  nebulizer  pressure  15  psi.  LC  and  source 
parameters are summarized in Table 6-1. Chapter 6    173 
 
Table 6-1:  Summary of LC and Ion Source Parameters 
LC Parameters 
Column  XDB-C8 RP column (150x4.6 mm,5 µm) with 
guard column of the same packing material 
Mobile phase  ACN:IPA:H2O-40:40:20 (V:V:V) 
Flow rate  0.7 mL/min isocratic 
Injection volume  50 µL 
Column Temperature  30ºC 
Run Time  25 minutes 
Mass Spectrometry Parameters 
Operating mode  ESI-positive mode 
Gas temperature  300ºC 
Gas flow  8 L/min 
Nebulizer Pressure  15 PSI 
Capillary Voltage  4500 V 
Scan mode  MRM 
 
6.2.4 Meconium Samples 
Drug  and  alcohol  free  blank  meconium  samples  used  for  development  and 
validation of the method were obtained from a previous project from babies of 
drug and alcohol-free mothers and were stored at -20±2°C within FMS. Three 
pretested pooled meconium blank samples were prepared by pooling 6 to 10 
blank meconium specimens and mixing them thoroughly; the approximate total 
weight  for  each  pooled  blank  sample  was  between  40–50  g.  The  pooled 
meconium  blanks  were  stored  at  -20±2°C  to  be  used  for  preparation  of 
calibratior and quality control specimens. 
Eighty-four  meconium  case  samples  were  collected  from  diapers  of  newborn 
infants delivered at the Royal Maternity Hospital in Glasgow. The meconium was Chapter 6    174 
recovered  using  wooden  spatulas  and  stored  in  plastic  tubes  at  -4°C  until 
transported to the laboratory. All samples were shipped in ice packs in closed 
containers, and they were stored immediately in the freezer at -20±2°C.  
The  stability  of  FAEEs  in  meconium  as  previously  reported  by  Moore  et  al. 
(2003)(153)  and  Pichini  et  al.  (2008)(159)  is  summarised  in  Table  6-2.  FAEEs 
degrade if not stored properly and therefore specimens should be immediately 
shipped  packed  in  ice  and  stored  in  the  freezer  to  eliminate  the  risk  of 
degradation of FAEEs. The longer-chain FAEEs appear to be more susceptible to 
heat and light; this was hypothesised as no ethyl arachidonate was detected in a 
study of 436 specimens analysed. This loss could be from exposure to light and 
heat, because the specimens were not shipped in ice and stored at a proper 
temperature.(153)  
Table 6-2:  Summary of FAEEs Stability Study by Moore et al.(153) 
 
It  has  been  reported  that  around  10%  degradation  of  FAEEs  from  the  initial 
concentration occurs after 3 freeze/thaw cycles.(159)  
6.2.5 Preparation of Stock Standard Solutions 
Individual stock standards were prepared at a concentration of 10 mg/mL for 
each analyte in cyclohexane. The intermediate standard was prepared from the 
individual stock standards at a concentration of 1 mg/mL. The working standard 
mixture solution was prepared at concentrations of 1, 10, and 100 mg/L from 
% loss of FAEEs  Temperature/Conditions  Hours/Days 
86%  Room temperature in light  24 hours 
60%  Room temperature in dark  24 hours 
40%  Room temperature in dark under argon  24 hours 
10%  Refrigerator  24 hours 
18%  Refrigerator  24 hours 
11%  Freezer  6 days 
≤ 50%  Freezer  43 days Chapter 6    175 
the intermediate standard solution to be used for spiking the calibrators. The 
working internal standard mixture (including ethyl-myristate-D5, ethyl palmitate-
D5, ethyl oleate– D5, ethyl stearate-D5, and ethyl heptadecanoate) was prepared 
at  a  concentration  of  100  mg/L  in  cyclohexane  from  a  stock  standard  of  10 
mg/mL. Internal standards used for the quantification of ethyl palmitate was 
ethyl palmitate-D5, for ethyl oleate was ethyl oleate–D5, for ethyl stearate was 
ethylstearate-D5.  Deuterated  ethyl  oleate-D5  was  used  for  the  remaining 
analytes  namely;  ethyl  arachidonate,  ethyl  palmitoleate,  ethyl  laurate,  ethyl 
myristate, ethyl linolenate and ethyl linoleate as deuterated internal standards 
of these FAEEs were not commercially available for purchase.  
Tuning  solutions  were  prepared  at  10  mg/L  in  mobile  phase  from  the  mixed 
stock standard solution (1 mg/mL for all analytes). Cyclohexane was evaporated 
and the mobile phase solutions reconstituted with mobile phase. All standards 
and tuning solutions were stored at -20± 2ºC. 
The  international  unit  used  for  the  concentration  of  FAEEs  in  meconium  is 
nmol/g which has been converted to ng/g for this project and the conversion is 
summarised in Table 6-3.    
6.2.6 Preparation of Quality Control (QC) Material 
Two QC's samples were prepared at two concentrations (400 and 8000 ng/g). An 
aliquot of 0.5 g from pooled meconium blank which was screened to be used for 
spiking QC were weighed into 15 mL screw cap round-bottom glass tubes and 
centrifuged at 2500rpm for 5 minutes. After centrifugation 250 µL of deionised 
water  was  added.  QC  samples  were  vortexed  for  0.5–1  minute  until  a 
homogeneous suspension was formed after spiking with a specified amount of 
the FAEEs standard mixture QC samples were vortexed for 0.5–1 minute and then 
internal standard will be added and follow the same steps of sample extraction 
procedure. The QC's were prepared and extracted fresh with each batch and the 
mean and standard deviation calculated to evaluate the acceptability of each 
batch. Chapter 6    176 
6.2.7 Sample Extraction Procedure 
Samples of 0.5 g of meconium were weighed into 15 mL screw cap round-bottom 
glass tubes, and centrifuged at 2500rpm for 5 minutes. After centrifugation 50 
µL of internal standards mixture (100 mg/L) was added to all tubes followed by 
250 µL of deionised water and 500µL acetone. Samples were vortexed for 0.5–1 
minute  until  a  homogeneous  suspension  was  formed,  and  then  5  mL  of 
cyclohexane  added  before  placing  the  tubes  in  a  tube  shaker  for  10min  and 
finally centrifuging at 2500 rpm. The organic layer was transferred to 5 mL screw 
cap disposable glass tubes, and the solvent was evaporated to dryness at 30ºC 
under a nitrogen stream. The samples were vortexed after being resuspended 
with 500µL of cyclohexane. The samples were then applied to preconditioned 
aminopropyl-silica solid-phase extraction (SPE) columns with 2 mL cyclohexane, 
and  the  sample  extract  was  collected  in  round-bottom  culture  tubes.  The 
analyte was eluted with 2 mL cyclohexane and collected in the same tube before 
evaporating to dryness at 30ºC under a nitrogen stream. The samples were then 
reconstituted with 120µL of mobile phase and 50µL injected onto the LC system.  
Table 6-3:  Conversion of FAEEs Concentrations from nmol/g to ng/g 
 
 
 
 
 
 
 
 
FAEES  Formula 
weight  ng/g  nmol/g 
Ethyl Laurate   229  1  0.0044 
Ethyl Myristate   257  1  0.0039 
Ethyl Linolenate   307  1  0.0033 
Ethyl linoleate   309  1  0.0032 
Ethyl Palmitoleate   283  1  0.0035 
Ethyl Palmitate   285  1  0.0035 
Ethyl Palmitate-D5  290  1  0.0034 
Ethyl Oleate   311  1  0.0032 
Ethyl Oleate-D5  316  1  0.0032 
Ethyl Stearate   313  1  0.0032 
Ethyl Stearate-D5  318  1  0.0031 
Ethyl Arachidonate   333  1  0.0030 Chapter 6    177 
6.3 Instrument Method Optimisation  
6.3.1 Optimization  of  the  Fragmentor  Voltage  and  Collision 
Energy 
MS/MS  characterization  of  the compounds  of  interest  was  achieved  using  the 
triple  quadrupole  and  electrospray  ionization  in  positive  ionization  mode. 
Compound specific optimization of MS/MS was performed using the automatic 
software optimizer (Mass Hunter) and product ion optimization. Analytes were 
dissolved in mobile phase at a concentration of 10  mg/L and fragmenter ion 
optimization was carried out to select the highest abundant precursor ions from 
the first quadrupole.  
Collision  energy  was  optimized  to  get  the  most  abundant  product  ions  at  a 
collision cell pressure of 10–50 psi using nitrogen gas for collision. Optimization 
results for the two most abundant ion transitions per analyte were selected in 
the multiple reaction monitoring scan mode (MRM). Similar product ions were 
generated when the same tuning solutions were injected in another LC/MS/MS 
using a Thermo Finnigan LCQ DECA XP Plus ion trap instrument.   
6.4 Method Validation  
6.4.1  Selectivity 
Selectivity is ‘the ability of an analytical method to differentiate and quantify 
the  analyte  in  the  presence  of  other  potentially  interfering  substance  in  the 
samples’.  There  are two  types  of  potential  interferences:  endogenous  matrix 
interferences  and  exogenous  interferences.  Exogenous  interferences  might 
include  structurally  related  analytes  of  interest,  interferences  or  non-
structurally  related  interfering  substances  in  biological  samples  such  as 
endogenous  matrix  component,  metabolites,  impurities  or  matrix 
components.(169;215;216) 
Selectivity  evaluation  was  carried  out  by  checking  any  interference  from 
endogenous  compounds  by  the  analysis  of  independent  replicate  blanks  of 
meconium from different sources compared with an unextracted FAEEs standard Chapter 6    178 
mixture of 1 mg/L prepared in mobile phase. There should be no signal or area 
response at the expected elution time of the analyte in the meconium blank.  
In  many  LC-MS/MS  metods,  both  analytes  of  interest  and  isotope-deuterated 
internal standards are not chromatographically separated; this was in order to 
see if there is a contribution of the monitored product ions (from analyte to 
internal standard and vice versa) causing changes to the signal measured. This 
was  assessed  by  duplicate  analysis  of  blank  meconium  spiked  with  internal 
standard  versus  blank  meconium  spiked  with  FAEEs  standard  mixture  at  a 
concentration  of  8000ng/g  without  adding  internal  standards.  Exogenous 
interferences with compounds structurally related to FAEEs was investigated by 
spiking blank meconium with fatty acid methyl esters (FAMEs) in duplicate at a 
concentration  of  8000ng/g  with  and  without  adding  the  analyte  of  interest 
(FAEEs) at the same concentration.  
6.4.2  Linearity 
Using the standard working solutions at concentrations of 1, 10, and 100 mg/L, 
calibration curves were prepared in meconium at concentrations ranging from 
20–16000ng/g. The concentrations of calibrator points were 20, 50, 100, 400, 
600, 1,000, 2,000, 4,000, 8,000, 12,000, and 16,000ng/g. The calibrators were 
prepared fresh before each batch. 
The calibration curve was generated by plotting the peak area ratio versus the 
spiked  analyte  concentrations,  and  the  correlation  of  coefficient  (R
2)  was 
calculated. The acceptable R
2 should be greater than 0.99. 
6.4.3  Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The  LOD  and  LOQ  were  determined  by  preparing  meconium  samples  with 
decreasing concentrations of each analyte within the expected range of the LOD. 
LOD  concentrations  were  1,  2,  5,10,  20,  50,  100,  and  400ng/g.  Regression 
analysis was undertaken, and the LOD and LOQ were calculated in accordance 
with  Miller  and  Miller.(217)  The  calculation  for  LOD  and  LOQ  is  described  in 
chapter 2 section 2.2.9. Chapter 6    179 
6.4.4  Accuracy and Precision 
Accuracy is determined by replicate analysis of QC samples at 2 concentrations 
(400  and  8000ng/g).  The  accuracy  was  calculated  as  a  percentage  of  the 
measured mean value against corresponding theoretical or nominal value (“true 
value”). The mean value should not deviate by more than 20% from the true 
value.  
Intra-day precision (within-day precision) was evaluated using five replicates of 
meconium control samples prepared at 2 concentrations (400 and 8000 ng/g) and 
extracted  and  injected  on  the  same  day.  Inter-day  precision  (between-day 
precision)  was  evaluated  using  six  meconium  control  samples  prepared  in 
duplicate at two concentrations (400 and 8000 ng/g) and then extracted and 
injected  over  a  time  period  of  6  days.  The  percentage  of  the  coefficient  of 
variance (%CV) was calculated, with an acceptable %CV% of <20%. 
6.4.5 Recovery study 
Recovery was evaluated at two QC levels (400 and 8000ng/g). The mean peak 
area ratio of 3 meconium blank samples spiked with FAEEs and d5-FAEEs was 
compared with the mean peak area ratio obtained for 3 meconium blank samples 
where d5-FAEEs standard mixture was added before the evaporation step. (215)  
6.4.6 Assessment of Matrix Effects 
The matrix effect was assessed using the post-column infusion approach. Mobile 
phase  and  three  pooled  blank  meconium  (extract)  were  injected  onto  the 
column simultaneously with FAEEs internal standards at a concentration of 10 
mg/L,  infused  at  constant  rate  into  the  eluate  using  a  post  column  tee 
connection.  The  presence  of  a  negative  or  positive  peak  or  response  would 
indicate ion suppression or ion enhancement, respectively. 
Matrix  effects  were  also  assessed  by  preparing  2  sets  of  spiked  samples  in 
triplicate at two concentrations (400 and 8000ng/g). The first set was prepared 
by spiking meconium blank samples, and the second set was prepared at the Chapter 6    180 
same concentration without the matrix. The matrix effect was expressed as a 
percentage of the mean of the peak area ratio of the two sets. 
6.4.7  Carryover 
Carryove  as  assessed  by  injecting  a  mobile  phase  blank  after  the  sample 
containing the calibration standard equivalent to the upper limit of quantitation 
(16,000ng/g).  
6.5 Results and Discussion 
6.5.1 Optimization  of  the  Fragmentor  Voltage  and  Collision 
Energy 
The fragmentor voltage was in the range of 100–140 for most of the FAEEs and 
 their deuterated analogues, for optimum abundance of the precursor ions as  
illustrated in Figures 6-1 and 6-2, respectively.  
 
 
Figure 6-1:  Fragmenter Ion Optimization of FAEEs 
 
0
50000
100000
150000
200000
250000
300000
350000
400000
60 80 100 120  140 160 180 200 220
Ethyl Laurate
Ethyl Linolenate
Ethyl Linoleate
Ethyl Arachidonate
Ethyl Myristate
Ethyl Oleate
Ethyl Palmitate 
Ethyl Palmitoleate 
Ethyl StearateChapter 6    181 
 
Figure 6-2:  Fragmenter Ion Optimization of D5-FAEEs and Ethyl Heptadecanoate 
 
Most analytes had an optimum collision energy of less than 10eV using LC-MS/MS 
as illustrated in Figure 6-3. However, using the same tuning solution with the ion 
trap  LC/MS/MS,  the  collision  energies  were  higher  (27-42  eV  for  the  same 
analytes).  The  collision  energy  and  product  ion  optimization,  using  triple 
quadropole LC-MS/MS was not fully achieved as it was not reproducible. This is 
most likely due to the low collision energy required to fragment the ions (less 
than 5ev) which is much lower compared to the Thermo ion trap LC-MS/MS. A 
summary of the molecular and product ions and optimised collision energy is 
summarised in Table 6-4. 
 
Figure 6-3:  Collision Energy Optimization of FAEEs and D5-FAEEs 
 
Multiple Reaction monitoring (MRM) transitions of quantifiers and qualifiers in 
addition  to  the  fragmenter  voltage,  collision  energy,  and  retention  time  are 
listed in Table 6-5. The FAEEs retention times ranged from 7–21 minutes. 
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Table 6-4:  FAEES and FAEEs-d5 Optimization of Product Ion and Collision Energy (CE) 
FAEEs  Molecular 
Ion 
Product  
Ions 
CE 
Ion Trap   Comment 
Ethyl Arachidonate  332.5  287  38  Commercial 
Ethyl Heptadecanoate  299  271  36  Commercial 
Ethyl Laurate  228.38  201  30  Prepared in house from 
its acid 
Ethyl Lenolenate  306.49  261/243  42  Commercial 
Ethyl Linoleate  308.51  263/245  32  Commercial 
Ethyl Miristate  256.43  229  32  Commercial 
Ethyl Oleate  310.53  265/247  30  Commercial 
Ethyl Palmitate  284.48  257  32  Commercial 
Ethyl Palmitoleate  283  237  30  Commercial 
Ethyl Stearate  312.53  285  34  Prepared in house from 
its acid 
Commercial Deuterated FAEEs-D5 
Ethyl Miristate-D5  262  230  30  Commercial 
Ethyl Oleate-D5  316  265  38  Commercial 
Ethyl Palmitate-D5  290  258  30  Commercial 
Ethyl Stearate-D5  318  286  32  Commercial 
 
 
 
Table 6-5:  MRM (m/z) Transitions for Quantification of FAEEs 
FAEEs 
MRM 
Transition 
(m/Z) 
Qualifier 
product 
ions 
Fragmentor 
voltage 
(V) 
CE 
(ev) 
Rt 
(min) 
Ethyl Laurate   229→201  -  84  2  7.06 
Ethyl Myristate   257→229  -  100  2  9.98 
Ethyl Linolenate   307→261  243  135  2  8.52 
Ethyl linoleate   309→263  245  120  2  11.16 
Ethyl Palmitoleate   283→237  -  108  2  10.44 
Ethyl Palmitate   285→257  -  136  6  14.24 
Ethyl Palmitate-D5  290→258  -  136  5  14.03 
Ethyl Oleate   311→265  247  135  2  15.23 
Ethyl Oleate-D5  316→265  247  140  2  14.94 
Ethyl Stearate   313→285  247  140  5  21.26 
Ethyl Stearate-D5  318→286  -  140  5  20.98 
Ethyl Arachidonate   333→287  -  128  5  9.98 Chapter 6    183 
6.5.2 Specificity 
No  endogenous  or  exogenous  interferences  were  identified  at  the  FAEEs 
retention  times  (as  summarised  in  Appendix  6-2)  or  from  structurally-related 
analytes, as illustrated in Figures 6-4 and 6-5. No contribution from the internal 
standards to the analytes or vice versa was observed as illustrated in Figure 6-6. 
 
Figure 6-4:  Exogenous Specificity Study Spiked Meconium with FAME Mix Standard alone 
8000ng/g against Spiked FAEES 8000ng/g plus FAME 8000ng/g Compared with Unextracted 
FAEES and Unextracted FAME of 10 mg/L. [The arrow indicates no interference].  
 
 
Figure 6-5:  Total Ion Chromatogram (TIC) of Extracted FAEEs 8000 ng/g in Meconium 
Versus Extracted Blank and FAME standard of 8000 ng/g with Internal Standard. 
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Figure 6-6:  Extracted FAAEs With and Without Internal Standard. 
[The arrow indicated no contribution from analyte to internal standard] 
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6.5.3 Validation Results 
All  regression  lines  had  >  0.995  over  the  concentration  range  from  LLOQ  -
16,000ng/g for each analyte as summarised in Table 6-6. With the exception of 
ethyl laurate and ethyl arachidonate, the LOD and LOQ were acceptable and are 
listed in Table 6-6. 
Table 6-6:  Linearity, LOD, and LOQ of FAEEs in Meconium 
 
 
 
 
 
 
 
Intra-day  and  inter-day  precision  for  all  analytes  met  the  criteria  for 
acceptability of <20%. However, the precision for ethyl arachidonate was close 
to the acceptable limit. The accuracy of all analytes ranged from 75–110%, as 
detailed in Table 6-7. The mean and QC ranges are also listed in Table 6-7. Ethyl 
laurate was not reported for the 400ng/g QC as this was below the LOQ.  
FAEES  Correlation Coefficient (R
2) and 
Regression Equations 
LOD 
(ng/g) 
LOQ 
(ng/g) 
Ethyl Laurate       0.998 (y = 0.00002x - 0.0002)  822  2740 
Ethyl Myristate  0.996 (y = 0.0001x + 0.02)  25  82 
Ethyl Linolenate  0.999 (y = 0.0007x + 0.173)  14  46 
Ethyl Linoleate   0.995 (y =0.0007x + 0.1984)  18  60 
Ethyl Palmitoleate   0.995 (y = 0.0002x + 0.0867)  14  46 
Ethyl Palmitate  0.992 (y = 0.0009x + 0.437)  11  37 
Ethyl Oleate   0.995 (y = 0.0007x + 0.2586)  11  38 
Ethyl Stearate  0.996 (y = 0.0011x + 0.2214)  11  37 
Ethyl Arachidonate    0.998 (y = 0.00002x + 0.0008)  102  339 Chapter 6    186 
Table 6-7:  Intra-day and Inter-day Precision and Accuracy 
 
6.5.4 Recovery and Matrix effect 
No ion suppression or enhancement was indicated for the mobile phase, or the 
three pooled blank meconium samples, as illustrated in Figure 6-7. The recovery 
for all analytes from meconium ranged from 56% to 138% as summarised in Table 
6-8. The percent matrix affect ranged from 54% to 118%. Most analytes (6 out of 
9)  demonstrated  ion  suppression  and  enhancement  (1–20%).  Three  of  the 
analytes  (ethyl  Laurate,  ethyl  myristate,  and  ethyl  arachidonate)  showed  ion 
suppression or enhancement of > 20%, although the post-column syringe infusion 
ion suppression study (see Figure 6-7) showed no negative or positive peak in the 
retention time of the FAEEs. No ion suppression or enhancement was observed.  
 
FAEES  QC 
(ng/g) 
QC 
Mean ±2SD 
(ng/g) 
QC Mean 
(ng/g) 
n=13 
Intraday 
%CV 
n=5 
Interday 
%CV 
n=6 
Accuracy % 
Ethyl Laurate  400 
8000 
- 
LOQ-5219 
- 
3641 
- 
11.3 
- 
12.1 
- 
76 
Ethyl Myristate  400 
8000 
241-622 
3827-9622 
432 
6725 
18.3 
10.6 
19.3 
17.14 
81 
89 
Ethyl 
Linolenate 
400 
8000 
337-547 
5376-9821 
442 
7598 
12.1 
9.8 
17.1 
13.9 
80 
108 
Ethyl Linoleate  400 
8000 
292-600 
5834-8679 
446 
7256 
11.2 
9.4 
11.2 
8.7 
90 
110 
Ethyl 
Palmitoleate 
400 
8000 
343-744 
6562-11880  5439221  9.7 
9.5 
10.6 
15.7 
81 
88 
Ethyl Palmitate  400 
8000 
219-509 
6404-10198  3648301  8.3 
4.2 
8.2 
8.9 
110 
97 
Ethyl Oleate  400 
8000 
258-598 
6884-10413 
428 
8648 
5.3 
3.7 
17.2 
7.3 
96 
93 
Ethyl Stearate  400 
8000 
283-630 
6739-11272 
456 
9005 
9.2 
11.1 
14.3 
15.2 
83 
89 
Ethyl 
Arachidonate 
400 
8000 
LOQ-705 
4883-9817  4837350  9.8 
15.5 
19.9 
18.7 
88 
85 Chapter 6    187 
 
Figure 6-7:  Ion Suppression Experiment. Figure (A) Overlaid Chromatograms  
of Mobile Phase, three pooled meconium blanks showed no ions suppression or 
enhancement. Figure (B) is same as (A) with separated chromatograms.  The expected 
retention time of FAEEs ranged from 7–21minutes between the black arrows indicated in (A) 
and (B) expected retention time. 
 
         Table 6-8:  Recovery and Matrix Effects for FAEEs 
 
 
 
 
 
 
 
 
FAEES  QC 
(ng.g) 
Recovery 
(%) 
Matrix Effect 
(%) 
Ethyl Laurate  400 
8000 
- 
56 
- 
54 
Ethyl Myristate  400 
8000 
80 
71 
153 
134 
Ethyl Linolenate  400 
8000 
114 
122 
93 
79 
Ethyl Linoleate  400 
8000 
93 
107 
102 
87 
Ethyl Palmitoleate  400 
8000 
126 
123 
96 
118 
Ethyl Palmitate  400 
8000 
113 
97 
116 
118 
Ethyl Oleate  400 
8000 
87 
99 
121 
108 
Ethyl Stearate  400 
8000 
138 
111 
99 
109 
Ethyl Arachidonate  400 
8000 
108 
81 
204 
157 
Overlaid Chromatogram mobile 
Phase and extracted pooled 
meconium extracted pooled blanks 
Mobile phase 
Extracted pooled blank 1 
   Extracted pooled blank 2 
Extracted pooled blank 3 Chapter 6    188 
6.5.5  Carryover  
No  carryover  was  observed  after  injecting  mobile  phase  after  the  highest 
calibrator (16,000ng/g) as illustrated in Figures 6-8 and 6-9. 
 
 
 
 
 
 
 
Figure 6-8:  Carryover study – Total Ion Chromatogram of Highest Calibrator 
(16,000ng/g) Versus Blank Mobile Phase. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-9:  Carryover Study – (MRM) Chromatogram of Highest Calibrator  
(16,000ng/g) Versus Blank Mobile Phase. 
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6.5.6  FAEEs in Meconium 
A  number  of  samples  had  concentrations  of  FAEEs  exceeding  the  ULOQ  and 
dilution was not always possible due to insufficient volume of sample remaining. 
Therefore, all results greater than the ULOQ were reported as >ULOQ, and all 
results that were less than lower limit of quantification (LLOQ) were reported as 
<LLOQ. A cut-off point of approximately 500ng/g (equivalent to 2nmol/g) was 
used to distinguish between positive and negative samples, although for most 
analytes the LLOQ is less than this value. 
A full list of the results for all FAEEs measured in the 84 meconium samples is 
listed in Appendix 6-3.  A total of 51 samples (61%) were positive for at least one 
FAEE  and  no  FAEEs  were  detected  in  33  samples  (39%).  Of  the  51  positive 
samples, 49% of these were positive for only one FAEE. A comparison between 
the positive and negative results for each individual FAEE detected in meconium 
is illustrated in Figure 6-10.  
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Figure 6-10:  Comparison of Positive and Negative Findings for Individual FAEEs in 
Meconium 
 
Three case samples (case numbers 4, 62, and 101) had a number of the FAEEs 
concentrations  exceeding the  ULOQ  and  are  summarised in  Table  6-9.  It  was 
observed that the concentration of individual FAEEs varies from case to case, as 
can been seen in case number 4 where ethyl linoleate was >ULOQ while ethyl Chapter 6    190 
palmitate is within the linearity range. However in case #62, ethyl palmitate was 
>ULOQ and ethyl linoleate was lower than that measured in case # 4.  
Table 6-9:  Case Samples With Results Exceeding ULOQ for most of FAEEs 
Case 
No. 
Ethyl  
Laurite 
(ng/g) 
Ethyl 
Myristate 
(ng/g) 
Ethyl 
Linolenate 
(ng/g) 
Ethyl 
Linoleate 
(ng/g) 
Ethyl 
Palmitoleate 
(ng/g) 
Ethyl 
Palmitate 
(ng/g) 
Ethyl 
Oleate 
(ng/g) 
Ethyl 
Stearate 
(ng/g) 
Ethyl 
Arachidonate 
(ng/g) 
4 
>ULOQ 
(342611) 
>ULOQ 
(124527) 
>ULOQ 
(46627) 
>ULOQ 
(214140) 
>ULOQ 
(56089)  5931  >ULOQ 
(56421)  906  >ULOQ 
(4522790) 
62 
>ULOQ 
(172912) 
>ULOQ 
(78746) 
>ULOQ 
(25803) 
>ULOQ 
(135051) 
>ULOQ 
(180002) 
>ULOQ 
(64782) 
>ULOQ 
(332134)  4976  >ULOQ 
(4267963) 
101 
>ULOQ 
(194179) 
>ULOQ 
(295840) 
>ULOQ 
(374173 
>ULOQ 
(532002) 
>ULOQ 
(462119) 
>ULOQ 
(23020) 
>ULOQ 
(283700)  4660  >ULOQ 
(8354465) 
 
The positive 95% confidence interval limit (CI) of all FAEE ranged from 2935–
49032ng/g as summarised in Table 6-10. The negative 95% CI limit of all FAEE's 
ranged from 14–56ng/g. This is comparable to a study by Gareri(152), with the 
exception of ethyl arachidonate which was 10 times higher in this study. 
 
Table 6-10:  The Positive and Negative FAEEs Results and the 95% of Confidence Interval 
Level 
 
 
FAEEs 
Number of 
Positive 
Cases 
 
Positive Mean  
ng/g 
n=87 
95%(CI) 
ng/g 
 
Number of 
Negative 
Cases 
 
Negative 
Mean ng/g 
n=87 
 95%(CI) 
ng/g 
 
Ethyl Laurate  10 
 
35154 
 
35153-35155 
 
79 
 
15 
 
14-15 
 
Ethyl Myristate  38 
 
25884 
 
2588-25885 
 
51 
 
53 
 
52-53 
 
Ethyl Linolenate  30 
 
30010 
 
30009-30010 
 
59 
 
50 
 
50-51 
 
Ethyl linoleate  31 
 
49032 
 
49031-49032 
 
58 
 
42 
 
41-42 
 
Ethyl 
Palmitoleate 
26 
 
39255 
 
39254-39256 
 
53 
 
25 
 
24-25 
 
Ethyl Palmitate  30 
 
7128 
 
7127-7129 
 
59 
 
35 
 
34-35 
 
Ethyl Oleate 
40 
 
31405 
 
31404-31405 
 
49 
 
32 
 
32-33 
 
Ethyl Stearate 
30 
 
2936 
 
2935-2938 
 
59 
 
56 
 
55-56 
 
Ethyl 
Arachidonate 
46 
 
514611 
 
514610-514611 
 
43 
 
26 
 
25-26 
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Cumulative results for all 9 FAEEs are shown in Figure 6-11. 37% of the samples 
were  negative  (<  500ng/g)  for  cumulative  FAEEs  and  63%  were  positive  (26% 
ranged from 500–999.99ng/g and 37% were ≥ 10,000ng/g). By plotting the cases 
that were < 10,000ng/g versus the concentrations, 4 samples were ≥ 5000ng/g as 
illustrated  in  Figure  6-12.    In  all  positive  samples,  at  least  3  analytes  were 
positive.  
Cumulative Concentrations of All FAEE's 
ng/g
23, 26%
33, 37%
33, 37%
 
 
 
 
 
 
 
 
Figure 6-11:  Cumulative concentrations of the FAEES in meconium  
 
FAEEs  quantified  in  case  #  101  have  been  summarised  in  Figure  6-13  which 
contains an overlay of chromatograms for this case in comparison to the highest 
standard of the calibration curve (16000 ng/g) with only ethyl stearate being 
within the ULOQ. 
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Figure 6-12:  Cumulative Concentration of all FAEE Results (500–10,000ng/g) 
 
 
 
 
 
 
 
 
 
   
 Figure 6-13:  Overlaid MRM chromatogram of High-Result FAEE Case samples  
 (101) against the Highest Point of Calibrator curve 
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Calibrator 
16,000ng/g
3 x1 0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
2.8
3
3.2
3.4
3.6
+ M R M (3 09 .00 00 0 ->  263 .00 00 0) C S _M _10 1.d   Sm oo th (1 )  
1
C ou nts  v s.  A cq ui si ti on  Tim e  (m in )
2 3 4 5 6 7 8 9 10 11 1 2 13 1 4 15 16 17 18 1 9 20 2 1 22 23 2 4 25
Ethyl Linoleate
Calibrator 
16,000ng/g
3 x 10
0
0. 05
0 .1
0. 15
0 .2
0. 25
0 .3
0. 35
0 .4
0. 45
0 .5
0. 55
0 .6
0. 65
0 .7
0. 75
0 .8
0. 85
0 .9
0. 95
1
+  M R M  (3 1 3.0 0 00 0  ->   28 5. 00 00 0 ) C S _M _ 10 1 .d   S m o ot h ( 1)  
1
C o u nt s  vs .  A c qu is i ti on  T i m e  (m i n )
12 13 14 15 16 1 7 1 8 1 9 2 0 2 1 2 2 2 3 2 4 2 5 2 6 2 7 2 8 29 30 31 32 33 34 35 36
Ethyl Stearate
COnc. 4660ng/g(14.9 
nmol/g)
Calibrator 
16,000ng/g
3 x1 0
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
+ M R M (3 33 .00 00 0 ->  287 .00 00 0) C S _M _10 1.d   Sm oo th (1 )  
1 1
C ou nts  v s.  Acq ui si ti on  Tim e  (m in )
1 2 3 4 5 6 7 8 9 10 11 1 2 13 1 4 15 16 1 7 18 1 9 2 0 21 2 2 23 24
Ethyl Arachidonate
Calibrator 
16,000ng/g
3 x 10
0 .1
0 .2
0 .3
0 .4
0 .5
0 .6
0 .7
0 .8
0 .9
1
1 .1
1 .2
1 .3
1 .4
1 .5
1 .6
1 .7
1 .8
1 .9
2
2 .1
2 .2
2 .3
2 .4
2 .5
+ M R M  (3 11 .0 00 00  -> 2 6 5.0 00 00 ) C S _M _ 10 1. d  S m o ot h ( 1)  
1
C o un ts  v s . A c qu i si ti on  Ti m e  (m in )
8 9 1 0 11 1 2 13 1 4 15 1 6 1 7 18 1 9 20 2 1 22 2 3 24 25 2 6 27 2 8 29 3 0 31 3 2
Ethyl Oleate
Calibrator 
16,000ng/gChapter 6    193 
Case  #  62  (highly  positive  for  most  of  FAEEs)  has  been  integrated  against  a 
negative FAEEs results and illustrated in Figure 6-14. The black arrows highlight 
where the expected peak of FAEEs should be.   
 
 
 
 
   
Figure 6-14:  MRM Chromatogram of Negative FAEES Case Samples 
in Meconium versus Positive Samples.  
Ethyl Laurate - Negative  
Ethyl Myristate - Positive  
Ethyl Palmitoleate - Negative  
Ethyl Palmitoleate - Positive  
Ethyl Palmitate - Negative  
Ethyl Palmiate - Positive  
D5-Ethyl Palmitate - Negative  
D5-Ethyl Palmiate - Positive  
Ethyl Laurate - positive  
Ethyl Myristate - Negative  
D5 Ethyl Stearate - Negative  
D5 Ethyl Stearate - Positive  
Ethyl Arachidonate -Negative 
Ethyl Arachidonate - Positive  
Ethyl Linoleate - Negative  
Ethyl Linolenate - Negative  
Ethyl Linolenate - Positive  
Ethyl Insolate - Positive  
Ethyl Oleate - Negative  
Ethyl Oleate - Positive  
D5 Ethyl Oleate - Negative 
 
D5 Ethyl Oleate - Positive  
 
Ethyl Stearate - Negative  
Ethyl Stearate - Positive  Chapter 6    194 
In order to correlate the FAEEs concentrations in meconium to assess maternal 
gestational  alcohol  exposure,  more  information  is  required  in  relation  to 
maternal  drinking  behaviours,  history  of  drug  and  alcohol  abuse,  quantity  of 
alcohol consumed, social status, time of drinking during gestation and stage of 
gestation, and age of the mother.  
No  correlation  between  the  concentrations  of  FAEEs  in  meconium  and  foetal 
alcohol exposure could be assessed in this study, as the samples were originally 
collected for the determination of the incidence of maternal drug use and the 
questionnaire  completed  by  the  mother  did  not  ask  specific  questions  about 
alcohol use. In any case, self-report is unreliable in these circumstances where 
the mother will not admit to drinking during her pregnancy for fear of punitive 
action. 
6.6 Conclusion 
An LC-MS/MS method has been developed and validated for the determination of 
FAEEs in meconium. This is the first LC-MS-MS method to use deuterated FAEEs 
as internal standards for the quantitation of FAEEs in meconium.  
The  mean  concentration  in  all  positive  cases  was  the  highest  for  ethyl 
arachidonate followed by ethyl linoleate and correlated well with another study.  
(152;154;155;218)    It  was  not  possible  to  correlate  the  FAEE  concentrations 
found and gestational alcohol exposure or to indicate the specificity of individual 
FAEE with minimal or no maternal alcohol abuse history.  195 
Chapter 7 - Conclusion and Future Work  
7.1 Conclusion 
This  project  initially  involved  the  development  and  validation of  quantitative 
methods for the analysis of common volatiles (methanol, ethanol, isopropanol, 
n-propanol and acetone) and alcohol biomarkers (beta-hydroxybutyrate, BHB and 
fatty acid ethyl esters, FAEEs) in biological matrices, utilising dual-column HS-
GC-FID, GC-MS and LC-MS/MS. This was achieved for each method in accordance 
with ISO/IEC 17025 and the methods were successfully applied to the analysis of 
real  case  samples.  The  stability  of  volatiles  and  BHB  in  blood  was  also 
investigated. 
The optimised HS-GC-FID method for volatiles was used to evaluate the use of 
two internal standards, namely n-propanol and t-butanol, for the quantitative 
analysis  of  volatiles  in  post-mortem  samples.  Both  methods  demonstrated 
excellent  linearity,  precision  and  accuracy.  n-Ppropanol  is  an  ideal  internal 
standard  for  use  with  the  dual-column  system  used  in  this  study  and  when 
applied to the analysis of ethanol in blood from living subjects, e.g. road traffic 
arrests.  
Other studies have warned against using n-propanol as an internal standard in 
putrefied samples due to the production of this volatile post-mortem. A high 
concentration  in  the  samples  would  result  in  an  increased  response  for  the 
internal  standard  and  would  correspond  to  an  underestimate  of  the  true 
concentration of volatiles in the sample. This is not supported with the findings 
in  this  study  because  the  majority  of  samples,  selected  due  to  extensive 
putrefication, had n-propanol concentrations close to the LOQ and therefore had 
a negligible effect. 
The use of ethanol to n-propanol ratio to determine whether ethanol formation 
has occurred is unlikely to be an effective indicator and other criteria must be 
considered, including the case history, condition of the specimens, distribution 
of ethanol in different matrices, and the concentration of ethanol. The internal Chapter 7    196 
standard  t-butanol  is  an  effective  alternative  internal  standard  for  the 
quantification of volatiles in post-mortem blood, including the ability to measure 
n-propanol. However, t-butanol co-elutes with acetone using DB-ALC1 or RTX-
ALC1 GC capillary columns.  
The  antioxidant  (0.2%  sodium  metabisulphite)  played  a  significant  role  in 
preventing oxidation between volatiles such as isopropanol to acetone, while the 
use of preservative alone such as (0.2 or 1% sodium fluoride) did not prevent 
oxidation  completely.  1%  sodium  fluoride  in  addition  to  0.2%  (0.2%  sodium 
metabisulphite) as an antioxidant improved the stability of the volatiles. These 
finding  supports  the  findings  of  another  study.(81)  The  stability  of  preserved 
blood samples, containing fluoride oxalate at 1-2%, was assessed after they were 
stored at  room temperature  for a  period of  between  1  to  5  years,  following 
initial tests for ethanol. Ethanol concentrations measured when compared with 
the initial test demonstrated recoveries of 50% or more in 85% of the samples 
tested. 
 
A further study evaluated ethanol stability over a period of six months, with 
significant  loss  and  formation  of  ethanol  observed  in  both  preserved  and 
unpreserved paired post-mortem blood samples. These cases were submitted to 
the toxicology laboratories of Forensic Medicine and Science for routine testing 
and were refrigerated after initial tests. Further losses in ethanol concentration 
were not significant following an additional storage period of 10 months in the 
freezer at -22°C. 
The  analysis  of  ethanol  in  bile  or  vitreous  humour  provides  the  forensic 
toxicologist with an alternative sample to blood in post-mortem cases where this 
is not available. In addition, lower ethanol concentrations in vitreous humour 
compared with blood may indicate post-mortem production of ethanol. Urine is 
not a suitable matrix to estimate ethanol or acetone concentrations in blood.  
A robust and sensitive method for the analysis of BHB in post-mortem blood and 
urine was validated. The analysis of different case samples in this study supports 
other  studies  that  have  suggested  BHB  is  a  suitable  biomarker  for  Alcoholic 
Ketoacidosis (AKA) or Diabetic Ketoacidosis (DKA). This study has highlighted the 
potential underreporting of the role of AKA in deaths associated with chronic Chapter 7    197 
alcohol abuse in the West of Scotland. Further, AKA does not always equate to 
low  or  negative  ethanol  levels.  High  levels  of  ethanol  were  reported  in  case 
samples  with  blood  BHB  levels  >250  mg/L,  which  is  in  agreement  to  other 
studies.  In  all  of  the  case  samples  with  high  blood  BHB,  the  acetone 
concentration was high and as such, acetone can be used as an initial biomarker 
for AKA but the concentrations measured are not well correlated to BHB.  
Acetone is volatile and is unstable in blood, and the production of other volatiles 
may  interfere  with  it  due  to  putrefaction,  therefore,  its  absence  does  not 
preclude  pathologically  significant  ketoacidosis  (BHB  >250  mg/L).  The 
recommendation following the findings in this study is that all cases associated 
with a history of chronic alcoholism, should be tested for BHB, even if acetone is 
low or absent. 
The method validation for BHB was successfully applied to post-mortem blood 
and urine, and plasma and urine from healthy subjects for the analysis of β-
hydroxy-β-methylbutyrate (HMB) and γ-hydroxybutyrate (GHB). 
The  first  LC-MS/MS  method  using  commercially  available  deuterated 
FAEEs(158;159) as internal standards for the quantitation of FAEEs in meconium 
was also developed and validated. A third of the meconium samples tested had 
FAEEs totalling more than 10,000 ng/g which is indicative of foetal exposure to 
chronic maternal alcohol use. The mean concentration in all positive cases was 
the highest for ethyl arachidonate followed by ethyl linoleate and this correlates 
well. 
7.2  Future work  
A larger study would be required to investigate the prevalence of n-propanol 
concentrations  in  putrefied  post-mortem blood  samples  from  a range of case 
types  to  fully  assess  the  risks  associated  with  the  use  of  this  volatile  as  an 
internal standard for quantifying volatiles.   
The evaluation of different GC capillary columns for better resolution between 
t-butanol and acetone would be of value, and in addition, to investigate the use Chapter 7    198 
of t-butanol as an internal standard with samples of high fat content as this has 
been highlighted in other studies as a potential interferent.   
Further stability investigations would be of interest to evaluate the effect of 
anti-coagulant  in  terms  of  antioxidation  and  to  investigate  the  optimum 
antioxidant  concentration  required  to  prevent  loss  or  formation  of  volatiles. 
Utilizing human whole blood would also help to evaluate the oxidative effect of 
enzymes,  and  extending  the  volatiles  investigated  to  include,  acetaldehyde, 
propionaldehyde  (propanal).  Investigation  of  the  stability  of  volatiles  using 
sodium metabisulfite without adding NaF to evaluate its role as a preservative 
should also be carried out. 
The study investigating the analysis of volatiles in vitreous humour and bile was 
limited due to the number of samples available for analysis and reanalysis. An 
extension  of  the  study  would  provide  greater  insight  into  the  relationship 
between femoral blood, vitreous humour and bile and the stability of acetone 
and ethanol in these alternative matrices.  
The evaluation of  the stability of BHB and GHB in blood in paired preserved and 
unpreserved sample when stored in different temperature and concentration of 
preservative would provide an insight into the presence of these substances at 
the time of death versus the time of collection. 
 A further investigation into the use of deuterated internal standards for each of 
the  FAEEs  tested  would  be  of  interest  and  then  applying  this  method  to 
investigate FAEE levels in maternal and newborn hair samples using HS-SPME-
GC/MS, as recommended by the Society of Hair Testing. A comparison could then 
be carried out between meconium and hair to identify which sample is better as 
an  indicator  of  foetal  alcohol  exposure.  The  long-term  stability  of  FAEEs  in 
meconium or BHB in postmortem blood has as yet not been fully investigated.  
Lastly, the role of BHB as a biomarker should be extended to analyze a wide 
range of case types where individuals have a history of acute and chronic alcohol 
misuse. 199 
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Appendix 3-1 Stability Study of volatiles using t-butanol as an Internal Standard 
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(I)                                                                                      (J) 
Stability graphs RT 25±2 °Cfor each analyte (20 and 80 mg/dL for all except acetone mg/L) (A) and (B) 
Ethanol, (C) AND (D) Acetone, (E) and (F) Isopropanol ,(G) and (H) Methanol and ,(I) and (J) n-propanol. 226 
 
Appendix 3-1 continued 
Stability results at RT 25±2, °Cof spiked blood.  The bolded figures showed deviation from the acceptable range. 
 
RT 
25±2°C    DAY  20  80 
         ETHANOL  ACETONE  ISOPROPANOL  METHANOL  N_PROPANOL  ETHANOL  ACETONE  ISOPROPANOL  METHANOL  N_PROPANOL 
No 
presertvative  G1  1  21  32  20  20  20  80  91  79  77  78 
0.2% Naf  G2  1  20  39  19  20  19  79  99  78  77  76 
0.2%Naf +0.2% 
antioxident  G3  1  20  31  20  20  21  78  99  78  76  75 
1% Naf   G4  1  20  28  20  20  20  78  99  78  76  75 
1% Naf + 0.2% 
anti oxidant  G5  1  19  31  19  19  20  76  89  77  76  78 
      MEAN  20  32  20  20  20  78  95  78  77  76 
      SD  0.75  4.10  0.43  0.46  0.41  1.50  4.74  0.86  0.66  1.47 
      2SD  1.50  8.21  0.86  0.91  1.23  2.99  9.47  1.73  1.32  2.94 
      u  0.6  1.0  0.4  0.8  0.6  2.3  2.9  1.6  3.1  2.3 
      Ue  1.2  1.9  0.8  1.6  1.2  4.7  5.7  3.1  6.1  4.6 
      Mean-Ue  19  30  19  18  19  74  89  75  70  72 
      Mean+Ue  21  34  20  21  21  83  101  81  83  81 
                       
No 
presertvative  G1  4  40  102  13  21  9  70  354  53  78  23 
0.2% Naf  G2  4  18  63  16  19  16  76  107  77  76  78 
0.2%Naf +0.2% 
antioxident  G3  4  20  49  18  19  21  77  87  80  77  75 
1% Naf   G4  4  18  78  14  19  16  74  141  72  75  68 
1% Naf + 0.2% 
anti oxidant  G5  4  19  35  18  19  20  76  89  77  74  77 
No 
presertvative  G1  7  50  94  13  20  15  104  190  66  75  64 
0.2% Naf  G2  7  18  77  15  19  15  76  155  71  77  69 
0.2%Naf +0.2% 
antioxident  G3  7  19  50  17  19  20  77  107  76  77  78 
1% Naf   G4  7  13  76  13  17  11  71  170  66  75  62 
1% Naf + 0.2% 
anti oxidant  G5  7  20  35  19  20  20  75  89  76  73  76 
No 
presertvative  G1  10  47  76  14  19  15  109  163  71  76  68 
0.2% Naf  G2  10  17  45  18  19  15  74  118  75  74  69 
0.2%Naf +0.2% 
antioxident  G3  10  19  53  17  19  20  75  105  58  73  77 
1% Naf   G4  10  11  109  12  20  9  74  134  74  75  72 
1% Naf + 0.2% 
anti oxidant  G5  10  20  38  19  19  20  75  92  77  73  77 
No 
presertvative  G1  15  43  70  14  19  13  2  93  70  70  2 
0.2% Naf  G2  15  14  64  15  18  12  71  127  69  71  65 
0.2%Naf +0.2% 
antioxident  G3  15  18  51  17  18  19  73  106  74  73  75 
1% Naf   G4  15  15  81  14  18  14  66  167  67  72  62 
1% Naf + 0.2% 
anti oxidant  G5  15  18  36  18  18  19  72  93  74  72  73 
No 
presertvative  G1  23  17  104  13  21  4  100  295  55  73  54 
0.2% Naf  G2  23  12  107  11  19  3  76  247  59  72  61 
0.2%Naf +0.2% 
antioxident  G3  23  16  56  15  17  15  74  108  74  74  76 
1% Naf   G4  23  16  96  12  19  14  71  202  63  72  66 
1% Naf + 0.2% 
anti oxidant  G5  23  19  37  18  19  20  69  77  71  70  71 
No 
presertvative  G1  30  29  103  11  18  6  95  281  57  75  47 
0.2% Naf  G2  30  21  95  12  22  11  78  246  62  77  60 
0.2%Naf +0.2% 
antioxident  G3  30  19  52  17  19  20  74  112  75  75  74 
1% Naf   G4  30  14  94  12  19  12  73  210  64  75  67 
1% Naf + 0.2% 
anti oxidant  G5  30  19  36  18  19  20  76  92  79  76  79 
No 
presertvative  G1  40  32  114  12  20  6  86  351  47  72  39 
0.2% Naf  G2  40  23  122  10  19  9  84  336  54  77  57 
0.2%Naf +0.2% 
antioxident  G3  40  18  52  17  19  19  73  105  74  74  75 
1% Naf   G4  40  14  114  11  19  11  69  274  57  74  62 
1% Naf + 0.2% 
anti oxidant  G5  40  19  37  18  19  20  73  89  75  73  76 
No 
presertvative  G1  50  28  185  5  20  5  87  305  51  71  41 
0.2% Naf  G2  50  23  110  10  18  7  80  343  50  78  51 
0.2%Naf +0.2% 
antioxident  G3  50  17  50  16  17  18  70  106  72  70  72 
1% Naf   G4  50  13  120  9  18  10  63  288  52  69  58 
1% Naf + 0.2% 
anti oxidant  G5  50  18  36  18  18  19  70  86  72  70  73 227 
 
          Appendix 3-1 continued - (4± 2°C) 
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    (I)                        (J) 
Stability graphs at 4±2°C for each analyte (20 and 80 mg/dL for all except acetone mg/L) (A) and (B) 
Ethanol, (C) AND (D) Acetone, (E) and (F) Isopropanol ,(G) and (H) Methanol and ,(I) and (J) n-propanol. 228 
 
Appendix 3-1 continued 
Stability results at 4±2°C, of spiked blood.  The bolded figures showed deviation from the acceptable range. 
 
 
 
 
4± 2°C    DAY  20  80 
         ETHANOL  ACETONE  ISOPROPANOL  METHANOL  N_PROPANOL  ETHANOL  ACETONE  ISOPROPANOL  METHANOL  N_PROPANOL 
No presertvative  G1  1  21  32  20  20  20  80  91  79  77  78 
0.2% Naf  G2  1  20  39  19  20  19  79  99  78  77  76 
0.2%Naf +0.2% 
antioxident  G3  1  20  31  20  20  21  78  99  78  76  75 
1% Naf   G4  1  20  28  20  20  20  78  99  78  76  75 
1% Naf + 0.2% 
anti oxidant  G5  1  19  31  19  19  20  76  89  77  76  78 
      MEAN  20  32  20  20  20  78  95  78  77  76 
      SD  0.75  4.10  0.43  0.46  0.41  1.50  4.74  0.86  0.66  1.47 
      2SD  1.50  8.21  0.86  0.91  1.23  2.99  9.47  1.73  1.32  2.94 
      u  0.6  1.0  0.4  0.8  0.6  2.3  2.9  1.6  3.1  2.3 
      Ue  1.2  1.9  0.8  1.6  1.2  4.7  5.7  3.1  6.1  4.6 
      Mean-Ue  19  30  19  18  19  74  89  75  70  72 
      Mean+Ue  21  34  20  21  21  83  101  81  83  81 
                       
No presertvative  G1  4  19  48  17  19  17  83  98  83  81  80 
0.2% Naf  G2  4  19  63  16  19  17  78  93  78  76  76 
0.2%Naf +0.2% 
antioxident  G3  4  20  37  19  19  21  73  88  73  71  74 
1% Naf   G4  4  18  67  16  19  18  73  89  74  71  73 
1% Naf + 0.2% 
anti oxidant  G5  4  20  32  19  19  20  76  90  77  75  78 
No presertvative  G1  7  18  77  15  20  15  69  182  68  75  61 
0.2% Naf  G2  7  18  85  14  19  15  74  161  71  78  66 
0.2%Naf +0.2% 
antioxident  G3  7  19  46  18  19  20  76  105  75  75  77 
1% Naf   G4  7  18  88  13  20  16  69  150  68  74  65 
1% Naf + 0.2% 
anti oxidant  G5  7  19  38  18  19  20  77  92  77  76  78 
No presertvative  G1  10  17  80  14  19  14  75  140  73  76  69 
0.2% Naf  G2  10  17  104  13  19  13  70  180  70  76  63 
0.2%Naf +0.2% 
antioxident  G3  10  20  51  17  19  20  77  109  75  75  77 
1% Naf   G4  10  18  126  10  19  15  74  200  67  74  69 
1% Naf + 0.2% 
anti oxidant  G5  10  18  23  19  18  19  77  98  77  75  78 
No presertvative  G1  15  17  65  15  18  15  68  155  67  73  59 
0.2% Naf  G2  15  18  86  13  19  15  74  124  72  74  69 
0.2%Naf +0.2% 
antioxident  G3  15  17  53  15  17  18  74  111  73  74  75 
1% Naf   G4  15  17  104  11  18  14  71  170  65  71  67 
1% Naf + 0.2% 
anti oxidant  G5  15  18  42  17  18  19  72  96  72  72  74 
No presertvative  G1  23  18  79  14  18  14  70  175  65  73  59 
0.2% Naf  G2  23  17  140  8  19  13  72  196  65  74  64 
0.2%Naf +0.2% 
antioxident  G3  23  19  60  16  18  20  75  120  73  74  76 
1% Naf   G4  23  18  75  14  19  16  73  171  66  72  69 
1% Naf + 0.2% 
anti oxidant  G5  23  19  46  17  18  20  72  102  72  71  74 
No presertvative  G1  30  27  76  14  19  14  89  193  65  76  61 
0.2% Naf  G2  30  18  99  12  20  15  64  364  51  77  44 
0.2%Naf +0.2% 
antioxident  G3  30  19  63  16  19  20  77  122  74  76  78 
1% Naf   G4  30  17  116  11  19  14  67  321  54  75  56 
1% Naf + 0.2% 
anti oxidant  G5  30  19  44  17  19  20  74  102  73  73  75 
No presertvative  G1  40  39  89  13  19  13  89  258  58  74  60 
0.2% Naf  G2  40  18  121  10  19  14  75  244  62  76  67 
0.2%Naf +0.2% 
antioxident  G3  40  19  63  15  18  19  74  123  72  73  76 
1% Naf   G4  40  17  75  13  18  15  72  192  64  72  67 
1% Naf + 0.2% 
anti oxidant  G5  40  19  46  17  18  19  76  104  75  74  77 
No presertvative  G1  50  40  92  13  18  12  89  253  57  71  59 
0.2% Naf  G2  50  14  190  4  19  8  69  234  60  72  61 
0.2%Naf +0.2% 
antioxident  G3  50  18  62  15  18  19  73  122  70  72  74 
1% Naf   G4  50  16  136  8  18  12  70  198  63  71  67 
1% Naf + 0.2% 
anti oxidant  G5  50  18  46  17  18  19  72  102  71  70  74 229 
 
Appendix 3-1 continued - (-20 ± 2°C)  
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(I)                           (J) 
Stability graphs at -22±2°C for each analyte (20 and 80 mg/dL for all except acetone mg/L) (A) and (B) Ethanol, (C) 
AND (D) Acetone, (E) and (F) Isopropanol ,(G) and (H) Methanol and ,(I) and (J) n-propanol. 230 
 
Appendix 3-1 continued 
Study 2 stability results at -22±2°C, of spiked blood.  The bolded figures showed deviation from the 
acceptable range. 
-22±2°C     DAY  20  80 
         ETHANOL  ACETONE  ISOPROPANOL  METHANOL  N_PROPANOL  ETHANOL  ACETONE  ISOPROPANOL  METHANOL  N_PROPANOL 
No presertvative  G1  1  21  32  20  20  20  80  91  79  77  78 
0.2% Naf  G2  1  20  39  19  20  19  79  99  78  77  76 
0.2%Naf +0.2% 
antioxident  G3  1  20  31  20  20  21  78  99  78  76  75 
1% Naf   G4  1  20  28  20  20  20  78  99  78  76  75 
1% Naf + 0.2% 
anti oxidant  G5  1  19  31  19  19  20  76  89  77  76  78 
      MEAN  20  32  20  20  20  78  95  78  77  76 
      SD  0.75  4.10  0.43  0.46  0.41  1.50  4.74  0.86  0.66  1.47 
      2SD  1.50  8.21  0.86  0.91  1.23  2.99  9.47  1.73  1.32  2.94 
      u  0.6  1.0  0.4  0.8  0.6  2.3  2.9  1.6  3.1  2.3 
      Ue  1.2  1.9  0.8  1.6  1.2  4.7  5.7  3.1  6.1  4.6 
      Mean-Ue  19  30  19  18  19  74  89  75  70  72 
      Mean+Ue  21  34  20  21  21  83  101  81  83  81 
                       
No presertvative  G1  4  21  32  19  20  20  80  85  79  78  78 
0.2% Naf  G2  4  16  55  18  20  14  81  88  81  78  80 
0.2%Naf +0.2% 
antioxident  G3  4  20  26  20  20  21  80  80  81  79  81 
1% Naf   G4  4  17  56  17  19  15  80  87  81  78  81 
1% Naf + 0.2% 
anti oxidant  G5  4  20  24  20  19  21  76  80  78  75  77 
No presertvative  G1  7  20  37  19  20  19  74  96  75  73  71 
0.2% Naf  G2  7  21  32  20  20  21  77  89  78  75  77 
0.2%Naf +0.2% 
antioxident  G3  7  21  25  21  20  21  77  79  78  76  78 
1% Naf   G4  7  20  28  20  19  21  77  82  79  76  78 
1% Naf + 0.2% 
anti oxidant  G5  7  20  23  21  20  21  77  77  78  76  78 
No presertvative  G1  10  20  51  18  20  18  72  100  73  72  69 
0.2% Naf  G2  10  20  33  19  38  20  77  89  78  75  76 
0.2%Naf +0.2% 
antioxident  G3  10  20  27  20  20  21  78  82  80  76  79 
1% Naf   G4  10  20  26  20  19  20  78  83  79  77  78 
1% Naf + 0.2% 
anti oxidant  G5  10  19  24  20  19  20  74  78  77  73  76 
No presertvative  G1  15  19  31  18  19  19  73  76  73  72  72 
0.2% Naf  G2  15  19  27  19  19  19  74  80  74  73  73 
0.2%Naf +0.2% 
antioxident  G3  15  19  24  19  19  19  74  75  75  73  74 
1% Naf   G4  15  19  24  19  18  19  72  78  74  71  73 
1% Naf + 0.2% 
anti oxidant  G5  15  19  22  19  18  20  70  76  72  69  71 
No presertvative  G1  23  19  31  19  18  19  74  82  75  74  73 
0.2% Naf  G2  23  19  27  19  18  19  75  80  75  73  74 
0.2%Naf +0.2% 
antioxident  G3  23  19  24  19  18  20  72  80  74  71  73 
1% Naf   G4  23  19  25  19  18  19  73  79  74  72  74 
1% Naf + 0.2% 
anti oxidant  G5  23  19  23  19  18  20  70  78  72  69  72 
No presertvative  G1  30  22  28  21  21  22  82  84  83  80  82 
0.2% Naf  G2  30  20  25  20  19  20  79  84  80  77  79 
0.2%Naf +0.2% 
antioxident  G3  30  19  23  20  19  20  74  81  76  72  75 
1% Naf   G4  30  20  24  20  19  20  79  83  80  76  80 
1% Naf + 0.2% 
anti oxidant  G5  30  20  23  20  19  21  71  81  74  68  74 
No presertvative  G1  40  20  24  20  19  20  72  71  72  70  72 
0.2% Naf  G2  40  19  24  19  19  19  72  81  73  71  72 
0.2%Naf +0.2% 
antioxident  G3  40  19  23  20  19  20  73  77  74  72  74 
1% Naf   G4  40  19  23  19  18  19  72  81  74  70  73 
1% Naf + 0.2% 
anti oxidant  G5  40  19  22  19  19  20  72  75  73  71  73 
No presertvative  G1  50  19  22  19  18  19  77  83  78  75  77 
0.2% Naf  G2  50  19  24  19  18  20  72  82  73  71  73 
0.2%Naf +0.2% 
antioxident  G3  50  19  22  20  19  20  74  79  75  72  75 
1% Naf   G4  50  18  23  19  18  19  73  81  75  71  74 
1% Naf + 0.2% 
anti oxidant  G5  50  19  22  19  15  19  70  77  73  68  72 231 
 
Appendix 3-2 Stability Study of volatile using n-propanol Internal standard – (4± 2°C) 
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(G)            (H)  
Stability graphs at 4±2°C for each analyte (20 and 80 mg/dL for all except 
acetone mg/L) (A) and (B) Ethanol, (C) AND (D) Acetone, (E) and (F) Isopropanol 
and (G) and (H) Methanol. 232 
 
Appendix 3-2 Stability results at 4±2 °Cof spiked blood.  The bolded figures showed deviation from 
the acceptable range.
4±2°C  Group  Day  20 
80 
      ETHANOL  ACETONE  ISOPROPANOL  METHANOL  ETHANOL  ACETONE  ISOPROPANOL  METHANOL 
No presertvative  G1  1  21  32  18  20  75  86  74  76 
1% Naf  G2  1  21  25  18  19  75  84  75  75 
2%Naf  G3  1  21  24  18  19  78  83  77  77 
1% Naf + 0.2% 
anti oxidant  G4  1  21  22  18  19  77  78  76  76 
2% Naf + 0.2% 
anti oxidant  G5  1  21  22  18  19  76  77  75  75 
    MEAN  21  25  18  19  76  82  75  76 
    SD  0.14  4.02  0.32  0.45  1.23  3.93  1.30  0.65 
    2SD  0.43  12.06  0.97  1.36  3.68  11.80  3.90  1.95 
    u  1  1  1  1  2  3  2  3 
    Ue  2  2  1  2  5  7  5  6 
    Mean-Ue  19  22  17  18  71  75  71  70 
    Mean+Ue  22  27  20  21  80  88  80  82 
 
No presertvative  G1  4  24  48  16  20  78  117  76  79 
1% Naf  G2  4  21  23  18  19  77  89  77  78 
2%Naf  G3  4  21  30  18  19  78  88  78  77 
1% Naf + 0.2% 
anti oxidant  G4  4  21  26  18  19  77  82  78  77 
2% Naf + 0.2% 
anti oxidant  G5  4  21  26  18  19  78  83  78  77 
No presertvative  G1  7  28  56  16  20  87  148  74  82 
1% Naf  G2  7  20  38  17  19  76  95  77  76 
2%Naf  G3  7  20  34  17  19  77  89  77  77 
1% Naf + 0.2% 
anti oxidant  G4  7  21  29  18  20  79  85  77  79 
2% Naf + 0.2% 
anti oxidant  G5  7  20  30  17  19  78  86  78  78 
No presertvative  G1  10  35  102  12  20  87  196  65  76 
1% Naf  G2  10  20  41  17  19  76  100  77  76 
2%Naf  G3  10  20  37  17  19  76  93  77  75 
1% Naf + 0.2% 
anti oxidant  G4  10  21  32  18  19  77  88  77  76 
2% Naf + 0.2% 
anti oxidant  G5  10  20  32  17  18  77  87  77  75 
No presertvative  G1  15  43  76  14  20  106  164  73  82 
1% Naf  G2  15  20  47  16  20  79  111  77  82 
2%Naf  G3  15  20  42  17  20  79  93  77  80 
1% Naf + 0.2% 
anti oxidant  G4  15  21  35  17  20  80  91  77  81 
2% Naf + 0.2% 
anti oxidant  G5  15  21  36  17  20  80  89  78  81 
No presertvative  G1  23  59  95  12  21  116  268  63  83 
1% Naf  G2  23  19  63  16  19  77  139  75  81 
2%Naf  G3  23  20  45  17  19  79  97  79  81 
1% Naf + 0.2% 
anti oxidant  G4  23  20  38  17  19  79  93  79  80 
2% Naf + 0.2% 
anti oxidant  G5  23  20  40  17  19  78  91  77  78 
No presertvative  G1  30  57  112  11  20  118  232  67  83 
1% Naf  G2  30  20  70  15  20  77  132  76  81 
2%Naf  G3  30  20  48  15  20  78  100  77  80 
1% Naf + 0.2% 
anti oxidant  G4  30  21  38  17  20  80  92  77  81 
2% Naf + 0.2% 
anti oxidant  G5  30  21  40  17  19  80  91  78  81 
No presertvative  G1  40  58  148  7  21  103  299  55  75 
1% Naf  G2  40  19  74  13  20  76  154  72  80 
2%Naf  G3  40  18  55  14  20  77  109  75  80 
1% Naf + 0.2% 
anti oxidant  G4  40  20  37  17  20  77  90  75  78 
2% Naf + 0.2% 
anti oxidant  G5  40  20  40  17  19  78  93  78  77 
No presertvative  G1  50  58  130  8  21  108  277  58  80 
1% Naf  G2  50  19  78  13  19  73  153  71  77 
2%Naf  G3  50  18  62  14  19  71  112  73  73 
1% Naf + 0.2% 
anti oxidant  G4  50  20  36  16  19  75  93  73  74 
2% Naf + 0.2% 
anti oxidant  G5  50  20  37  16  19  73  89  75  72 233 
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BHB Quality control charts at 50 mg/L (A and B), 300 mg/L (C and D) in blood and urine, respectively 
 
 
 
Quality Control ranges 
Blood  Urine 
50 
mg/L 
300  
mg/L 
50 
mg/L 
300  
mg/L 
Average  49  301  48  294 
Standard 
Deviation (SD) 
2.72  17.95  6.40  20.34 
CV%  5.6  6.0  13.2  6.9 
 Mean ± 2SD   43-54  265-336  36-61  253-335 234 
 
Appendix 4-2 BHB, Acetone and Ethanol Concentrations in Post-mortem                         
blood and urine 
(Shaded boxes information is not available) 
 
Case 
# 
 
Gender  Age 
BHB          
mg//L 
Acetone    
mg//L  Ethanol   mg/dL 
cause of death 
Blood  Urine  Blood  Urine  Blood  Urine 
1  M  55  135    146    79    1a- unascertained 
2  F  67  14  NEG  NEG  NEG  330  440 
1a- head injury(haemorrhage from scalp 
laceration) presumed fall                 2a- 
Acute  alcohol intoxication pulmonary 
thromboembolism 
3  F  41  NEG    NEG    NEG    1a- Stab wound of heart 
4  M  66  NEG  27  NEG  NEG  NEG  NEG  1a- Coronary artery atheroma; 1b- 
Ischaemic heart disease 
5  F  44  >500  >500  167  224  NEG  16  1a- Fatty degeneration of the liver                         
1b- Chronic alcoholic 
6  F  78  142  <10  NEG  NEG  232  225 
1a- Inhalation of smoke and fire gases in 
a house fire and hypertensive and 
valvular heart disease 
7  F  29  30    NEG    193    1a- Codeine and alcohol intoxication 
8  M  33  22  NEG  NEG  NEG  NEG  98  1a- Heroin and ketamine intoxication 
9  F  58  89  86  NEG  NEG  NEG  NEG  1a- Suspected alcohol related death 
10  M  54  13  NEG  NEG  NEG  325  393  1a- Chest injury; 1b Road traffic collision 
(driver) 
11  M  29  NEG  NEG  NEG  NEG  NEG  NEG  1a- Hanging 
12  M  29  NEG  NEG  NEG  NEG  NEG  NEG  1a- Heroin, methadone, diazepam 
intoxication 
13  M  39  23  NEG  NEG  NEG  NEG  NEG  1a- Bronchopneumonia and intoxication 
by heroin and methadone 
14  M  31  NEG    NEG    11   
1a- Hypoxia brain damage 
1b- Cardiac arrest; 1c- Cardiac 
enlargement 
15  F  33  19    NEG    60   
1a- Hypoxia -Ischaemic brain injury                                  
b- Cardiac arrest ; 1c- Heroin and alcohol 
intoxication- Cardiac enlargement 
16  M  73  195    50  56  NEG  NEG  1a- Ischaemic heart disease 
1b- Coronary artery atheroma 
17  F  18  >500  >500  >400  >400  NEG  NEG  1a- Diabetic ketoacidosis; 1b. Insulin 
dependent diabetic mellitus 
18  M  33  86  79  NEG  NEG  83  114  1a- Heroin intoxication 
19  M  19  10  NEG  NEG  NEG  NEG  NEG  1a- Head and chest injury                             
1b- Road traffic collision (driver) 
20  F  28  10  NEG  NEG  NEG  NEG  33  1a- Bronchopneumonia; 1b- Morphine 
intoxication 
21  M  44  NEG    NEG    NEG    1a- Cardiac enlargement 
22  F  30  21  97  NEG  NEG  16  NEG  1a- Incised wound of arm 
23  F  36  85  >500  NEG  332  NEG  NEG  1a- Viral pneumonia with secondary 
bacterial infection 
24  F  34  20  NEG  NEG  NEG  174  266  1a- Heroin and alcohol intoxication 
25  F  38  29  NEG  NEG  NEG  NEG  13  1a- Head injury 
26  M  81  73  47  NEG  NEG  15  18  1a- Acute pylonephritis; 2a- Coronary 
artery atheroma 
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Appendix  4-2  continued 
27  F  47  NEG  NEG  NEG  NEG  19  NEG  1a-Ischaemic heart disease and 
bronchopneumonia 
28  F  38  57  NEG  NEG  NEG  NEG  NEG  1a- Acute exacerlation of chronic 
obstructive airways disease 
29  M  71  NEG  NEG  NEG  NEG  205  164  1a- Multiple injuries; 1b- Road Traffic 
accident (pedestrian) 
30  F  66  237  452  15  26  NEG  NEG  1a- Acute hepatic necrosis; 1b- 
paracetamol Toxicity 
31  M  62  19  NEG  NEG  NEG  NEG  NEG  1a- Hanging 
32  M  62  28    NEG  NEG  14  NEG  1a- Probable sepsis, source uncertain 
33  F  44  15  NEG  NEG  NEG  NEG  NEG  1a- Ischaemic heart disease  1b- 
Coronary artery atheroma 
34  F  53  42  NEG  NEG  NEG  NEG  NEG  1a- Multiple injuries; 1b- Fall from height 
35  F  55  26    NEG    NEG    1a- Upper gastrointestinal haemorrhage; 
1b- Duodenal ulcer 
36  M  34  16  NEG  NEG  NEG  21  31  1a- Gamma- hydroxybutyrate (GHB) 
intoxication 
37  F  43  22  NEG  NEG  NEG  140  208  1a- unascertained 
38  M  67  14    NEG  NEG  NEG  NEG  1a- Ischaemic heart disease; 1b- 
Coronary artery atheroma 
39  F  48  69    NEG  NEG  NEG  10  1a- Head injury 
40  M  52  42  93  NEG  NEG  227  373  1a- Bronchopneumonia; 1b- Chronic 
alcohol abuse 
41  M  40  99  NEG  NEG  NEG  329  442  1a- Acute alcohol intoxication 
42  M  57  10  NEG  NEG  NEG  NEG  NEG  1a- Hanging 
43  F  44  NEG    NEG    58   
1a- Hypoxic brain damage; 1b. 
Cardiorespiratory arrest; 1c. Acute 
severe asthma 
44  M  23  NEG  NEG  NEG  NEG  NEG  NEG  1a- tramadol and methadone intoxication 
45  M  48  111    31  67  19  31  1a- Alcoholic ketoacidosis; 1b- Chronic 
alcohol abuse 
46  M  42  23  NEG  NEG  NEG  10  16  1a- Myocardial fibrosis  and ischaemia - 
cause unascertained 
47  F  37  NEG  NEG  NEG  NEG  NEG  15  1a- Heroin and methadone intoxication 
48  F  33  14  NEG  NEG  NEG  NEG  NEG  1a- Heroin intoxication 
49  M  59  18  NEG  NEG  NEG  56  79  1a- Hanging 
50  M  24  25  NEG  NEG  NEG  155  204  1a- Hanging 
51  M  40  NEG  NEG  NEG  NEG  NEG  NEG 
1a-Bronchopneumonia; 1b- Chronic 
obstructive airways disease                    
2a- Methadone intoxication 
52  M  64  76    NEG    NEG    1a- Cardiac enlargement 
53  M  61  135  74  NEG  NEG  15  12  1a-Bronchopneumonia; 1b- Chronic 
obstructive pulmonary disease 
54  M  63  38  NEG  NEG  NEG  NEG  NEG  1a- Head Injury; 1b. Presumed fall 
55  F  44  57  NEG  NEG  NEG  10  NEG  1a- Bronchopneumonia 
56  M  42  19  NEG  NEG  NEG  83  117  1a- Heroin intoxication 236 
 
 
Appendix  4-2  continued 
57  F  34  NEG    NEG    NEG    1a- Multiorgan failure; 1b. Hypothermia 
and drug intoxication 
58  F  45  NEG  NEG  NEG  NEG  NEG  NEG  1a- Clozapine intoxication 
2a- Resolving Bronchopneumonia 
59  M  57  NEG  NEG  NEG  NEG  NEG  NEG  1a- Ischaemic heart disease; 1b- 
Coronary artery atheroma 
60  M  41  54  NEG  NEG  NEG  59  103  1a- Drowning 
61  M  62  NEG    NEG    65    1a- Ischaemic heart disease and  
Bronchopneumonia 
62  F  41  NEG  NEG  NEG  NEG  NEG  19 
1a- Methadone and dehydrocodone 
intoxication; 1b- Coronary artery 
atheroma 
63  M  63  17  NEG  NEG  NEG  235  260  1a- Hanging 
64  M  61  NEG  NEG  NEG  NEG  73  10  1a- Hanging 
65  F  42  NEG  NEG  NEG  NEG  34  NEG  1a- Multiple injuries; 1b- Fall from height 
66  F  26  NEG  NEG  NEG  NEG  33  98  1a- Heroin intoxication 
67  M  25  25  NEG  NEG  NEG  146  272  1a- Heroin, methadone and alcohol 
intoxication 
68  M  49  NEG    NEG    NEG    1a. Hed and chest injuries; 1b. Road 
traffic accident 
69  M  44  NEG  NEG  NEG  NEG  NEG  NEG  1a- Heroin intoxication 
70  M  33  NEG    NEG    NEG    1a- Hanging 
71  M  32  27  45  NEG  NEG  NEG  NEG  1a- Fatty degeneration of the liver; 1b. 
Chronic alcohol abuse 
72  M  44  16  NEG  NEG  NEG  241  287  1a- Fatty degeneration of the liver                           
1b- Chronic alcoholic abuse 
73  M  71  208  308  67  84  NEG  NEG  1a- Acute puelonephritis; 1b- Possible 
hypothermia 
74  M  35  145  335  83  183  NEG  NEG 
1a- Fatty degeneration and cirrhosis of 
the liver             1b- Chronic alcoholic 
abuse 
75        53  NEG  NEG  59(liver 
blood)  NEG  External case 
76      18    NEG    NEG    External case 
77      19  NEG  NEG  NEG  204  266  External case 
78      32    NEG    NEG    External case 
79  M  33  NEG  NEG  NEG  NEG  NEG  27  1a- Cocaine Related Cardiac Arrythmia 
80  M  24  11  NEG  NEG  NEG  243  287  1a- head and chest injury 
1b- Fall from height 
81  F  40  249  498  121  145  NEG  66  1a- Fatty degeneration of the liver                                    
1b- Chronic alcoholic abuse 
82  M  51  NEG  NEG  NEG  NEG  NEG  NEG  1a- Ischaemic heart disease; 1b- 
Coronary artery atheroma 
83  M  49  13  NEG  NEG  NEG  NEG  25 
1a- Ischaemic heart disease; 1b- 
Coronary artery atheroma 2a- 
Hypoglycaemia due to insulin 
dependents diabetes mellitus 
84  M  36  13  NEG  NEG  NEG  NEG  NEG  1a- Coronary artery atheroma 
85  M  42  12  NEG  NEG  NEG  131  143  1a- Hanging 
86  F  35  33    NEG    NEG    1a- unascertained 
87  M  42  NEG  NEG  NEG  NEG  11  NEG  1a- Heroin and Alcohol Intoxication 
88  M  48  29  NEG  NEG  NEG  190  267  1a- Heroin and alcohol intoxication 
89  M  34  >500  >500  297  >400  NEG  NEG  1a- Drowning; 1b. Diabetic ketoacidosis; 
Insulin dependent diabetic mellitus 
90  M  45  16  NEG  NEG  NEG  124  169  1a- Sharp force injury of neck 237 
 
 
Appendix  4-2  continued 
91  M  37  NEG  NEG  NEG  NEG  196  198  1a- Stab wound of chest 
92  F  29  17    NEG    168    1a- Hanging 
93  F  24  46  348  NEG  226  NEG  NEG  1a- Hanging 
94  M  41  16    NEG    NEG    1a- Hanging 
95  M  46  18  NEG  NEG  NEG  12  75  1a- Sudden unexpected death in 
epilepsy; 1b- Old head injury 
96  F  70  16    NEG    17    1a- Drowning 
97  M  65  16  NEG  NEG  NEG  247  315  1a- Chest injury; 1b- Road Traffic 
accident (driver) 
98  M  67  383  358  72  85  338  392  1a. Alcohol related death 
99  M  38    158  45  58  NEG  18  1a. Undetermined 
100  M  80  215  497  82  111  23  14  1a. Hypothermia 
101  M  25  24  NEG  NEG  NEG  38  84  1a. Unascertained 
102  M  36  11    NEG    NEG    1a. Unascertained 
103      10            External case 
104  M  61  263  >500  42  147  193  286 
1a. Ischaemic heart disease and gastro 
intestinal haemorrhage from erosive 
oesophagitis.  2a. Fatty degeneration of 
the liver 
105  F  56  396    177    34    1a. Fatty degeneration of the liver due to; 
1b. chronic alcohol abuse. 
106      31            External case 
107  M  25  14  23  NEG    NEG    1a. Methadone, heroin and cocaine 
Toxicity. 
108      0            External case 
109  M  39  19    NEG  NEG  NEG  NEG  1a. Methadone and alcohol Intoxication 
110  F  57  >500  >500  399  620  NEG  NEG 
1a-Alcoholic Stetosis  and Ischaemic 
heart disease; 1a Fatty degeneration of 
the liver; 1b- Chronic Alcoholic 
111      >500  >500  419  448  85  NEG  External case (Expected Ketoacidosis) 
112  M  42  >500    469    30  NEG 
1a-Ischaemic heart disease  1b- 
Coronary artery atheroma 2a- Insulin 
dependent diabetes mellitus 
113  F  36  165    40    NEG    Fatty  degeneration of the Liver Chronic 
Alcohol Abuse 
114      420            Suspected  Alcoholic ketoacidosis -BHB 
requested (External Case) 
115  M  36  24    14    314    1a. Fatty  degeneration of the Liver; 1b. 
Chronic Alcohol Abuse 
116  M  43  11  14  NEG  NEG  376  476 
1a. Acute alcohol intoxication; 1b. Fatty 
degeneration of the liver due to chronic 
alcohol abuse 
117  F  60  44    NEG    55   
1a. Hepatic Failure,; 1b. Fatty  
degeneration of the Liver; 1c. Chronic 
Alcohol Abuse; 2a. Fracture of the 
humerus from fall 
118      44            Suspected GHB intoxication 
(External Case) 
119  M  64  51    NEG    112    1a- unascertained Chronic Alcohol 
Abuse 
120      372    57  71  257  305 
Fatty  degeneration of the Liver; Chronic 
Alcohol Abuse 
(External Case) 
121  M  76  48    NEG    NEG    1a. Perforation of oesophagus; 1b. 
Chronic stricture 
122  M  43  >500    169  247  NEG  NEG  1a. Fatty  degeneration of the Liver 
Chronic Alcohol Abuse 
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Appendix 5-2 GHB concentrations in blood and urine postmortem case samples 
 (Shaded boxes information is not available) 
Case # 
 
Gender  Age 
GHB mg/L 
Cause of Death             
Blood  Urine  
1  M  55  NEG    
1a- unacertained 
2  F  67  20  NEG 
1a- head injury (haemorrhage from scalp laceration)                                 
1b- presumed fall                                 
 2a- Acute  alcohol intoxication pulmonary 
thromboembolism 
3  F  41  NEG     1a- Stab wound of heart 
4  M  66  11     1a- Coronary artery atheroma   1b- Ischaemic heart 
disease 
5  F  44  22 *  NEG 
1a- Fatty degeneration of the liver                                                                
1b- Chronic alcoholic 
6  F  78  13 *  14 
1a- Inhalation of smoke and fire gases in a house fire 
and hypertensive and valvular heart disease 
7  F  29  NEG    
1a- Codeine and alcohol intoxication 
8  M  33  13  NEG 
1a- Heroin and ketamine intoxication 
9  F  58  10  12 
1a- Suspected alcohol related death 
10  M  54  27  NEG 
1a- Chest injury   
1b Road traffic collision (driver) 
11  M  29  15  NEG 
1a- Hanging 
12  M  29  11  NEG 
1a- Heroin, methadone, diazepam intoxication 
13  M  39  NEG  NEG 
1a- Bronchopneumonia and intoxication by heroin 
and methadone 
14  M  31  13    
1a- Hypoxia brain damage                  
1b- Cardiac arrest  
1c- Cardiac enlargement 
15  F  33  25    
1a- Hypoxia -Ischaemic brain injury                                                                   
1b- Cardiac arrest                            
 1c- Heroin and alcohol intoxication- Cardiac 
enlargement 
16  M  73  NEG  NEG 
1a- Ischaemic heart disease               
1b- Coronary artery atheroma   
17  F  18   NEG    
1a- unacertained (Pending further investigation) 
18  M  33  NEG  NEG 
1a- Heroin intoxication 
19  M  19  23  NEG 
1a- Head and chest injury                  
1b- Road traffic collision (driver) 
20  F  28  27  NEG 
1a- Bronchopneumonia                    
1b- Morphine intoxication  
21  M  44  16    
1a- Cardiac enlargement 
22  F  30  17  NEG 
1a- Incised wound of arm 
23  F  36  NEG  NEG 
1a- Viral pneumonia with secondary bacterial 
infection 
24  F  34  21  NEG 
1a- Heroin and alcohol intoxication 245 
 
Appendix 5-2 continued 
25  F  38  17  NEG 
1a- Head injury (Pending further investigation)  
26  M  81  28  23 
1a- Acute pylonephritis             
 2a- Coronary artery atheroma 
27  F  47  13  NEG 
1a-Ischaemic heart disease and 
bronchopneumonia 
28  F  38  17    
1a- Acute exucerlation of chronic obstructive 
airways disease 
29  M  71  13  NEG 
1a- Multiple injuries                            
 1b- Road Traffic accident (pedestrian) 
30  F  66  NEG  NEG 
1a- Acute hepatic necrosis             
1b- paracetamol Toxicity 
31  M  62  14  NEG 
1a- Hanging 
32  M  62  NEG    
1a- Probable sepsis, source uncertain 
33  F  44  14    
1a- Ischaemic heart disease           
1b- Coronary artery atheroma   
34  F  53  16    
1a- Multiple injuries                             
1b- Fall from height 
35  F  55  14    
1a- Upper gastrointestinal haemorrhage                                       
1b- Duodenal ulcer 
36  M  34  >500  >500 
1a- Gamma- hydroxy butyrate (GHB) 
intoxication 
37  F  43  22  NEG 
1a- unacertained 
38  M  67  19    
1a- Ischaemic heart disease          
1b- Coronary artery atheroma  
39  F  48  NEG  NEG 
1a- Head injury  
40  M  52  20    
1a- Bronchopneumonia                    
1b- Chronic alcohol abuse 
41  M  40  23    
1a- Acute alcohol intoxication 
42  M  57  17    
1a- Hanging 
43  F  44  18    
1a- unacertained (Pending further 
investigation) 
44  M  23  15    
1a- tramadol and methadone intoxication 
45  M  48  27    
1a- Alcoholic ketoacidosis                             
1b- Chronic alcohol abuse 
46  M  42  14    
1a- Myocardial fibrosis  and ischaemia - cause 
unacertained 
47  F  37  14    
1a- Heroin and methadone intoxication 
48  F  33  20    
1a- Heroin intoxication 
49  M  59  26    
1a- Hanging  
50  M  24  16    
1a- Hanging  246 
 
 
Appendix 5-2 continued 
51  M  40  23    
1a- Bronchopneumonia                   
1b- Chronic obstructive airways disease                                               
2a- Methadone intoxication 
52  M  64  <10     1a- Cardiac enlargement 
53  M  61  25    
1a- Bronchopneumonia                
1b- Chronic obstructive pulmonary disease   
54  M  63  23  15 
1a- unacertained (Pending further investigation) 
55  F  44  22  NEG 
1a- Bronchopneumonia        
56  M  42  10  NEG 
1a- Heroin intoxication 
57  F  34  12    
1a- Multiorgan failure (Pending further investigation) 
58  F  45  19    
1a- Clozapine intoxication                                 
 2a- Resolving Bronchopneumonia   
59  M  57  17  NEG 
1a- Ischaemic heart disease          
1b- Coronary artery atheroma  
60  M  41  NEG    
1a- Drowning 
61  M  62  29    
1a- Ischaemic heart disease  and  Bronchopneumonia  
62  F  41  14  19 
1a- Methadone and dehydrocodone intoxication                                   
1b- Coronary artery atheroma  
63  M  63  30  NEG 
1a- Hanging 
64  M  61  22  18 
1a- Hanging 
65  F  42  19  NEG 
1a- Multiple injuries                            
1b- Fall from height 
66  F  26  22  NEG 
1a- Heroin intoxication 
67  M  25  26  NEG 
1a- Heroin, methadone and alcohol intoxication 
68  M  49  21    
  
69  M  44  27  NEG 
1a- unacertained (Pending further investigation) 
70  M  33  22    
1a- Hanging 
71  M  32  23  NEG 
1a- Suspected seizure-related death (Pending further 
investigation) 
72  M  44  NEG  21 
1a- Fatty degeneration of the liver                                                            
1b- Chronic alcoholic abuse 
73  M  71  18  NEG 
1a- Acute puelonephritis                   
1b- Possible hypothermia 247 
 
 
Appendix 5-2 continued 
74  M  35  NEG  NEG 
1a- Fatty degeneration and cirrhosis of the liver                             
1b- Chronic alcoholic abuse 
75           60 
External case 
76        23    
External case 
77        29  NEG 
External case 
78        50    
External case 
79  M  33  32  NEG 
1a- unacertained (Pending further investigation) 
80  M  24  19  NEG 
1a- head and chest injury                  
1b- Fall from height 
81  F  40  NEG  NEG 
1a- Fatty degeneration of the liver                                                              
1b- Chronic alcoholic abuse 
82  M  51  NEG  NEG 
1a- Ischaemic heart disease           
1b- Coronary artery atheroma  
83  M  49  18  NEG 
1a- Ischaemic heart disease           
1b- Coronary artery atheroma 2a- Hypoglycaemia 
due to insulin dependents diabetes mellitus  
84  M  36  17  NEG 
 1a- Coronary artery atheroma  
85  M  42  46  NEG 
1a- Hanging 
86  F  35  25    
1a- unacertained (Pending further investigation) 
87  M  42  NEG  NEG 
1a- Cardiomegaly (Pending further investigation 
88  M  48  14  NEG 
1a- Heroin and alcohol intoxication 
89  M  34  NEG  NEG 
1a- Drowning (Pending further investigation) 
90  M  45  14  NEG 
1a- Sharp force injury of neck 
91  M  37  12    
1a- Stab wound of chest 
92  F  29  20    
1a- Hanging 
93  F  24  29  NEG 
1a- Hanging 
94  M  41  15    
1a- Hanging 
95  M  46  27    
1a- Sudden unexpected death in epilepsy                                                 
1b- Old head injury 
96  F  70  21    
1a- Drowning 
97  M  65  22    
1a- Chest injury                                   
 1b- Road Traffic accident (driver) 
98  M  67  38  25 
Alcohol related death 
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Appendix 5-2 continued 
99  M  38     38 
Undetermined 
100  M  80  14  18 
Hypothermia 
101  M  25  54  NEG 
Unascertained 
102  M  36  65    
Unascertained 
103        369    
Suspected GHB/GBL Intoxication 
104  M  61  26  22 
Ischaemic heart disease and gastro 
intestinal haemorrhage from erosive 
oesophagitis.  Fatty degeneration of the 
liver due to chronic alcohol abuse 
105  F  56  25    
Fatty degeneration of the liver due to 
chronic alcohol abuse. 
106        300      Suspected GHB/GBL Intoxication 
107  M  25  30  2.00 
 Methadone, heroin and cocaine 
Toxicity. 
108        >500  >500 
Suspected GHB/GBL Intoxication 
109  M  39 
56 
  
Methadone and alcohol Intoxication 
110  F  57  12.00  8.00 
1a-Alcoholic Stetosis  and Ischaemic 
heart disease ,                       1a Fatty 
generation of the liver                                                                                     
1b- Chronic Alcoholic 
111        11  9  External case (Expected Ketoacidosis) 
112  M  42  82    
1a-Ischaemic heart disease  1b- 
Coronary artery atheroma                                                                
2a- Insulin dependent diabetes mellitus 
113  F  36  30    
Fatty  degeneration of the Liver Chronic 
Alcohol Abuse 
114  M     27    
Suspected  Alcoholic ketoacidosis -BHB 
requested 
115  M     45    
Fatty  degeneration of the Liver Chronic 
Alcohol Abuse 
116  M     32  17 
Very Fatty Liver , Cardiac enlargement 
117  M     17    
Hepatic Failure, Fatty  degeneration of 
the Liver Chronic Alcohol Abuse 
118  M     264    
Suspected GHB intoxication 
119  M     44    
1a- unacertained  Chronic Alcohol Abuse 
, Fatty Liver 
120  M     59    
Fatty  degeneration of the Liver Chronic 
Alcohol Abuse 249 
 
Appendix 5-3 GHB QC Charts 
GHB - BLOOD_50 mg/L
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(C)              (D) 
GHB quality control charts at 50 mg/L (A and B), 300 mg/L (C and D) in blood and urine, respectively.  
 
QC Ranges 
Blood  Urine 
50 mg/L  300  mg/L  50 mg/L  300  mg/L 
Average  49  293  50  314 
Standard 
Deviation (SD) 
2.61  20.11  3.12  22.42 
CV%  5.4  6.7  6.3  7.1 
Mean ± 2SD   43-54  253-333  44-56  270-359 250 
 
Appendix 5-4 HMB/BHB and GHB QC Charts 
HMB, BHB and GHB - Plasma_10 mg/L
-4
-2
0
2
4
6
8
10
12
14
16
18
20
0 2 4 6 8 10 12 14 16
Observation
HMB
BHB
GHB
 
HMB, BHB and GHB - Urine_10 mg/L
-10
-5
0
5
10
15
20
25
30
0 2 4 6 8 10 12 14
Obser vati on
HMB
BHB
GHB
 
(A)    (B) 
HMB, BHB and GHB -Plasma_50 mg/L
10
20
30
40
50
60
70
80
90
0 2 4 6 8 10 12 14 16
Observation
HMB
BHB
GHB
 
HMB, BHB and GHB - Urine_50 mg/L
10
20
30
40
50
60
70
80
90
0 2 4 6 8 10 12 14
Observation
HMB
BHB
GHB
 
(C)                                (D) 
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(E)                                (F) 
Quality control charts for HMB, BHB and GHB in plasma and urine. at 10 mg/L (A and B), 50 mg/L (C 
and D) and 300 mg/L (E and F)  
 
10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L 10 mg/L 50 mg/L 300 mg/L
AVERAVE 7.29 50 304 8.84 50 305 6.39 49 304 13 60 307 9.19 49 299 8.15 50 296
STDEV 2.14 4.26 26.96 0.97 1.78 13.71 1.62 2.54 14.26 3.95 8.14 44.53 1.61 2.96 10.34 5.16 5.03 10.97
2 SD 4.27 8.52 53.93 1.94 3.55 27.43 3.24 5.08 28.51 7.90 16.28 89.07 3.23 5.93 20.68 10.32 10.06 21.93
Mean + 2SD 12 59 358 11 54 333 10 54 333 21 76 396 12 55 319 18 60 318
Mean - 2SD 3 42 250 7 47 278 3 44 276 5 44 218 6 43 278 0 40 274
PLASMA URINE
HMB GHB BHB HMB GHB BHB
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Appendix 6-1 Preparation and optimization of in house deuterated internal standard  
 
Materials used for preparation in-house deuterated standards were ethanol 
Deuterated (D6) D, 99 % Anhydrous, from Cambridge Isotope Laboratories.Inc. 
(CIL) USA.  Ethanol 100 AR 99.9% Joseph Miller (Denaturants), Liverpool.  Thionyl 
Chloride from Sigma Aldrich Company Ltd.Dorset,UK 
Fatty acids standards (Arachidonic acid Approx. 99% GC grade, Heptadecanoic 
acid 98%, Linoleic Acid minimum ≥ 99%, Linolenic ≥ 99%. Lauric acid (Dodecanoic 
acid) 98%, Myristic acid 99-100%., Oleic Acid ≥ 99% GC grade, Palmitic acid 
minimum 99% GC grade, Palmitoleic Acid Approx. 99% GC grade, Stearic acid 
Grade I 99%  GC grade) were obtained from Sigma Aldrich Company 
Ltd.Dorset,UK 
FAEEs deuterated internal standard was prepared according to Pragst, et al. 
(220)10 mg of each FAEEs added with ethanol-D6 Place in dry ice at -78ºC add 
10uL thionyl chloride Heat at 40ºC for 2 hours. Cyclohexane was added after 
evaporation at 10 psi, then followed by vortex another evaporation steps.  This 
later step was repeated two times and then bring it up with cyclohexane to have 
2 mg/mL final concentrations and stored at-20ºC. 
 
 
 
 
 
 
Chemical reaction during preparation of deuterated FAEES  
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Appendix 6-1 continued 
Purity of in house deuterated internal standard 
Deuterated in-house internal standards were prepared at concentration of 50 
mg/L to carry out the purity study. From stock solution (2 mg/ mL) a working  
standard of a concentrations of 50 mg/L was prepared. A 100 µl of 50 mg/L was 
added to a labelled vial. Cyclohexane was evaporated to dryness. 100 µL 
methanol was added to give final concentration was of 50 mg/L. All standards 
were stored at -20ºC 
Intrumentation and conditions  
Gas chromatography-mass spectrometry (GC-MS) was utilised using an Agilent 
GC-MS 7890A GC system, a 5975 mass spectrometry detector (MSD), and 
ChemStation software (Agilent, UK). A DB-5+ DG capillary column (30m x 0.25 
mm I.D., 0.25 µm film thickness), purchased from Agilent Technologies Ltd., UK, 
was used. Additional instruments included a nitrogen evaporator, micro-
centrifuge, heater block, and vortex.  
The  GC Program conditions of 50°C for 1 minutes then 10°C /min to 250°C  for 
60 minutes, total run time was 27 minutes using splitless mode. The ions for 
corresponding analytes were extracted includes(D5-ethyl arachidonate 338, D5- 
Ethyl Laurate 234, D5-ethyl myristate 262, D5-ethyl linolenate 312, D5 ethyl 
linoleate 314, D5-ethyl Palmitoleate 288, D5-ethyl palmitate, 290, D5-ethyl 
oleate 316 and D5-ethyl stearate 318, D5ethyl heptadecanoate 304). 
 Area percent report was generated and area peak percent of analyte in relation 
of the total peak areas present in the same chromatogram were for non 
derivatized ranging from 32-89%. Intensity report was also printed and the 
intensity for the area of (m/z+2), (m/z+3), (m/z+4), (m/z+5) were listed in the 
same excel sheet. purity was calculated as the percentage of the area intensity 
(m/z+5) for  all internal standards versus the sum intensities of m/z+2 plus 
m/z+3 plus m/z+4 plus m/z+5.  The purity ranged from 81- 98 % for as indicated 
in  253 
 
Appendix 6-1 continued 
Purity of in-house deuterated standards 
Internal Standard 
Molecular 
ions from 
GC/MS  
RT  (Area)  
M/z+2   
(Area)  
M/z +3 
(Area)  
M/z+4 
(Area)  
M/z+5 
Total  
Intensities 
Purity 
% 
Ethyl arachidonate-D5  337.4  22.302  4790  4171  5200  59872  74033  81 
Ethyl heptadecanoate-
D5  303.4  20.188  1280  4875  55632  3229696 
3291483  98 
Ethyl laurate-D5  233.3  14.997  225  676  3274  118720  122895  97 
Ethyl lenolenate-D5  311.4  20.799  3103  3023  6547  647616  660289  98 
Ethyl linoleate-D5  313.4  20.751  708  5633  14801  851072  872214  98 
Ethyl miristate-D5  261  17.212  917  3097  53936  1796608  1854558  97 
Ethyl oleate-D5  315.4  20.828  3091  5366  13177  389376  411010  95 
Ethyl palmitate-D5  289.4  19.234  606  4703  96920  3643392  3745621  97 
Ethyl palmitoleate-D5  287.4  19.013  453  4318  6252  552064  563087  98 
Ethyl stearate-D5  317.5  21.083  1016  4730  23400  1598464  1627610  98 
 
 
Fragmenter ion optimization of In house d5-FAEEs and ethyl heptadecanoate 
 
Most analytes have a collision energy of less than 10ev using LC/MS/MS triple 
quadrupole However, using the same tuning solution with the ion trap 
LC/MS/MS, the collision energies were higher (27-42 eV for the same analytes)  
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Appendix 6-1 continued  
Fragmentor ion optimization of in house internal standard was carried out and 
the range of optimum fragmentor voltage was between 100 and140  
FAEES and FAEEs-d5 Optimization of product ion and Collision Energy (CE) 
Name   Molecular 
Ion 
Product  
Ions  
Collision Energy  
By 
 Deca LC/MS/MS  Comment  
FAEEs 
Ethyl Arachidonate  332.5  287  38  Commercial  
Ethyl heptadecanoate   299  271  36  Commercial  
Ethyl Laurate  228.38  201  30  Prepared in house from its acid  
Ethyl Lenolenate  306.49  261/243  42  Commercial  
Ethyl Linoleate  308.51  263/245  32  Commercial  
Ethyl Miristate  256.43  229  32  Commercial  
Ethyl Oleate  310.53  265/247  30  Commercial  
Ethyl plamitate   284.48  257  32  Commercial  
Ethyl Plamitoleate  283  237  30  Commercial  
Ethyl Stearate  312.53  285  34  Prepared in house from its acid  
Ethyl heptadecanoate   299  271  36  Commercial  
Ethyl Plamitoleate  283  237  30  Commercial  
Commercial Deuterated FAEEs- d5 
Ethyl Miristate_d5  262  230  30  Commercial   
Ethyl Oleate_d5  316  265  38  Commercial  
Ethyl plamitate_d5   290  258  30  Commercial  
Ethyl Stearate_d5  318  286  32  Commercial  
 In house Deuterated FAEEs- d5  
Ethyl Arachidonate_d5  338  287  30  Prepared in house from its acid  
Ethyl heptadecanoate_d5   304  272  40  Prepared in house from its acid  
Ethyl Laurate_d
5  234  202  27  Prepared in house from its acid  
Ethyl Lenolenate_d5  312  261/243  30  Prepared in house from its acid  
Ethyl Linoleate_d5  314  263/245  32  Prepared in house from its acid  
Ethyl Miristate_d5  262  230  30  Prepared in house from its acid  
Ethyl Oleate_d5  316  265  38  Prepared in house from its acid  
Ethyl plamitate_d5   290  258  30  Prepared in house from its acid  
Ethyl Plamitoleate_d5  288  237  30  Prepared in house from its acid  
Ethyl Stearate_d5  318  286  32  Prepared in house from its acid  
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Appendix 6-1 continued 
Collision energy and product ions optimization using triple quadropole LC/MS/MS  
were not fully achieved  it was not reproducible ,this could be because very 
small CE was needed to fragment those ion (less than 5ev) which is too low 
compared to ion trap LC/MS/MS.   
Collision energy of  FAEEs analytes, including both commercial and In house  
internal standards, were lower than 10ev in a range of 2–6 (table 5-2); this made 
the optimization for some analytes more difficult, possibly due to the fragility of 
some compounds at this low collision energy. The optimum published collision 
energy of FAEEs ranged between 10 and 30 using triple quadrupole 
LC/MS/MS.(159) Collision energy was in a range of 27-42 ev when it was 
optimized by other ion trap LC/MS/MS in the same laboratory. This could be 
another reason not to have another ion transition for all analytes to be used as 
qualifiers  
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Appendix 6-2 Endogenous interference Study 
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(A) EXTRACTED pooled meconium blank samples with no internal standard versus unextracted 
FAEEs at concentration of 1 mg/L. (B) magnified peak  of ethyl arachidonate  overlaid with extracted 
meconium blank.  The arrow indicated no endogenous interference from analyte in extracted blanks. 
 
Appendix 6-2 continued
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Urine using GC-MS 
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th  Saudi  International 
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The Effect of Preservative and Anti-oxidant Reagents in Aged 
Reconstituted  Ante-mortem Blood after Short- Term Storage 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
Abstract 
The stability of common volatiles was investigated under controlled conditions over a period of 50 
days. Blood was spiked with ethanol, methanol, isopropanol and n-propanol at 20 and 80 mg/dL 
and acetone at 20 and 80 mg/L. Aliquots were stored at 25, 4, and -22 ºC with or without a 
preservative  (sodium  fluoride)  or  antioxidant  (sodium  metabisulphite).  Samples  were  analysed 
using headspace gas chromatography with a flame ionisation detector (HS-GC-FID and utlising t-
butanol as internal standard. Acetone levels increased while isopropanol and n-propanol levels 
decreased in both preserved and unpreserved samples at room temperature and when refrigerated. 
Methanol  remained  stable  in  the  presence  of  a  preservative  and  antioxidant  in  all  conditions. 
Formation of ethanol was observed in samples stored at room temperature or refrigerated without 
preservative. All volatiles were stable when stored in the freezer.  
An evaluation of the stability of ethanol in real case samples was also undertaken. Blood samples 
collected  under  Section  5  of  the  Road  Traffic  Act  1988  are  stored  in  vials  containing  both 
preservative and anticoagulant. A total of 219 blood samples received within Forensic Medicine 
and Science at the University of Glasgow over a period of 5 years were initially analysed and 
refrigerated until the case was heard in court. Following completion the samples were removed 
from the refrigerator and stored at room temperature for varying periods of time spanning 5 years. 
A loss of on average 30% of the ethanol content was observed when the samples were re-analysed.  
Finally, seventy-one paired preserved and unpreserved post-mortem blood samples stored in the 
refrigerator for six months were re-analyzed. Loss of ethanol was observed in approximately 50% 
of the 71 preserved samples and 40% of unpreserved samples. An increase in ethanol concentration 
of between 34 to 55% was observed in approximately 7% of the preserved samples and 25% of 
unpreserved samples after 6 months of storage in a refrigerator.  
Key words: volatiles, stability, preservative 
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Simultaneous determination of of ß-hydroxy-ß-methylbutyrate (HMB), 
beta-hydroxybutyrate (BHB) and gamma-hydroxybutyrate (GHB) in 
urine and plasma using gas chromatography mass spectrometry (GC-
MS) 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
 
 
Abstract  
β-hydroxy-β-methylbutyrate (HMB) or  β-hydroxyisovaleric acid (β-HIV) is available as a nutritional 
supplement and is taken to increase strength and muscle mass in humans involved in resistance training 
programmes. Although in 1999 the International Olympic Committee’s medical advisory board categorized 
HMB as a legal substance the potential for misuse is considerable.  
The aims of this study were, to develop and validate a method for the determination of HMB in plasma and 
urine and to simultaneously determine other structurally related compounds, such as BHB and GHB and 
apply this method to analyse real case samples.  
A GC-MS method was developed for the simultaneous determination of HMB, BHB and GHB in plasma and 
urine using deuterated GHB-d6 as an internal standard. The method was linear over a range of 10-500 mg/L 
with a correlation coefficient (R
2) greater than 0.99.  The inter-day and intra-day precision was measured in 
both matrices at less than 10%. The recovery and accuracy ranged between 42-77% and 98-102% 
respectively for all analytes in both plasma and urine. The limits of detection (LOD) for HMB, GHB and 
BHB were 2.3, 1.0 and 2.2 mg/L in urine respectively, and 2.3, 1.5 and 0.9 mg/L in plasma.  The lower limits 
of quantification (LLOQ) were 7.7, 3.3 and 7.3 mg/L and 7.8, 5.1 and 2.9 mg/L respectively, in urine in 
plasma.  
 
Keywords:  β-hydroxy-β-methylbutyrate  (HMB)  or  β-hydroxyisovaleric  acid  (β-HIV);  β-hydroxybutyrate 
(BHB); gamma-hydroxybutyrate (GHB); Plasma; Urine 
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A Liquid Chromatography Tandem Mass Spectrometry Method for the 
Quantification of Fatty Acid Ethyl Esters in Meconium. 
 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
 
Abstract 
 
Babies born from mothers who consume alcohol during pregnancy are at elevated risk to have 
Neonatal alcohol related birth defects (ARBDs), Foetal Alcohol syndrome (FAS) and alcohol-
related neurodevelopment disorders (ARNDs). To facilitate earlier diagnosis and treatment and to 
prevent undesirable outcomes, screening for fatty acid ethyl esters as alcohol biomarkers could 
confirm maternal alcohol consumption. Foetal exposure of alcohol can cause central nervous 
system dysfunction, pre- and postnatal growth problems, cardiac defects in neonates and attention 
deficit disorders may leads to mental retardations.  
A Liquid Chromatography Mass spectrometry tandem MS (LC/MS/MS) method have been 
developed and validated for detection and quantification of fatty acids ethyl esters in meconium 
includes: ethyl lenolenate (E18:3), ethyl linoleate (E18:2), ethyl palmitoleate (E16:1), ethyl 
palmitate (E16:0), ethyl oleate (E18:1), ethyl stearate (E18:0) and ethyl arachidonoate (E20:4). The 
internal standards used were deuterated includes ethyl oleate-D5, ethyl steareate-D5 and ethyl 
palmitate-D5.  
The method have been applied to eighty four real neonatal meconium case samples  collected from 
Glasgow Royal Infirmary  in order to investigate the neonatal exposure to alcohol in the absence of 
maternal drinking history. Results have been compared with the published data to identify the most 
specific and sensitive fatty acid ethyl ester biomarker. The cut-off point to distinguish the positive 
from negative was also evaluated 
 
Key Words:  Meconium, Fatty acid ethyl esters, Alcohol, LC/MS/M 
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Internal Standards for the Determination of Common Volatiles by 
Headspace Gas Chromatography Flame Ionisation Detection. 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
 
Abstract 
The most common method for sensitive and precise analysis of ethanol and other volatile in 
biological fluids and tissues is Gas Chromatography.  This methods can also distinguish between 
ethanol and other volatiles and by using dual column system and it is fitted with dual column 
capability  and provides  two sets of data that can used in combination with increased confidence to 
identify analytes of interest, since it reduces the number of false positive results due to other post-
mortem volatiles that may be eluting in the same retention time.  . Head Space - Gas 
Chromatography copelled with Flame Ionization Detector (HS-GC-FID) technique is common in 
forensic and toxicology laboratories for medico-legal investigations and the interpretation of 
toxicology results.   
A wide range of volatile compounds may be produced in post-mortem specimens.  n-propanol is 
amongst these and is considered to be an indicator of putrefaction. Several studies have therefore 
recommend that n-propanol should not be used as an internal standard for quantification of alcohol 
by (HS-GC-FID).  A comparison between  two validated  procedures and evalauation of dual 
column system used  have been carried out  using  n-propanol and t- butanol as an internal 
standards.  The two validated methods used were robust, sensitive, and fully validated using GC-
FID-HS.  The correlation coefficients (R
2) were >0.999 over the linear range of 10–500 mg/dL 
(and mg/L for acetone). The inter-day and intra-day precision was between 1-5% for all analytes in 
all methods used.  
One hundred and twenty one putrefied post-mortem blood samples received within laboratories of  
Forensic Medicine and Science  were analysed using both  methods.  Evaluation of other volatile 
levels mainly the amount of n-propanol and it is relation with ethanol level in post-mortem blood 
have been evaluated. The putrefied post-mortem blood samples produced several results in which 
n-propanol was present at a level that could be viewed as a result of putrefaction. It might tend to 
underestimate the concentration of other volatiles if n-propanol is used as an internal standard in 
post-mortem samples that are positive for n-propanol.  
Key words: volatiles, n-propanol, ethanol, putrefaction274 
 
 
Quatification of Gamma-Hydroxybutyrate (GHB) in Postmortem Blood 
by using Gas Chromatography Mass Spectrometry. 
 
Huda M. Hassan and Gail A. A. Cooper 
Forensic Medicine and Science, School of Medicine, 
University of Glasgow, G12 8QQ, Scotland 
e.mail:Huda.Hassan@formed.gla.ac.uk: 
web.mail: hassanh11@googlemail.com 
 
   
 
Abstract  
 
Gamma–hydroxybutyric acid (GHB) and its precursors, gamma butyrolactone (GBL) and 1, 4 
butanediol (DB), are increasingly popular drugs of abuse. GHB misuse and accidental overdosing 
may lead to death and GHB has been detected in post-mortem blood in concentrations ranging  
from 3.2 – 168 mg/L in cases with no previous history of GHB use (Fieler, Coleman and Baselt, 
1998).  A sensitive and specific method for the determination of GHB in blood and urine was 
modified from a method previously validated and published (Hassan et al. 2009) using GC-MS.  
The method has been applied to identify GHB-related fatalities in postmortem cases and to evaluate 
the levels in postmortem cases with no known history of GHB intoxication.  
 
Keywords: GHB; GC-MS; Postmortem; Blood; Urine 
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